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ABSTRACT 
This research project has been an endeavor in understanding how Human Papillomavirus 
(HPV) vaccine policy became gendered in Canada, how women in Ontario negotiated the 
concepts of “risk” and “gender” deployed in pharmaceutical marketing and public health 
programming, and how they folded these mediations into decision making about the 
vaccine.  Eighteen months of ethnographic fieldwork revealed that the federal and 
Ontario governments developed HPV vaccine policy by using gender based analyses 
frames, based on the parameters of Merck Frosst’s gender-based marketing. This case 
study of the HPV vaccine highlights how corporations and governments work hand and 
hand to set public health policy in the neoliberal era of public health. However, these 
sales/governance strategies and the gendered at-risk subject formation they created and 
circulated were not passively integrated by women into their daily lives. The women 
interviewed – mothers of daughters affected by the grade eight school vaccination 
program, women university students and patients at a hospital vaccine clinic – 
demonstrated that the concepts of “risk” and “gender” are productive and movable 
ontological modes of being, which shift in and out of focus depending upon the context. 
Mothers were intensely focused on gender and doing mothering, students were doing 
gender politics and intermittent risk, and patients were living with risk. What 
sales/governance strategies had tried to “fix,” women continually unfixed. These 
accounts of situated risk and gender demonstrated that when assembled, women’s 
experiences helped transform their ethical being or sense of self.  This knowledge of the 
self then informed vaccination decisions. Thus, decision making was not a discrete event 
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or a linear, cost-benefit analysis. Instead it was an inherently social and cultural process, 
which was embedded in women’s experiences of finding meaning in their efforts to be 
good mothers, strong young women emerging into adulthood and pre-cancerous patients 
seeking respite amid the anxiety of protracted medical procedures.  Women’s ontological 
decision making provides an analytical framework through which to tie together risk- and 
gender-related theory, individual accounts of risk encounters and the social, political, 
historical and economic context in which these mediations occur.   
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CHAPTER ONE – Introduction: Research Focus and Scope 
Introduction: Setting the Ethnographic Stage 
Generally an anthropological dissertation starts off with an illustrative anecdote. Such 
an anecdote serves a double purpose. It works to place the reader within the “thick” 
(Geertz 1983) of the ethnographic experience of the writer and metaphorically 
references the research project at hand. However, this dissertation cannot begin with 
one particular research-related vignette. Such an approach would be disingenuous and 
would reflect neither the research project goals nor the resulting analysis. Throughout 
the research project, the objective was to understand women’s numerous and varied 
responses to medicalization and specifically the human papillomavirus (HPV) vaccine. 
As Lock and Farquhar note, “what has emerged from interest in the human body, as it is 
lived, is a multiplicity of bodies. . . . [T]hey cannot be summed up in any one kind of 
narrative” (2007:2). With this in mind, here are three snapshots of ethnographic 
encounters with interviewees who have left a lasting, post-fieldwork, impression on me. 
First there was Carmen, a fellow mother and academic. During our interview, this 
poised and self-assured professor was a bit rattled. Besides being somewhat harried 
because it was back-to-school time, Carmen also faced the decision of whether or not to 
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have her daughter vaccinated against HPV.  Emily had entered grade eight and on the 
first day of school had brought home a large packet of forms to be signed that included 
everything from pizza ordering to school accident insurance requests.  Also included 
was an HPV vaccine consent form. The consent form needed to be returned in four days 
in order for Emily to be eligible for the three-phased shots. The stress of the decision 
making process was visible on Carmen’s face. Having the responsibility of making 
health decisions for someone else is a weighty proposition and Carmen was anxious and 
uncertain about her decision making. As she said, “It’s a catch-22”; she was not facing a 
clear-cut, win-win decision. If she did not vaccinate her daughter and she developed 
cervical cancer, Carmen would never forgive herself. However, if she put Emily 
through an unnecessary vaccination experience and exposed her to vaccine side-effect 
risk, she also would not forgive herself. 
Second there was Sylvana, a university student who persistently sought, for over six 
months, to arrange an interview with me so that she could share her HPV story. Sylvana 
was a health sciences major, frequent medical consumer and had experienced HPV 
infections. Sylvana could not come to a definitive decision whether or not to be 
vaccinated and wanted to be interviewed because she needed someone to talk to 
regarding her HPV experiences. The stigma associated with being a woman who had 
contracted a sexually transmitted infection (STI)1 enforced a “culture of silence” around 
1 Please note that medical and policy terms relating to HPV and the vaccine are explained 
in the glossary, which can be found in Appendix A. 
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HPV infection and this left her with limited social avenues through which to share her 
experiences.  
Third there was Rebecca, a 40-year-old mother of one who had experienced HPV 
infection in the form of varying grades of cervical dysplasia or pre-cancer, for ten years 
and was now a patient at the hospital-based vaccine clinic. Because of her infections, 
she was subject to a slew of medical procedures, including everything from protracted 
Pap testing to colposcopies to LEEPs. Rebecca felt that it was not possible to prevent 
HPV infection, but only to “contain” (Douglas 2002[1966]) it. Rebecca was anxious 
about her pre-cancerous state and was skeptical as to whether or not the vaccine would 
stave off future infection of HPV strains she had not already been exposed to.  Her 
motivation to get vaccinated stemmed directly from her stress-ridden experiences with 
cervical dysplasia. While there was no guarantee, Rebecca was willing to give the shot a 
try.  
As these vignettes indicate, researching the HPV vaccine was an intense experience. 
This intensity was exacerbated by the topicality of the vaccine as an issue of public 
debate and concern. As a mother and graduate student, I moved in and out of 
communities in which the vaccine was discussed daily. The lines between the “field” 
and my personal time were porous. When I volunteered at a reading program for 
elementary school children at my children’s school, other mothers wanted to know what 
I thought of the vaccine and even went so far as to ask me if they should get their 
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daughters vaccinated. When asked this question, I tried to maintain a balanced approach 
by outlining the information that was circulating for and against vaccination. As I had 
two boys, I was never directly asked if I had my own children vaccinated. The issue of 
the vaccine was so timely that I should not have been surprised when one evening 
during fieldwork I attended a home-based yoga class and walked into an HPV kitchen 
vaccination. The mother of the household was taking a vial of the vaccine out of her 
fridge so that her neighbour, a nurse, could administer it to her teenage daughter. The 
vaccine, however, was not just a matter of discussion among the people I encountered 
daily, but dominated the mainstream media as well. It was not uncommon for 
newspapers at the time to frequently feature articles on the vaccine, or to wake up to 
stories about the vaccine when the morning alarm went off. Vaccine advertisements 
were also routinely visible on the subway and even made appearances during the 
Saturday morning cartoon hour. The “field” seemed to be everywhere.  
 
As a result of this immersion in the vaccination “field,” this research project makes a 
marked departure from existing social science literature on the vaccine. Current 
literature addresses several topics: the vaccine and minority health within bounded 
groupings demarcated by ethnicity (see Fernandez et al. 2009; Lazcano-Ponce et al. 
2001; Livingston et al. 2010; Luque et al. 2011, Lucque et al. 2010; Pitts et al. 2009); 
parental attitudes towards vaccination (see Chapman 2010; Das et al. 2010; Dempsey et 
al. 2006; Ogilvie et al. 2007); women’s knowledge concerning HPV and the vaccine 
(see Medieros and Ramada 2010; Pitts and Clarke 2002) which often pits women’s 
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views against those of men; gay men and the vaccine (see Epstein 2010); health care 
provider attitudes towards the vaccine (see Mishra and Graham 2012); and the framing 
of the vaccine as a prophylactic measure against cancer and not as an STI prevention 
tool (see Braun and Phoun 2010; Mamo et al. 2010; Prescott 2010; Wailoo et al. 2010).  
While these topic areas vary, each study is narrow in scope as none are the result of 
long term fieldwork engagement.  Nor do these studies offer a critical treatment of the 
concepts of “gender” and “risk.”  In short, existing research does not offer in-depth 
qualitative data concerning vaccine negotiation or provide adequate political, economic, 
historical and social contextualization to robustly understand and make sense of 
decision making.  
In exploring the narratives of women like Carmen, Sylvana and Rebecca, this research 
project remedies these shortfalls by providing accounts of “situated risk” (Boholm 
2003:158) and gender. In examining situated risk, anthropologists are able to move 
between three points: grand theory relating to risk; individual accounts of risk 
encounters; and the political, social, historical and economic context in which risk is 
produced and negotiated. Situated risk allows for the critical analysis of the “structural 
dimension[s]” that affect individual risk negotiation and provides textured ethnographic 
accounts of such mediation (Boholm 2003:158). This goes beyond existing research in 
other social science fields highlighting risk, which generally focuses on meta theory 
(see Beck and Willms 2004; Castel 1991; Dean 1999; Giddens 1991; Giroux 2010; 
Gordon 1991; Ewald 1991; Fox 1997; Petersen 1997; Rothstein 2006) or individual 
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accounts (see Bond et al. 2012; Brown et al. 2013; Crighton et al. 2013; Gross and 
Shuval 2008; Lear 1995; Russell and Kelly 2011; Spencer 2013; Thing and Ottesen 
2013; Tuinstra et al. 1998; Walls Dr et al. 2010; Zinn 2008). Concentrating solely on 
grand theory leaves out the important human element of risk, and only researching 
individual experiences reproduces risk-related governance strategies, albeit 
unintentionally. Highlighting individual accounts of risk without adequate 
contextualization reinforces the new public health’s focus on individual self-regulation 
(Petersen 1997). However, as important as the situated risk concept is, it does not 
address how gender intersects with risk-related decision making, nor the specific 
governance techniques associated with gendered risk-making (Lupton 1999a; Moore 
2010). As a result, this research project focuses on both situated risk and gender through 
the additional inclusion of theory from Allen (2008), Butler (2008), Douglas (1992, 
2002[1966]), Lupton (1997a, 1997b), Moore (2010) and Nettleton (1996, 1997) in order 
to incorporate a feminist perspective into the analysis. 
 
A] Research Agenda and Analytical Frames 
 
In order to provide situated accounts of risk and gender, fieldwork occurred over an 18-
month period and included multiple sites. Research began with three months of archival 
study to determine how HPV vaccine policy became gendered in Canada when the virus 
is gender blind and associated with cancer affecting individuals of all genders (Braun 
and Phoun 2010). The archival research tracked how the concepts of “gender” and 
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“risk” were deployed in pharmaceutical and policy discourses vis-à-vis the HPV 
vaccine. This meant pouring over documentation which included Gardasil® advertising 
campaigns, popular media accounts, parliamentary debates, federal and provincial press 
releases, accounts of lobbying before the federal Finance Committee, and federal 
regulatory decisions regarding the vaccine. Critical discourse analysis of these sources 
revealed that messaging relied upon the overarching notion that women are a 
“feminine” (Bartky 1990, Moore 2010) grouping – a homogenous and static “whole” 
that is inherently at risk for ill health. Merck Frosst was the first to deploy this 
governance technique as a selling mechanism for the vaccine, but if this 
conceptualization of women had not been in the ether, it would not have been picked up 
again in the gendered policy making processes surrounding the vaccine. Thus, the 
marketing tactics and policy development surrounding the vaccine functioned 
tautologically as sales/governance strategies. This archival research provided baseline 
data on how “gender” and “risk” were deployed in these discursive knowledge nodes 
and I drew on it as I formulated interview schedules.  
 
The next step in the research process was to understand how these concepts were 
received, amalgamated and refuted by women. This entailed interviewing three cohorts 
of women: mothers negotiating the vaccine for their daughters in a school-based 
immunization program, university students who were targets of HPV vaccine promotion 
in campus health clinics, and patients who attended a hospital-based HPV vaccine 
clinic. Interviews focused on how women negotiated the concepts of “risk” and 
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“gender” in their daily lives vis-à-vis the vaccine. How did women make sense of and 
experience these concepts? What did these concepts mean to them? How did these 
experiences affect their vaccine decision making? In answering these questions, I 
examined the vicissitudes of power – how power was deployed and how it was 
processed. However, in order to avoid repeating the power techniques used in the 
sales/governance strategies of the pharmaceutical and governmental discourses 
surrounding the vaccine – i.e. assuming women occupy a static, whole and homogenous 
at-risk grouping – I paid close attention to the nuances and flexibility that women 
employed regarding risk and gender. I paid specific attention to the variability women 
applied to their mediations of risk and gender in their everyday lives.  
 
To get at the heart of women’s experiences of situated risk and gender, data analysis 
followed Foucault-inspired governmentality approaches to risk (Castel 1991; Giroux 
2010; Gordon 1991; Lupton and Petersen 1996; Nettleton 1997; Petersen 1997; Rose 
2007; Rothstein 2006; Turner 1997) and late Foucault theory (1987, 1989, 1990[1978], 
1991, 1997, 1999). Foucault’s governmentality writings are frequently taken to task for 
their predetermined nature (Sawicki 1991). However, once the spectrum of his writings 
is examined, the tightly woven governance strategies of the governmentality period are 
unraveled, ever so slightly, in his later work focusing on subjectivities. Foucault, if the 
full scope of his work is taken into account, acknowledges the construction of subjects 
within the frameworks of power relations, but also the possibility that such subjects are 
able to level their own limited “critiques” even though enmeshed in the webs of power 
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(Allen 2008:21).  Women’s narratives provided an intersubjective “space” where 
subject formation and realizations/actualizations of the self intersected.  It was in this 
“space” that health negotiation and decision making occurred. Correspondingly, 
interviews provided moments of generative pause. Not only did interviews allow for 
contemplation, they were productive events. Mothers and students ruminated on and 
processed how HPV infection and HPV vaccine risk was being transmitted by 
governmental and pharmaceutical discourses and how they were hybridizing or 
rejecting these messages. However, women were communicating far more than an 
account of their vaccine decision making during interviews. When in the thick of a 
pause, each woman created a narrative that contributed to her continually developing 
sense of self that re-inscribed and re-enforced her identity. Women are not always 
portrayed as “doers,” but throughout vaccine negotiation and decision making women 
worked towards becoming “ethical” beings: women who create their own “telos” or sets 
of codes for maneuvering daily life (Foucault 1997:265). Scripting one’s telos is a 
temporary transfer of power and this reflects women’s ability to be “self-constituting” 
(Butler 2008:2). Therefore, women enacting situated risk and gender demonstrated that 
risk could be harnessed and “practiced” (Zaloom 2004:368), a concept akin to Butler’s 
treatment of gender.  
 
Fieldwork data revealed that something quite specific took place when women spoke of 
their decisions whether or not to have their daughters or themselves vaccinated against 
HPV.  Their ethical agency, in an overarching sense, involved aspects of Thompson’s 
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“ontological choreography” (2005). In the case of patients, and more tangentially 
students, ontological choreography was joined by the “biographical disruption” (Bury 
1982) of being chronically ill. When ontological choreography and biographical 
disruption intersected, women consciously and pointedly engaged in re-ordering. Thus, 
the concepts of risk and gender were movable ontological modes – risk and gender 
moved in and out of focus depending on the context. For mothers, risk was a theoretical 
construct; their daughters were just moving into their teenage years and the last thing 
they wanted to do was explore adolescent sexuality with their daughters. HPV risk was 
for the mothers a distant proposition.  As a result, mothers focused abundantly on 
gender and “doing mothering” (Glenn 1994). For students, HPV risk was intermittent as 
many had experienced transient HPV infections in the form of genital warts and the 
beginnings of low-grade cervical dysplasia. Students were also worried about long term 
vaccine side effects and were outraged at the gendering of HPV and the vaccine. 
Students based their vaccination decisions on the type of gendered being they wanted to 
be – one that was not put in a pre-determined, at-risk “box” (Douglas 2002[1966]:125, 
172). Students were, therefore, dealing both with risk and gender in equal measure. The 
risk students experienced, however, was nothing like the risk patients were living with. 
Patients thought the risk was so all encompassing that there was no means by which to 
escape it, but only strategies through which they could contain it. Due to the intensity of 
risk for patients, which they recounted in their diagnostic and treatment narratives, 
gender took a backseat. Narratives across all three cohorts indicated that in relation to 
women’s senses of self, risk and gender were elastic concepts. In response to the 
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creation and circulation of a totalizing and static gendered and risky HPV-related 
subject – which attempts to keep women in order and prompts them to follow orders – 
women re-ordered their lives. This re-ordering also led women to take part in 
ontological decision making. Vaccine decision making was not the product of 
individual rational choice, but of social and cultural processes. Women’s vaccine 
decisions were layered into, and a result of, their active and situated experiences with 
gender and risk. Their situated experiences of doing mothering, doing gender politics 
and intermittent risk, and doing risk detail, respectively, their efforts to be good 
mothers, strong young women emerging into adulthood, and pre-cancerous patients 
seeking a “pause” amid the anxiety of protracted medical procedures. Each of these 
states of being was directly linked to the vaccine decisions of the three cohorts:  
mothers’ overwhelming decisions to have their daughters vaccinated, students’ 
decisions not to be vaccinated with a small portion delaying making a decision, and 
patients’ unanimous decisions to be vaccinated in an effort to take a step back from 
HPV infection. 
 
Conclusion: Summary of Chapters 
 
These analytical conclusions are the products of a long journey through fieldwork and 
participatory analyses. Before recounting this journey, a précis of the chapters to come – 
a brief sketch of the ethnography as it unfolded – is provided.  
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In chapter two, gender-based analyses (GBA) relating to the HPV vaccine, whether it is 
of gender-based pharmaceutical marketing approaches or governmental gender-based 
policy making in Canada, are examined, and the part these pharmaceutical and 
governmental frames play in constructing the girl/woman who is at-risk for cervical 
cancer are explored. This framing leverages hegemonic cultural logics concerning 
gender and risk, and functions as a sales/governance strategy that places girls/women in 
a pre-determined box removed from the sites of power. In order to keep girls/women in 
this box, the HPV vaccine is positioned as a cancer fighting mechanism.  This side steps  
HPV as a sexually transmitted infection, and proffers a vast platform for 
sales/governance because cancer, as opposed to STIs, is culturally interpreted as wide 
reaching, mysterious, fear inducing and multi-causal.  It is important to emphasize that 
GBA as applied in the case study of the HPV vaccine, treats gender as pertaining 
primarily to women. In this rendering, women are translated into an undifferentiated 
and static grouping – a grouping of tangible at-risk subjects.  This chapter serves as a 
historical, economic and political contextualization to trace women’s responses to this 
very subject formation. 
 
Chapter three focuses on methodological approaches and experiences in the field. Once 
I completed the archival research, my goal was to find people, places and spaces where 
I could connect with women to unearth their experiences of the HPV vaccine. Securing 
an institutional arrangement – meaning a clinical space to conduct participant 
observation – was a challenge, but one that was arranged, albeit in a modified form. In 
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addition, the enthusiastic response received from women regarding the research project, 
including the additional student cohort, was most unexpected. As such, I discovered on-
the-ground HPV policy that had a clinical, as opposed to governmental, impetus, as well 
as the integral part that HPV infection stories played in HPV vaccine decision making 
for many women. It also became evident that findings could solicit strong and 
emotional responses from other academics in conference settings. Thus, tracing how 
women mediated the concepts of “gender” and “risk” within the confines of vaccine 
negotiation took on enriched dimensions that required fluid approaches to fieldwork.  
 
While chapters two and three provide the theoretical and methodological foundations 
for the research project, the next chapters move into women’s responses to the HPV 
vaccine. In chapter four, I explore mothers’ narratives in regard to their vaccine decision 
making for their middle school-aged daughters. Mothers exhibited anxiety, strong 
emotions (both in terms of enthusiasm and disdain) and uncertainty regarding their HPV 
vaccine decision making. The weight of HPV vaccine decision making was exasperated 
by the relatively short period of time they had in which to make a decision.  
 
Continuing along the theme of women’s response to vaccine decision making, chapter 
five features women university students’ experiences with HPV infection and vaccine 
decision making. This chapter is about students’ HPV stories, as Sylvana so eloquently 
put it. Students called for widespread sexual health education of sexually transmitted 
infections (STIs), and specifically HPV. In interviews students off-loaded their anxieties 
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of having contracted an STI and receiving very little social support. Students 
passionately discussed the gendering of HPV and the HPV vaccine, both through 
commercial advertising and within the governmental realm of current school-based 
vaccination programming in Ontario. This gendering was so off-putting to students, 
along with their concerns of potential vaccine side effects, that the majority of those 
interviewed decided not to get vaccinated or to delay vaccination.  
 
In chapter six, patients at the hospital HPV vaccine clinic talked about their experiences 
with cervical dysplasia diagnoses, the resulting treatments and deliberations regarding 
the vaccine. Their sense of cancer risk had a different frame of reference than that of 
other women interviewed – they had been engaged with risk in the past, experienced 
risk in the present and were waiting to see if it would rear its head in the future. Patients 
with frequent cervical dysplasia presentations were suspended in a liminal, pre-
cancerous state. They were at-risk for cancer, but knew this risk might never 
materialize, particularly if they underwent interventions to remove the pre-cancerous 
cells. Patients talked about how difficult it was to prevent HPV infection and instead 
looked to contain HPV. HPV vaccine decision making among patients rested squarely 
on their experiences with cervical dysplasia. This being said, however, patients had a 
tempered view of the vaccine and its effectiveness given their medical histories. 
 
In chapter seven, the women’s narratives of three cohorts are tied together through an 
exploration of the conjunctures and disjuntures of their lived experiences of situated risk 
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and gender. This is where the central thesis of this dissertation is explained in full. 
There were indeed similarities among the cohorts – students and patients experienced 
widespread stigma for having contracted HPV infections. Mothers and students focused 
intensely on gender in the HPV vaccine debate and their vaccine decision making. All 
women had to mediate the “traffic” (Rapp 2000:185) between the at-risk gendered 
subject formation that HPV-related pharmaceutical and governmental discourses 
created and their own lived experiences of situated risk and gender. Women’s narratives 
indicated that the concepts of risk and gender were movable ontological modes of 
being. Narratives from all three cohorts demonstrated that in relation to women’s senses 
of self, risk and gender were elastic concepts. What sales/governance strategies tried to 
make concrete, women re-tooled by finding meanings in ways that governance 
strategies could not predict or control. Narratives also demonstrated that decisions 
regarding vaccination were ontologically driven. The identities women fashioned when 
re-ordering risk and gender were directly linked to vaccine uptake outcomes. 
 
In the conclusion (chapter eight), findings are reiterated in order to establish the 
theoretical and pragmatic contributions this research project makes to the discipline of 
medical anthropology. The greatest impact this research project has is its ethnographic 
exploration of situated risk and gender. As Lupton (1999a) and Moore (2010) have so 
eloquently established, there is little existing research that explores the impact of risk on 
women and their bodies in a critical fashion. Current risk-oriented research that features 
women, although unintentionally, reproduces this gender as an undifferentiated 
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grouping that requires intervention because of their “feminine” vulnerability. As such, 
gender norms are re-inscribed over and over in existing research. This research project, 
however, attempts to remediate this troubling trend by exploring the nuanced and 
layered fashion through which women negotiated risk and gender vis-à-vis the HPV 
vaccine. Women’s negotiations revealed complex on-the-ground re-ordering of gender 
and risk and the ontological basis for vaccine decision making.  Throughout these 
negotiations women were engaged in generative pauses – moments in which their 
identities were constantly being re-worked and re-fashioned. Thus, what 
sales/governance strategies tried to fix, women continually un-fixed. 
 
Before reading further, however, please be assured that the research and findings are not 
intended to evaluate scientific research and practices regarding HPV, the vaccine or 
cervical dysplasia interventions. Nor is this research project an attempt to judge women 
who are vaccinated against HPV. Instead, this is an endeavor to take a step back from a 
social science of medicine perspective, and analyze how sales/governance strategies 
organized women’s “individual realities” (Petryna 2002:119) and how women 
responded to this type of organization. I am very aware of the toll cancer takes on 
families as members of my immediate family have died of cancer, live with and are in 
remission from cancer. Throughout the fieldwork and the analysis of the resulting data, 
I have been ever mindful of individuals and families facing cancer; these experiences, 
while not an overt part of this research project, were nonetheless, never far from my 
consciousness.  
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CHAPTER TWO - The Introduction of the HPV Vaccine in 
Canada: Gender-Based Risk-Making     
 
Each culture has its own special risks and problems.  To which particular bodily margins 
its beliefs attribute power depends on what situation the body is mirroring. It seems that 
our deepest fears and desires take expression with a kind of witty aptness. To understand 
bodily pollution we should try to argue back from the known dangers of society to the 
known selection of bodily themes and try to recognize what appositeness is there. 
[Douglas 2002(1966):150] 
 
Introduction 
 
In this chapter, gender-based analyses (GBA) relating to the HPV vaccine are examined 
– whether it is gender-based pharmaceutical marketing approaches or governmental 
gender-based policy-making in Canada.  GBA have played a crucial role in constructing 
the girl/woman who is at-risk for cervical cancer.  This scripting harnesses hegemonic 
cultural logics concerning gender and risk, and functions as a sales/governance 
mechanism, which places girls/women in a pre-determined box removed from the sites 
of power.  In order to keep girls/women in this box, the HPV vaccine is positioned as a 
cancer fighting mechanism. This curious framing, which sidesteps HPV as a sexually 
transmitted infection, provides an expanded platform for sales/governance because 
cancer is culturally interpreted as far reaching, mysterious, fear inducing and multi-
causal.   It is important to emphasize that GBA related to the HPV vaccine treat the 
concept of gender as pertaining primarily to women. In this rendering, women are 
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translated into an undifferentiated and static grouping – a group of tangible subjects.   
The aim of this chapter is to provide a historical, economic and political 
contextualization to the subject formation of the HPV-related girl/woman-at-risk and to 
provide the requisite background needed to trace how women respond to this subject 
formation. 
 
A] The Governmental Roll Out of the HPV Vaccine 
 
Mass media accounts generally describe the introduction of the HPV vaccine to Canada 
as a swift development (Gordon 2009, Gulli et al. 2007, Picard 2007).  This is, however, 
not the case. In 2005, the Public Health Agency of Canada released a report entitled 
Canadian Human Papillomavirus Vaccine Priorities Workshop, (the workshop took 
place November 17-18 of that year).  The aim of this workshop was to “examine the 
current Canadian and international status of HPV vaccine research and develop national 
research priorities before the vaccines become approved for use in Canada” (Public 
Health Agency of Canada 2005:iii).  When referring to vaccines, the report referenced 
both Gardasil® and Cervarix®, but Gardasil® received approval in July of 2006 for 
girls/women whereas Cervarix® did not receive such approval until much later in 
February of 2010 (Notice of Decision for Gardasil®, Health Canada 2006; Picard 
2010). At the outset, the workshop report discusses HPV as being connected to multiple 
genders, but most of the document’s text positions HPV as a “woman’s issue.”  This is 
selective framing as HPV presents in women, men, intersex and transgendered 
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individuals and is linked to gender-specific and gender-blind cancers (Parkin and Bray 
2006).  Individuals with male sexual organs can develop penile cancer, and those with 
female genitalia can develop cervical, vaginal and vulvar cancers; any gender can 
develop oropharyngeal (throat) or anal cancer from HPV, as well as HPV-related genital 
warts and recurrent respiratory papillomatosis, which present as warts in the throat 
region (Centers for Disease Control and Prevention 2012). However, the Public Health 
Agency of Canada report emphasizes the utility of HPV vaccines in primarily 
preventing cervical cancer. 
 
Attendees of the November workshop included senior federal bureaucrats, scientists, 
researchers, physicians and numerous representatives from Merck Frosst and 
GlaxoSmithKline Biologics (PHAC Workshop Report 2005:28-30).  Thus, 
pharmaceutical companies were present “at-the-table,” even before Merck Frosst 
officially submitted its request for Health Canada approval of Gardasil® on December 
12, 2005.2   It could be argued that the presence of pharmaceutical companies at the 
governmental planning workshop is a conflict of interest, but their presence should not 
be surprising considering the current era of what the federal government calls “smart 
regulation” (Graham 2005:1469). Industry now plays a significant role in governmental 
regulation processes, from initial consultations regarding the introduction of a product 
to Canada to its regulatory approval and eventual roll out.  Smart regulation was 
introduced in March 2005 and aims to “restructure Canada’s regulatory policy . . . [to] 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Merck Frosst’s application was processed in seven months due to its application being 
given priority review status (Health Canada Summary of Basis Decision 2006). 
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streamline and speed up approval for new drugs, foods, biotechnology products, 
veterinary products and pesticides”  (Graham 2005:1469).   Smart regulation is geared, 
simultaneously, to expediting the integration of new business ventures into the 
Canadian marketplace and safeguarding the public interest through strong regulatory 
frameworks.  Graham is skeptical that the government is able to meet these dual 
priorities and posits that business interests generally trump those of public health 
(2005).  Within smart regulation frameworks, pharmaceutical companies pay user fees 
in order to have their drugs reviewed by Health Canada’s Therapeutics Product 
Directorate (TPD).  As Lexchin observes, “as funding for the operations of the TPD 
shifts from the government to the drug companies, a situation is created in which the 
drug companies could be perceived to be setting the priorities” (1999:173).  User fees 
are a “cost-recovery” measure.  For example, in 2004, 51 percent of TPD’s budget came 
from user fees; the remaining was sourced from government monies (Silversides 2010).  
It is not surprising that Gardasil® received expedited approval from the TPD given this 
regulatory climate.   
 
On February 15, 2007, the National Advisory Committee on Immunization (NACI) 
released a report on the HPV Vaccine. This was a crucial document in determining the 
roll out of the vaccine because NACI is charged with providing physician 
recommendations regarding who should be vaccinated and when, and how the vaccine 
should be administered. This document is exhaustive and references HPV infections in 
women and men, but primarily focuses on the linkage between HPV and cervical 
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cancer.  The NACI report was publicly released before the Health Canada Summary 
Basis of Decision on the vaccine was issued in March, 2007.  A Summary Basis of 
Decision document provides the approval for a pharmaceutical to be used in Canada 
whereas NACI is charged with recommending how a vaccine should be utilized.  Thus, 
the document providing the framework of how a vaccine should be administered was 
distributed before the vaccine was approved for use in Canada.  Interestingly, the 
Summary Basis of Decision mentions that boys from nine to 15 had been included in 
Gardasil® clinical trials, but that research was ongoing in boys and men from 16 to 26 
years of age (2007:17).   
 
On March 27, 2007 the Canadian Medical Association Journal (CMAJ) published a 
“thought piece” in its news section called Debate begins over public funding for HPV 
vaccine.  This is a balanced article that outlines the potential benefits of the vaccine and 
potential objections to a public inoculation campaign.3 CMAJ’s concerns center on the 
lack of long-term data on HPV vaccine immunity and the social uproar a publicly 
funded vaccination campaign for a sexually transmitted infection could cause. The piece 
also discusses vaccinating boys, but mentions that “publicly funded programs are not 
expected for several years” (Comeau 2007:913).  CMAJ could not have been more 
wrong. Soon after the NACI report was issued, the Conservative government 
announced, as part of its April 2007 annual budget, that $300 million would be funneled 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 This is a thoughtful piece given the amount of sensationalized writing surrounding the 
vaccine that has circulated in the last six years since the approval of the vaccine in 
Canada; see for example, a 2007 Maclean’s article entitled Our Girls are not Guinea 
Pigs by Gulli et al. 
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on a per capita basis to the provinces and territories “to help establish a national vaccine 
program that will help protect women and girls from cancer of the cervix” (April 16, 
2007, Department of Finance press release).  This press release positioned HPV and the 
HPV vaccine strictly as a women’s-only issue.4  
 
In early August 2007, the Ontario government followed suit and announced it would 
offer the HPV vaccine to grade eight girls free of charge in the public school system. In 
its official announcement, the provincial government proclaimed, “we’re providing this 
vaccine to women at a young age so we can help prevent the spread of HPV and save 
lives” (August 2, 2007 press release, Office of the Premier:1).  There is no mention in 
this release of HPV in connection with other genders or cancers, nor the part they play 
in the transmission of the virus.  The Province of Ontario followed the federal lead in 
promoting the vaccine for use on women/girls only and as a means to “save” them from 
cancer.  Premier Dalton McGuinty made the announcement in the lobby of Women’s 
College Hospital in Toronto, flanked by female physicians in lab coats. Little did I 
know at the time that I would conduct a portion of my hospital-based fieldwork at this  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 This press release did not mention the connection between Merck Frosst and the 
governing Conservatives.  A former staff member of the Prime Minister’s inner circle, 
Ken Boessenkool, worked for the lobbying firm Hill+Knowlton and had acquired Merck 
Frosst as a client.  Ken Boessenkool’s linkage to both Merck Frosst and the government of 
the day were heatedly discussed in House of Commons debates	  (Priddy, House of 
Commons Debates, 2007, April 17) and numerous mainstream media outlets (Gillespie 
2007, McGregor 2007, O’Malley 2007).  
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very hospital in 2010.5  The Government of Ontario’s public health program to provide 
vaccinations to grade eight girls in school settings is ongoing, although participation is 
tepid.   For example, 40 percent of grade eight girls in Toronto did not receive the 
vaccination when it was offered to them in grade eight and so in early September 2012 
Toronto Public Health announced that it would be delivering free vaccinations to 
teenage girls aged 14 to 19.  The Province of Ontario agreed to provide funding for the 
Toronto Public Health Program (Bradley 2012).  Interestingly, in April 2013, Prince 
Edward Island announced that it would fold boys into its existing grade-six vaccination 
program, which had previously been geared towards girls only.   Prince Edward Island 
positioned this policy development as a benevolent act towards women. The Deputy 
Chief Public Health Officer, Dr. Lamont Sweet, was quoted as saying, “boys can be the 
source of the virus for their female partners. By preventing boys from carrying the 
virus, you in turn will prevent girls from getting the virus which causes cervical cancer” 
(CBC News, April 19 2013:1). A few weeks later, the Province of Alberta announced 
that  it too was looking into offering the vaccine to boys alongside grade-five girls who 
were already offered the shot. According to The Canadian Press, Alberta Health was to 
investigate the proposal in depth during the summer of 2013 (Cotter 2013). 
 
It is crucial to mention that during the period of federal and Ontario provincial 
endorsements of the vaccine for use in girls and women, scientific literature on HPV, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 Fieldwork was conducted in collaboration with Sunnybrook Health Sciences Centre, 
but in the summer of 2010, the Sunnybrook Women and Babies program was housed at 
Women’s College Hospital during the building of a new wing on their home campus. 
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particularly epidemiological studies, was gender blind.  This literature, generally, 
focused on the linkage between HPV and male, female and multi-gendered cancers (see 
Munoz et al. 2006; Parkin and Bray 2006). Dr. Harold Zur Hausen, the Nobel Prize 
winner who discovered the link between HPV and cervical cancer, publicly questioned 
in 2008 (and he continues to question) the gendering of HPV-related vaccines and 
suggested boys should also be inoculated, as is public health policy in Austria 
(Zechmeister et al. 2010).  In Canada in 2006, Dr. Gail Beck, then president of the 
Federation of Medical Women of Canada advocated for public, subsidized HPV 
vaccination campaigns to be available to both girls and boys. During a presentation to 
the federal Standing Committee on Finance in Ottawa on the HPV vaccine, she argued, 
“I would caution us to address this infection as one that is important to both men and 
women, thus the need to include both in any strategy. Clearly we need a national 
strategy that is informed by our diversity” (Standing Committee on Finance 
Proceedings, September 19, 2006:11).6  In 2012 the Federation of Medical Women of 
Canada again made a call to “de-gender” (Paoletti 1997:27-35) the HPV vaccine; the 
current Federation president, Dr. Vivian Brown, was quoted by The Canadian Press as 
stating that, “both sexes contribute to the transmission of HPV. Both sexes are at risk of 
developing a variety of HPV-related diseases – including cancer. So it follows that both 
sexes should be protected. But currently, that’s not the case” (Branswell 2012:1).  The 
point here is that science/medicine did not gender HPV and the vaccine. This was a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 It is disconcerting that public health issues are debated within the context of a federal 
Standing Committee on Finance and not within a health forum. This points to the 
increased corporatization of health policy. 
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governmental rendering; federal and provincial governments devised and carried out 
gendered policy, which was based on Merck Frosst’s marketing lead. 
 
Figure 1: HPV Vaccine Policy Timeline in Canada 
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B] Harnessing Hegemonic Cultural Discourses of Risk and Gender 
 
1. Merck Frosst’s Gender-Based Marketing 
 
Why is there an emphasis on vaccinating women in policy documents? In other words, 
why is HPV so clearly gendered in public health programming? The answers to these 
questions lie in the roll out strategy for the vaccine developed by Merck Frosst, that 
leads public health policy-making in an environment where there is little existing 
research on the prevalence, awareness, knowledge of or beliefs about HPV in Canada.  
In 2007, the magazine Pharmaceutical Executive awarded Merck Frosst its first “brand 
of the year” award for the Gardasil® campaign. The Gardasil® roll out strategy was 
three-pronged: first, to release the vaccine for nine- to 26-year-old girls and women; 
second, to focus on women aged 26 to 45; and, third, to make it available to boys and 
men (Herskovits 2007:70).  Each phase of the strategy hinged upon gender-based 
analyses – gender cohorts were researched exhaustively and made the target of each 
section of the marketing campaign.7  Merck Frosst’s marketing campaign hinged on the 
gendering of HPV and positioning Gardasil® as a cancer fighting mechanism for 
women, side stepping the issue of sexual health and related cancers in other genders.   
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  This is a common tactic in current marketing sciences and is called “segmented 
marketing” (Sheth et al. 2000).  
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Pharmaceutical Executive describes the marketing campaign as “play[ing] on cancer 
fears, but [drawing] on themes of safeguarding your children (for moms) and 
empowerment (for girls)” (Herskovits 2007:68).  Merck Frosst conceived of and 
delivered a two-part advertising campaign. The first part, “Make the Connection,” 
appeared prior to the approval of the vaccine and was intended to increase awareness of 
HPV.  The second phase, post-approval, was a branding effort called “Tell Someone”.  
It was intended to, “tap into ‘women’s natural inclination’ as talkers and sharers” 
according to the Merck Frosst vice-president assigned the Gardasil® portfolio 
(Herskovits 2007: 68). The “Tell Someone” campaign evolved into the two types of 
Gardasil® advertisements that are circulating in Canada today: those targeting young 
women of university age (through television, magazines, large banners at university 
student centers, university sponsored day planners and posters in university washroom 
stalls); and those targeting the mothers of girls near the grade eight vaccination age and 
the girls themselves (through television and women’s magazines). The “mom” 
campaign works to specifically support Ontario’s official in-school HPV vaccination 
program.8  (See figures 2 and 3 for marketing examples of both campaigns.)
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  As the Ontario government rolled out the school-based vaccination campaign, it did not 
initiate a public information campaign concerning HPV or the vaccine.  Merck Frosst 
marketing campaigns filled that gap.  
 
	   28	  
 
	   29	  
	  
Figure 2 - “Make the Connection” Pamphlet/Advertorial 
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Figure 3 – “Tell Someone” Campaign Commercial  
	  
The television advertisement featured in figure 3 is transcribed below. 
 
Woman 1 (Latino-looking woman in late 30s or early 40s): Well, it’s a cancer caused 
by a virus. I mean, I can’t get over that. I want to tell anyone. 
 
Woman 2 (Latino-looking woman, university age): I just found out cervical cancer is 
caused by certain types of a common virus. Cancer caused by a virus: HPV. The Human 
Papillomavirus. I didn’t know that. 
 
Woman 3 (Light-skinned woman of Afro-Caribbean descent, mid-30s): I was stunned at 
how many people have HPV. I’m stunned. Millions, millions – that’s insane. 
 
Woman 4 (White physician, mid-40s, wearing white lab coat with stethoscope around 
neck): For most women HPV clears on its own, but for some cervical cancer can 
develop. 
 
Woman 5 (Light-skinned woman of Afro-Caribbean descent with a “tween”-aged 
daughter): Voice over says the following – That’s why it’s important to talk to your 
doctor about Pap tests.  
 
Woman and daughter do not speak during this shot. At bottom of screen the following 
text appears: Tell-someone.com 877-NOW-TELL. 
 
Woman 6 (White, mid-30s): I feel like it’s my responsibility just to tell everyone I know. 
 
Woman 7 (Latino-looking, mid-30s): I just want to tell someone I love. I want to tell my 
sister. I want to tell my mom. I want to tell everyone I know. 
 
Woman 8 (same woman as #7, but wearing different clothes): Tell Someone. 
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Woman is wearing a t-shirt with Tell Someone on the front. The advertisement ends 
with this image. 
 
 
2. Sales/Governance Strategies 
 
 
How can a pharmaceutical branding campaign gender a virus and subsequent public 
health programming? It is not simply that the multi-national pharmaceutical corporation 
with the most dollars or persuasive lobbyists triumphs.  Rather, the situation is more 
complex – economic power is embedded in, and not above, social, cultural and 
historical processes (Morrison 1995:320).  In this specific case, Merck Frosst 
strategically harnessed western hegemonic cultural logics and discourses surrounding 
risk and gender in order to develop marketing campaigns to sell its vaccine.  This was a 
two-part process which involved: (1) circulating HPV-related information that 
leveraged cultural logics surrounding risk and gender in order to brand HPV as a 
woman-only concern and (2) arranging consumer buy-in through self-regulation. The 
first step was to disseminate HPV-related “expert knowledge” (Foucault 1989:52).  As 
publicly available government information on the vaccine was limited, Merck Frosst 
readily filled that void.  Merck Frosst used the advertorial, “Make the Connection”, 
(figure 2) to inform women about HPV. It contains information on cervical cancer, what 
HPV is and the many different HPV strains. This information is supported by statistics 
of the global incidence of cervical cancer, an anatomical drawing of a woman’s 
reproductive system and endorsements provided by leaders in the field of women’s 
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health in the United States.  While this is a paid advertisement, it reads and looks as 
though it is a medical information brochure.   
 
Figure 3 provides a transcript and two still shots of a television advertisement for the 
“Tell Someone” component of the Gardasil® marketing campaign.  This advertisement, 
like the “Make the Connection” advertorial, also aims to inform women about HPV, 
particularly the trajectory of the virus, whether it “clears on its own” or turns into 
cervical cancer. Both examples of Gardasil® marketing urge women to take an active 
role in preventing HPV.  The “Make the Connection” advertorial states: “It’s your 
health, it’s your life. So take control.”  Taking control in the advertorial involves 
visiting a physician to regularly undergo a Pap test.  Taking control in the “Tell 
Someone” commercial involves spreading the word about HPV – telling the women you 
know about it and speaking to a physician about Pap testing.  It is important to note that 
these two advertisements were developed and released prior to the approval of 
Gardasil® by the Food and Drug Administration (FDA) in the United States. Because of 
this Merck Frosst was not able to mention the Gardasil® vaccine by name in its 
advertisements.  The next wave of Gardasil® advertising, post-FDA approval, is 
discussed in chapters four and five. Chapter Four features a Gardasil® “mom” 
advertisement (figure 5), which depicts a mother and a daughter, and urges the mother 
to talk to her doctor about her daughter’s vaccination.  Chapter Five includes a post-
approval Gardasil® advertisement aimed at female university students (figure 7). This 
advertisement encourages female students to visit their campus health clinics to get 
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vaccinated.  The knowledge of HPV provided in the pre-approval advertisements and 
the push to get women vaccinated in the post-approval advertisements work together to 
scare women about HPV and to create a “need” for inoculation against HPV.  
 
The second step involved getting consumer buy-in, literally. Merck Frosst created such 
a need for the vaccine in its multiple advertising campaigns that consumers asked their 
doctors for it.  This is a common tactic of pharmaceutical companies and is called 
direct-to-consumer advertising (Mintzes 2010).  This tactic is essentially 
pharmaceutically directed self-regulation.  As such, Gardasil® sales tactics also 
function as governance strategies.  Such a governance approach works to deploy “a 
mode of power par excellence designed to produce a market-based notion of agency and 
subjectivity” (Giroux 2010:30).  To critique this governance strategy, I am employing 
Foucault’s concept of governmentality (1991). The governmentality approach to risk 
focuses on how governments “work together to govern – that is, manage and regulate – 
populations via risk discourses and strategies” (Lupton, 1999a: 1).9  Governmentality is 
not necessarily about governmental institutions, though. Instead it is about their ability 
through “persuasion” to get those they are governing to enact their policies and 
directives (Giroux 2010:51-52).  Within the current, contemporary climate of  “new”10 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 At the beginning of Chapter Three the rationale for utilizing a governmentality 
approach to risk in the analysis of the archival portion of the research project will be 
explained.   
10 Nettleton (1996) calls this the “rise of a psycho-socio-environmental/epidemiological 
model” (34), which has replaced the biomedical approach.  This shift results in moving 
away from treating disease to preventing disease. Prevention policy, which is delivered 
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public health that emphasizes neo-liberal devolution of governmental responsibility 
(Lupton and Petersen 1996), governing approaches focus more and more on “the art of 
self-government, connected with morality” (Foucault, 1991:91).  As such, preventative 
strategies, or “technologies of power” (Foucault, 1999:14), center on the promotion of 
self-regulation, which works to attain and maintain an idealized form of self (Turner 
1997).  Contemporary health discourse focuses on a version of the self “that is 
autonomous, subjective and active” (Nettleton 1997:209).  In other words, it is up to you 
to ensure that you meet the standards of health and to manage any potential health risks.  
Thus, if a person falls sick, it is due to their lack of self-restraint.  Idealized 
conceptualizations of the self are then steeped in the notions of self-discipline and the 
ability to continually reinforce an identity that promotes one’s health.  
 
All individuals are expected to be “active citizens,” whether or not they are actually part 
of  “targeted populations” (Dean 1997:147), albeit, the lines between those who are 
targeted and those who are not are porous – all can be at-risk at anytime. This is part 
and parcel of the “colonization of the future” (Giddens 1991:117, 182) whereby risk has 
become a foundational tenet of governance strategies. As such, “it seems that we are no 
longer simply concerned with the governance of risk but we are now in an era of 
governance by risk” (Rothstein 2006:216, emphasis in the original).  Governance 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
via health promotion strategies, is predicated upon the tenets of “’risk’, ‘surveillance’, 
and the ‘rational self’” (Nettleton 1996:34). 
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through pre-detection, or creating what Rose11 calls “pre-patients” (2007:20) opens up 
increasingly fertile ground for surveillance (Castel 1991:288).  
 
The expansive surveillance mandate of the new public health functions by “mainly 
incorporate[ing] voluntary actions on the part of citizens but also [by] us[ing] 
legislation, much of which is enshrined in public health acts” (Lupton and Petersen 
1996:5).   As is seen with the Gardasil® campaigns, women are urged to accept greater 
responsibility for their health through direct-to-consumer advertising. But Gardasil® 
sales are also ensured because of the Ontario province-wide grade eight public school 
vaccination program for girls.  As the Province of Ontario did not initiate a public 
information campaign alongside the grade eight programming, Merck Frosst’s multi-
pronged Gardasil® advertising campaigns worked to ensure that a need for the vaccine 
was maintained.  In the case of Gardasil®, the responsibility for the health of the 
population was no longer entirely under the purview of the state.  While the 
responsibility for keeping risk at bay is that of the individuals, what is deemed to be a 
risk is established through the joint workings of the pharmaceutical company and 
policy-making processes.  Together they create a guaranteed market for the sale of the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 In his work on risk and governmentality, Rose puts forth the notion of biological 
citizenship (Rose and Novas 2002). In biological citizenship, governmentality is linked 
to governance via the body (Rose and Novas 2002:2). Biological citizenship follows the 
dominant trend in risk theory literature as it does not critically address gender. As is 
discussed in Chapter Seven, “situated risk” (Boholm 2003:158) provides more fertile 
ground through which to pursue risk and gender in tandem. Moreover, Giroux posits that 
in the current neo-liberal landscape, individuals are organized not “as citizens but as 
consumers” (2010:2).   
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product.  This would not happen, however, if prevailing cultural logics did not support 
the notion of women being perpetually at-risk. 
 
3. Deploying Gender as Risk 
 
In the case of the HPV vaccine being a certain gender puts one at risk.  As a girl/woman 
being female positions you as needing particular protection from cancer stemming from 
HPV, yet this not deemed necessary for men.  Douglas asserts that “arguments about 
risk are highly charged, morally and politically” (2002[1966]: xix).  As such, the 
attribution of being at-risk for potential illness encourages moral governance through 
the framing and fixing of difference.  This morality is used to keep those who threaten 
the social order – or the equilibrium of those in power – safely within their pre-
determined “box” (Douglas 2002[1966]:125, 172).12 When in a box, those at-risk can be 
contained and governed.  When placed within the box, one has to follow the rules or 
norms.  The norm “is not simply and not even a principle of intelligibility; it is an 
element on the basis of which a certain exercise of power is founded and legitimized . . . 
Perhaps we could say it is a political concept” (Foucault 1999:50).13 Thus, this at-risk 
categorization reflects not only women’s subordinate status in western society, but also 
works to maintain this subordination.  The cultural messaging surrounding the HPV 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12 Douglas refers to “Chinese-box-like” structures, where boxes fit within boxes, each 
indicating the multiple layers of derivative structures sitting within the overall structure, 
or the main box, a metaphor for society as a whole (2002[1966]:125). 
13 Foucault is drawing upon Canguilhem’s (1989) work on the normal versus abnormal in 
this discussion. 
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vaccine, both in the pharmaceutical marketing campaigns and the Ontario government 
policy of subsidizing in-school vaccination for girls only, works to keep women and 
girls firmly in their at-risk box. This is a governance strategy to keep women in their 
place in the social hierarchy – it does not relegate them to the margins, but keeps them 
firmly tucked away from spheres of influence. 
 
There is, of course, a long history of keeping women in their place through being 
labeled at-risk.  In medicine, as in society, women have been portrayed as “especially 
threatening to the moral order and social stability of society, largely due to the 
seemingly uncontrollable and dangerous nature of their sexuality” (Lupton 2003:143). 
Douglas elaborates further: 
 
Such patterns of sexual danger can be seen to express symmetry or hierarchy. It 
is implausible to interpret them as expressing something about the actual relation 
of the sexes. I suggest that many ideals about sexual dangers are better 
interpreted as symbols of relation between parts of society, as mirroring designs 
of hierarchy or symmetry, which apply in the larger social system. 
[2002(1966):4] 
 
In other words, positioning women as sexually threatening is not reflective of gender 
relations – those between men and women within a heterosexual framework – but of 
society’s tendency to classify and find a place for everyone so as to not disturb existing 
power structures. Correspondingly, for several hundred years, women have been 
positioned as the “other” in medicine, unwell and inferior to men (Lupton 2003:143).  
Women have been, and continue to be, portrayed as faint-hearted, prone to disease, the 
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vessels for spreading sexually transmitted infections and the cause of emotional turmoil 
for their children. Medicine has woven the tale that women are tautologically passive 
receptors of disease and active, deleterious agents of disease (Lupton 2003:143).  
Women are represented as such in medical textbooks. For example, Martin (2007) 
reports that medical texts depict male and female reproductive organs as “systems of 
production,” but frame male organic matter in an active and positive light, all the while 
depicting female organic matter in disparaging terms (417). Sperm is generally 
described as being “produced,” whereas, “ova merely sit on the shelf, slowly 
degenerating and aging like overstocked inventory” (Martin 2007:418).  Sperm is also 
depicted as “penetrating the egg” through “mechanical and chemical means” after the 
egg has “drifted along the fallopian tube” (Martin 2007:420-421).  Martin finds that 
such imagery haunts historical and contemporary re-presentations, even when research 
has detected new patterns of reproduction.  For example, in spite of the discovery by 
John Hopkins scientists that the sperm and egg adhere similarly to positive and negative 
strips of Velcro, the process is still described using the old imagery. Martin explains: 
 
Although this new version of the saga of the egg and the sperm broke through 
cultural expectations, the researchers who made the discovery continued to write 
papers and abstracts as if the sperm were the active party who attacks, binds, 
penetrates, and enters the egg. The only difference was that the sperm were now 
seen as performing these actions weakly. [2007:421]  
 
Likewise, Lawrence and Bendixen (1992) note that medical textbooks, from the late 
1890s to the late 1980s, depict male and female forms in a similar manner.  Anatomical 
imagery and accompanying text place a primacy on male bodies by using these bodies 
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as the ideal benchmark and then describe female bodies through the ways they differ 
from the male “standard.”  These cultural conceptualizations also translate into medical 
practice. Gynecology, as a medical specialty, holds no equivalent area of research or 
service for men even though they possess their own specific set of genitalia.  As such, 
female genitalia are classified as risky and are subjected to surveillance throughout a 
women’s lifecycle.  Hanson notes that other potential cancer sites, such as the “liver, 
pancreas, lymph glands, lung, kidney, or other less accessible organs” are not accorded 
the same surveillance (2000:60). Correspondingly, women are routinely screened for 
breast and cervical cancer due to their unique at-risk status and because these areas are 
simple to reach (Kaufert 2000). Hanson notes, “this opens up the possibility that 
genitalia focus in cancer may be as much a case of what is routinely screened rather 
than what is ultimately most dangerous” (2000:60).  That being said, gynecology 
continues be a way in which medicine constructs risk in women which cannot be 
construed in men.  Gynecology keeps women “visible”(Foucault 1989:111) in medicine 
and continual “subjects” of surveillance and control (Lupton 2003:161).  
 
Thus, the sexually active, “feminine” body (Bartky 1990) was (and is) viewed as 
needing to be monitored and sheltered from harm.   Protecting oneself is not thought to 
come “naturally” for the “weaker”, second sex.14  But making genitalia and sexual 
activity visible is also a long-standing governance technique.  Foucault notes that 
instead of “repressing” the subject of sex, modern power structures amplify it 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14 This is a not very subtle reference to de Beauvoir’s well-known tome (1989[1952]).  
	   40	  
(1990[1978]:72).  He urges readers to look at how power functions in “positive 
mechanisms, insofar as they produce knowledge, multiply discourse, induce pleasure, 
and generate power” (1990[1978]:73).  It is through promoting discussion about sex, 
sexuality and gender that power structures are able to make women visible and 
simultaneously keep them within the box Douglas speaks of (2002[1966]). But with the 
case of the HPV vaccine, early research based in the United States indicates that parents 
are not likely to vaccinate their daughters if they feel that the vaccine promotes 
adolescent sexuality (Constantine et al. 2007; Dekker 2006; Olshen et al. 2005).  In 
some studies parents even described the vaccine as a means of promoting and 
encouraging adolescent sexuality, a concept they were clearly uncomfortable with.  
Given this research, Merck Frosst did not harness tried and true methods of highlighting 
women’s sexual risk or risks relating to sexuality, that is, focusing upon HPV as an STI.  
Instead, Merck Frosst chose to frame HPV solely as a cancer-causing virus – one that 
specifically causes cervical cancer – and sidestepped the fact that HPV is transmitted 
through sexual contact, including genital touching (Burchell et al. 2011,Vanslyke et al. 
2008).  Merck Frosst was well aware that positioning the HPV vaccine as a tool to fight 
STI in girls/women was not a smart marketing move; in this case, sex would not sell.15  
Instead, Merck Frosst developed a strategy to sell the vaccine by playing upon cultural 
notions of the “female” who needs to be protected from cancer.  Mixing the cultural 
notions of the “weaker” sex that must be protected and cancer as a frightening, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
15 Sex, of course, was meant to sell when Merck Frosst introduced an advertising 
campaign for the use of the vaccine in young men in 2012. This campaign positioned 
Gardasil® as a genital wart fighter for its male customers (Merck Frosst 2011a). 
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mysterious and omnipresent illness16 (Sontag 1999) was the perfect marketing 
prescription.  In Merck Frosst’s marketing of the HPV vaccine, cancer kept girls/women 
visible but sex invisible.  Even though this tactic differs slightly from Foucault’s 
summation of visibility and sexual relations, the power technique employed reflects 
Foucault’s ideas.  It is also interesting to note that Merck Frosst focused on cervical 
cancer and not vaginal, vulvar, anal or throat cancer in women.  This is because cervical 
cancer is an easier cultural sell than the other cancers associated with HPV.  
 
As will be discussed below, the main tenets of Merck Frosst’s marketing campaign – 
the gendering of the vaccine and its positioning as a cancer panacea – spilled over into 
Canadian public health policy making.  Some may call this the “pharmaceuticalization 
of public health” (Biehl 2007:222), but it can be argued that this is really a case of the 
replication of hegemonic conceptualizations of gender and risk in policy making. Merck 
Frosst was the first to deploy these governance techniques as a selling mechanism, but if 
these conceptualizations were not in the ether, they would not have been picked up 
again in policy making.  The policy sphere, as with all other facets of daily life, is rife 
with the circulating, yet static, cultural “ideals” of gender and risk.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16 I am not stating that cancer is not a terrible illness for those who suffer from it. Rather, 
I am pointing to a very specific set of western cultural notions and logics about cancer 
that are emotionally charged and that Merck Frosst leveraged in the selling of its vaccine: 
cancer is feared, not widely understood, most individuals know or know of someone who 
has suffered from cancer and this is a disease all parents wish to protect their children 
from.  
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4. Gender-Based Analyses (GBA) in Policy Making 
 
Policy documents indicate that government officials at the federal level17 examined the 
issue of the HPV vaccine within a GBA frame (Greaves 2009; Health Canada 2000, 
2003a, 2003b; House of Commons 2005; Status of Women Canada 2004; Tudiver 
2009). GBA is a policy development approach that the federal government has been 
using since the mid-1990s. The federal government first committed itself to using GBA 
in 1995 in conjunction with the 4th World Conference on Women held in Beijing.  That 
same year the federal government released The Federal Plan for Gender Equality 
(1995), a cornerstone document mapping the federal government’s blueprint for GBA 
implementation.18 In 1999, Health Canada specifically committed itself to using GBA 
while developing policy and programs.  In 2003 Health Canada implemented a five-year 
plan to ensure that GBA would be in “full-effect” across departmental initiatives 
(Health Canada 2003a:2). The goal of implementing GBA is to bring about gender 
equality in government programming and, hence, to the country as a whole (Hankivsky 
2012).  As the name indicates, GBA places a primacy on “gender as an essential 
variable in policy analysis” (Hankivsky 2012:172).  Thus, gender is the pivotal axis 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
17 While theoretically health is under provincial jurisdiction in Canada, the drive to bring 
the HPV vaccine to Canada occurred at the federal level. Not only is the federal 
government charged with approving pharmaceutical products, it is also responsible for 
allocating the initial $300 million for transfer to the provinces on a per capita basis to get 
the vaccination programs started. 
18 The critique of GBA featured here is meant to apply only to the case study of the HPV 
vaccine in Canada. GBA is a framework used in many disciplines, such as development 
studies, and research regarding the vaccine is not intended to speak for the 
conceptualization or implementation of GBA in other circumstances.  
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through which policy is analyzed and programs are developed, regardless of their aims 
or orientation.  Health Canada defines GBA as: 
 
An analytical tool that systematically integrates a gender perspective into the 
development of policies, programs and legislation, as well as planning and 
decision-making processes. It helps to identify and clarify the difference 
between women and men, boys and girls, and demonstrates how these 
differences affect health status, access to, and interaction with, the health care 
system. [Health Canada 2003a:1] 
 
Health Canada also describes GBA as, “a catalyst for change” by ensuring that a 
“gender equality perspective” is folded into the development of health policy (2003b:1). 
Health Canada also uses GBA “to promote sound scientific research, and provide 
relevant health information and evidence” (2003b:1).  Accordingly, the framework has 
been adopted in women’s health research conducted at Canadian universities and non-
profit, health-oriented organizations (Abramson 2009; Jackson et al. 2009; O’Sullivan 
and Amaratunga 2009). Such studies have examined topics as far reaching as wait times 
for surgery, diagnostic tests and communicable disease outbreaks.  
 
Within health research and program design, GBA is a tool that amplifies the difference 
between men and women and puts in place “a semblance of order,” where, on the 
ground, difference is often difficult to demarcate (Douglas 2002 [1966]:5). Such a move 
works to “impose system on an inherently untidy experience” (Douglas 2002 [1966]:5). 
Therefore, conceptually, GBA in health research and program design pits men against 
women, views them as undifferentiated “wholes” and places a primacy on the effects of 
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gender on health. Hankivsky (2012) argues that much debate has taken place over the 
adoption and application of GBA in health research and program design, but not much 
discussion has been focused on the underlying theoretical tenets of the framework. 
Hankivsky critiques GBA in health research and program design for its conceptual 
treatment of gender.  In practice, the reference to gender within prevailing health-
oriented GBA frameworks generally refers to women and not men.  This pragmatic 
application of GBA is evident in the December 2007 Canadian Immunization 
Committee (CIC) report on the HPV vaccine. This CIC report focused on cost-effective 
analyses of the vaccine, a common policy exercise that is often an analytical subset of a 
GBA.  The cost-effectiveness model aims to develop policy that reaches the widest 
audience possible with “tangible” health benefits, all the while containing costs 
(Hankivsky 2007a).  Vaccination programs tend to fare well in this type of analysis 
because the outcomes are simple to measure – the number of individuals vaccinated can 
easily be tallied.  The first cost-effective analysis in the CIC report focuses on females 
only, although the report does cite many studies in the bibliography on HPV that 
include both females and males (2007).  The authors chose not to bring this data into 
their analysis, thereby invoking gendering from the very beginning of the policy-
making process. The second cost-effectiveness analysis in the CIC report includes boys, 
but no mention is made of potential HPV-related cancer rates in boys. In this analysis 
the HPV vaccine is presented as an “altruistic” (Epstein 2010:75) vaccine and HPV as a 
“woman’s issue”– boys should be vaccinated to help eradicate cervical cancer in 
women.   A third cost-effectiveness analysis document has also been circulating, but 
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was prepared by a consulting firm for the Public Health Agency of Canada (Krueger 
2008). This report was not presented as a Public Health Agency of Canada document, 
but nevertheless was funded by the Agency.  This report also examines the cost-
effectiveness of vaccinating girls and the eventual influences upon cervical cancer 
mortality rates.  It concludes that there is no evidence to suggest that vaccinating boys 
will significantly reduce cervical cancer mortality (Krueger 2008:32). Therefore, in 
these GBA modeling exercises, the ideal of “gender equality” translates into positioning 
women as needing much more assistance than their male counterparts, with women 
occupying a homogenous and static contingent of society, whose very essence – gender 
– puts them at risk.  In this sense, HPV vaccine-related policy processes have reinforced 
circulating gender norms, as many health policies do (Moore 2010). 
 
In addition to a lack of focus on both women and men, cost-effectiveness analyses do 
not invoke any form of “diversity analysis” (Hankivsky 2007b:156) as it plays out 
within a gender grouping.  For example, how does a woman’s age, marital status, 
religion, geographic location or income level affect her ability to take advantage of a 
specific program?  As a case in point, women who do not have access to regular Pap 
screenings, such as Aboriginal, racialized, immigrant, homeless and other marginalized 
girls and women, are more susceptible to developing cervical cancer and make up a 
large portion of the approximately 400 cervical cancer deaths in Canada each year 
(CWHN 2007). The issues these marginalized women face are not addressed in current 
HPV-related policy in Canada or Ontario.  Thus, the concept of “female” that is plugged 
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into HPV vaccine-oriented GBA frameworks insinuates that all women will encounter 
health related challenges and barriers, regardless of class, race, age, educational, 
religious or geographical standing.  GBA relies upon the “assumption – either made 
implicitly or explicitly – that gender is the most frequent[ly] occurring, structural and 
important inequality for consideration” (Hankivsky 2012:174).   
 
It is only fair to mention, though, that early GBA documentation does make reference to 
“diversity” among women. For example, The Federal Plan for Gender Equality (1995) 
states that: 
 
A gender-based approach ensures that the development, analysis and 
implementation of legislation and policies are undertaken with an appreciation 
of gender differences. This includes an understanding of the nature of 
relationships between men and women, and the different social realities, life 
expectations and economic circumstances facing women and men. It also 
acknowledges that some women may be disadvantaged even further because of 
their race, colour, sexual orientation, socio-economic position, region, ability 
level or age. A gender-based analysis respects and appreciates diversity. [19] 
 
This perspective, unfortunately, has not been applied in the HPV vaccine example.  
 
HPV vaccine-oriented GBA offer a one-dimensional treatment of gender – or, more 
appropriately women – which harkens back to standard second wave feminist fare when 
scholars focused on the wide-sweeping subordination of women (Ortner 1974; Rosaldo 
1974). While seeking to understand “why sexual asymmetry [is] a universal fact of 
human societies” (Rosaldo 1974:22), academics developed totalizing theories to address 
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this polemic. Rosaldo posited that women’s oppression stemmed from the positive 
cultural values associated with men’s activities in the public sphere of business and 
politics which were then contrasted with the negative cultural values associated with 
women’s activities in the private sphere of the home (1974:41).  Ortner also drew on 
cultural associations of gender to account for the subjugation of women.  Ortner argued 
rather persuasively, that women’s inferior status was linked to her association with 
nature (mothering, breastfeeding, nurturing, and so on), whereas men were seen as 
belonging to culture (higher office, business, politics and general spheres of influence, 
and so on)(1974). Ortner’s schema is particularly relevant to one of Merck Frosst’s 
HPV vaccine advertising campaigns, which is directed at mothers.  They are told in the 
advertisements that it is their specific duty to protect their daughters by getting them 
vaccinated (this campaign and mothers’ reactions to it are covered in more detail in 
Chapter Four).   Rosaldo’s and Ortner’s theories still have saliency today for these 
gendered cultural associations continue to circulate in medical, pharmaceutical and 
governmental discourses.  But their totalizing of women is problematic. Not all women 
face subjection in the same way, one’s class, age, education, geographic location, race, 
ethnicity and religion also play a part, as has been explored more exhaustively in more 
recent feminist anthropology (see Abu-Lughod 2008[1993]; di Leonardo 1998; 
Scheper-Hughes 1999; Tsing 1993; Visweswaran 1994). This scholarship, which 
coincides with third-wave feminism, focuses on the intersection of race, class, 
marginality and gender around the globe. However, as Visweswaran states, “it is not 
enough to consider race, class, and sexuality as additive categories to a central concept” 
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(1994:75),19 the central concept being, of course, gender.  All aspects of 
intersectionality need to be given due consideration. GBA’s epistemological focus, 
which appears to be stuck in a previous analytical era, explains why Aboriginal groups 
such as the Native Women’s Association of Canada have been particularly displeased 
with GBA. In a 2007 report, the Native Women’s Association of Canada declared, 
“Canada and others who have applied a GBA have failed to do so in a way that is 
sensitive to the multiple needs of Aboriginal women, who suffer not only from 
gendered discrimination, but racism and other forms of oppression. For example, 
Aboriginal two-spirited women also suffer from discrimination based on their sexual 
orientation and women with disabilities also must deal with discrimination based on 
disability” (6). The federal government’s GBA approach to the HPV vaccine deploys a 
distilled and vexing conception of gender.  While the federal government’s motivations 
may be more benign than that of Merck Frosst’s – it is not trying to sell vaccines – GBA 
is tasked with addressing a universal health disadvantage that women, as a homogenous 
group, will experience. Thus, all women are at-risk all of the time.  
 
Might we better serve women’s health by taking a step back and re-conceiving how the 
concept of gender is deployed in governmental policy and, as a result, how risk is 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
19 In May 2013, the federal government announced it would be instituting an improved 
GBA framework called “GBA+”.  Status of Women Canada explained that “the ‘plus’ in 
the name highlights that gender-based analysis goes beyond gender, and includes the 
examination of a range of other intersecting identity factors (such as age, education, 
language, geography, culture and income)” (2013:1). While it is too soon to evaluate this 
initiative, the name and premise calls for pause – it sounds similar to what Visweswaran 
warned against: keeping gender as the primary axis of analysis while adding on other 
positionality factors for consideration. 
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attributed?  Weed and Butler (2011) urge just this. In reference to the invocation of 
GBA by international non-governmental bodies, such as United Nations agencies, Weed 
and Butler insist that: 
 
[G]ender is formed in relation to other social and political modes of social 
organization and is itself actively producing and reproducing such modes, 
including the family, labor, class, slavery, imperialism, immigration politics, and 
the state, to name a few . . . . Since gender is not an isolated factor or element on 
such a map, but is itself mobilized in a constitutive and productive relation to 
those other modes of organizing political life, the only way to gauge its 
usefulness is by tracking those effects. [2011:4-5]   
 
In this quotation, Weed and Butler attempt to establish gender as a wide-open concept, 
not one that is entirely pre-determined.  To further explain, one must acknowledge that 
gender “is a practice of improvisation within a scene of constraint. . . . The terms that 
make up one’s gender are, from the start, outside oneself in a sociality that has no single 
author (and that radically contests the notion of authorship itself)” (Butler 2004:1).  The 
constraint that Butler speaks about is demonstrated by the fact that policy – as well as 
pharmaceutical marketing campaigns – scripts subject formation20. Petryna also notes 
that policy orders an individual’s identity or sense of self and influences how this 
identity is communicated, interrogated and absorbed into daily life (2002). In the case of 
the HPV vaccine policy and pharmaceutical marketing strategies, the at-risk girl/woman 
comes into being. The at-risk girl/woman is firmly put in a Douglas-described box in 
order to maintain societal order – in short, the gender asymmetrical status quo.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
20 Giroux (2010) argues that neoliberalism is “also a political project, intent on producing 
new forms of subjectivity and sanctioning particular modes of conduct” (7-8). Merck 
Frosst’s campaign brings this point into relief. 
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Conclusion 
 
The purpose of this chapter is to provide a historical, economic and political account of 
how the HPV vaccine was introduced in Canada.  The chapter charted how, through 
descriptions of the sales/governance strategies employed, Merck Frosst and the federal 
government set the stage for the Province of Ontario to take up a gendered public health 
program which offered the HPV vaccine to grade eight girls free of charge.  This public 
health programming hinged on the notion of the HPV-related at-risk girl/woman.  As a 
result of this circulating and gendered at-risk rendering, HPV-related subject formations 
were created.  It is the objective of this research project to assess how this subject 
formation has been turned into everyday “subjectivities” (Biehl et al. 2007).  In other 
words, how do women mediate, hybridize and reject the at-risk categorization they are 
subjected to? How do they respond to such one dimensional, static and totalizing 
renditions of gender – or, more succinctly, scripts of being a woman – that are 
entrenched in risk discourses?  As the next chapter outlines, I interviewed mothers who 
had daughters at or near the school-based vaccination age of grade eight.  But as 
fieldwork progressed I discovered that official HPV vaccine policy had seeped into 
other women’s lives, and other cohorts of women who were not mothers were also 
being encouraged to take up the vaccine –  university-aged women and women who are 
being vaccinated against HPV (in my case, women attending a gynecology unit at 
Sunnybrook hospital and its HPV vaccine clinic).  Thus, what was originally a focused 
research endeavor turned into an exercise in fluid ethnography.  
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CHAPTER THREE - Gathering Women’s Narratives:  Lived 
Experiences of Negotiating Gender and Risk 
 
The worthiest of questions are not at all guaranteed to remain stable through the empirical 
course of their resolution, and what instability and mutation they exhibit make unstable 
and liable to mutation every one of their epistemological and ontological fortifications. 
[Faubion 2009:162] 
 
Introduction 
 
In this chapter methodological approaches used throughout my field research are 
recounted and I outline my experiences in the field.  As indicated in the previous 
chapter, in the first stage of fieldwork I conducted a three-month archival search in 
order to answer the first of my three research questions: (1) How did the HPV vaccine 
become gendered within the Canadian policy landscape, and how did this in turn lead to 
gendered public health programming?  This first phase of field research allowed me to 
re-shape the parameters of the research project by clarifying the theoretical 
underpinnings of the research project and in turn I was able to narrow down my two 
subsequent research questions: (2) How are women appropriating, hybridizing or 
refuting notions of “gender” and “risk” that are deployed in association with the HPV 
vaccine? and (3) How are their experiences of risk and gender folded into their vaccine 
decision making?  Armed with these revised research questions, I set out to find people, 
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places and spaces where I could conduct my research.  As I quickly discovered, 
securing an institutional arrangement – meaning a clinical space to conduct participant 
observation – was a challenge but one that was finally arranged, albeit in a modified 
form from what I had originally anticipated. In addition, the enthusiastic response I 
received from women regarding the research, and the discovery of an additional cohort 
to interview, was most unexpected.  Throughout my fieldwork, it was imperative that I 
remain flexible as approaches and questions were continually being fine-tuned. I 
discovered that on-the-ground HPV policy also had clinical, as opposed to 
governmental, impetuses and that HPV infection stories were an integral component of 
HPV vaccine decision making for many women. I also learned that my findings could 
solicit strong and emotional responses from academics and interview participants alike.  
While change (hence uncertainty) can be unnerving, it can also lead to research 
opportunities never previously anticipated.    
 
A] Research Questions: Preparing for and Delving into the Intersubjective 
Space 
 
The archival research conducted to trace the introduction of the HPV vaccine in Canada 
was a critical endeavor in contextualizing women’s narratives by tracking the creation 
and circulation of expert HPV vaccine knowledge, and how this information deploys the 
concepts of gender and risk to enact sales/governance strategies.  In tracing this history, 
I examined what topics were circulating, and “who does the speaking, the positions and 
viewpoints from which they speak, the institutions which prompt people to speak about 
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it and which store and distribute the things that are said” (Foucault 1990[1978]:11).  I 
utilized a governmentality frame to elucidate gendered risk-making based on Foucault 
but updated to include work by Castel (1991), Giroux (2010), Gordon (1991), Lupton 
and Petersen (1996), Nettleton (1997), Petersen (1997), Rose (2007), Rothstein (2006) 
and Turner (1997).  Through my archival research, the processes through which risk 
categories are created and circulated were highlighted.  Furthermore, Douglas’s  (1992, 
2002[1966]) and Lupton’s (1994, 1995, 1999a, 1999b, 2003) writings illuminate how 
this risk making creates a product.  In this case, this product is the category of the at-
risk girl/woman.  Thus, a theoretical métissage consisting of governmentality 
approaches to risk, Douglas’s cultural writings on risk and Lupton’s more recent work 
on gender and risk,21 was assembled to answer the first research question: (1) How did 
HPV vaccine policy and subsequent public health programming become gendered? The 
results of the archival research in answer to the first research question were not 
particularly surprising.  Merck Frosst, a multinational pharmaceutical company, led 
governmental policy, which was predicated on static and one-dimensional portrayals of 
women.   
 
Invoking alternate risk epistemologies, such as the “global risk society” work of Beck 
and Willhems (2004) and Giddens (1991) would not have provided the breadth or 
epistemological foundation to answer this question.  While the governmentality 
perspective emphasizes the role of governance technologies as they are deployed in 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
21 Lupton also fuses governmentality and cultural approaches to risk in her research. 
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their multiplicity in regard to risk, the risk society approach highlights the embedded 
nature of risk within modern societies “as a feature of the ontological conditions of 
humans within current social forms” (Dean 1999:132).  Dean explains that Beck’s risk 
society theory is framed in the “totalizing assumption . . . [of] risk” (1999:135, 
emphasis in original).  According to Beck, risk is ubiquitous in the modernization 
period, affecting all in equal probability, regardless of socio-economic standing.   Beck 
asserts that while situations like “poverty [are] hierarchical, smog is democratic” 
(2004:130).  Such a risk framework does not conceptualize risk as stemming from 
discrete and calculable incidents, but as phenomena which cannot be “spatially, 
temporally, and socially bounded” (Beck 2004:115).   Giddens offers a similar theory 
whereby the risks of “high modernity” are considered to be globalized, treacherous and 
on a scale not seen in pre-modern times (1991:4).  While Giddens’s writing is situated 
within the cold war era (for example, he makes reference to the nuclear arms race), his 
work predicts further “ecological catastrophe” (as was evidenced by the Chernobyl 
disaster in the late 1980s) due to scientific “advancement” (1991:4).  As such, Giddens 
views the future as uncertain and this requires all to be “open to contingent happenings” 
(1991:28). Both Beck and Giddens advance the risk society thesis as a steadfast critique 
of modernity.  Fox posits that Beck also employs the risk society thesis in an effort to 
mobilize against the injustices of capitalism in the wake of the failure of socialism when 
the old tenets of class gave way (1997).  As a result, there is an increased possibility to 
organize along new lines.  However, regardless of intentionality, even Beck admits that 
his critique of modernity is incompatible with governmentality approaches to risk. Beck 
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describes Foucault’s theories as, “paint[ing] modern society as a technocratic prison of 
bureaucratic institutions and expert knowledge in which people are mere wheels in the 
giant machine of technocratic and bureaucratic rationality” (2000:222). Conversely, 
Beck argues that his risk society thesis is predicated upon continually fluid political 
structures and management. What Beck misses in his critique is that governmentality 
approaches to risk emphasize core governance strategies that are tweaked depending 
upon the context – within a constant there is fluidity.  In the case of the HPV vaccine in 
Canada and Ontario, Merck Frosst is governing in tandem with national and provincial 
health authorities through the pivotal promotion of self-regulation. While present day 
governance strategies vis-à-vis women and health differ slightly from a century ago, the 
product is still the same; the pre-patient at-risk girl/woman remains a mainstay. 
 
However, there were also two other research questions to be addressed.  The theoretical 
approach utilized to answer the first research question was not germane to the second 
research question: (2) how are women appropriating, hybridizing or refuting the notions 
of  “risk” and “gender” that are deployed in association with the vaccine? In question 
two, the concept of “risk” is meant to invoke notions of risk as espoused by Fox (1997) 
and Ewald (1991).  Fox discusses how in pre-modern times, the concept of risk did not 
carry negative connotations, but focused on the potentiality of procuring “losses and 
gains” (1997:12).  Today, Fox argues, risk “has been co-opted as a term reserved for a 
negative or undesirable outcome, and as such, is synonymous with the terms danger or 
hazard” (1997:12).  Ewald, perhaps one of the most cited authors regarding definitions 
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of risk, posits that risk “is a category of understanding” (1991:199).  Therefore, risk 
itself is not a loaded concept or event, it is the meaning that is attributed to or affiliated 
with it in governance strategies that creates the notion of danger or a hazard.  Whether it 
is the insurance industry, which Ewald is writing about, or vaccination policy, 
governing strategies work to define what is and who is at risk22.  The notion of “gender” 
in question two signifies the homogenous and static rendition of women as perpetually 
at risk for illness and disease, as circulated in Merck Frosst marketing and used in GBA.  
As Moore explains, “Gender can refer to a set of ideas and images that we recognize as 
pertaining to, for example, traditional femininity, even if we don’t subscribe to the 
practices those ideas and images entail” (2010:106). As Hankivsky also (2012) argues, 
this approach to gender pits men against women, views each as undifferentiated 
“wholes” and places a primacy on the effects of gender on health.  The essence of 
research question two, however, is to understand how governance formulated versions 
of risk and gender work themselves out on-the-ground in women’s daily lives.   
 
As was found with question two, the theory used in the archival research was also not 
relevant to the third research question: (3) How are women’s on-the-ground experiences 
of “risk” and “gender” folded into their vaccine decision-making?  Correspondingly, all 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  22	  This use of risk is not meant to propagate Beck’s notion of “manufactured uncertainty” 
(2000:216).  Manufactured uncertainty refers to risk that is a product of and a factor 
inherent to modernity. While Beck argues that he is both a realist and a constructivist 
(2000:212), his writings veer more to the realist side of the risk equation than 
governmentality approaches to risk, which emphasize the construction of risk as a 
governance technique. 
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three socio-cultural approaches to risk – the cultural, governmentality and risk society 
frames – operate at a meta-theoretical level.  Their epistemologies serve an important 
purpose, but do not operate on an experiential plane.  As Lupton notes, “there remains 
much room for investigations addressing these issues which bring together theories on 
risk with empirical research and go beyond the universal ‘risk subject’ that tends to 
appear particularly in the ‘risk society’ and ‘governmentality’ perspectives” (1999a:6).  
Additionally, Lupton observes, “the theorization of risk has tended to neglect the 
insights offered by contemporary feminist theory and the sociology of the body in 
understanding the links between gender, embodiment, subjectivity and risk” (1999a:7-
8).   
 
Nettleton posits that Foucault’s later work – which focuses on the development of the 
self within power structures – brings forth the possibility of researching individuals 
negotiating risk by exploring their grounded experiences (1997:219).  Lupton invokes 
similar strategies in her research concerning women’s health and risk (1997b).  In The 
History of Sexuality: An Introduction (1990[1978]), Foucault stresses, “power is 
everywhere; not because it embraces everything but because it comes from everywhere” 
(93).  Power is both recognizable and not easily identified (Highway 1998).   Power is a 
fluid set of relations that expand, contract, submerge and re-emerge depending upon the 
context.  Power also does not belong to those with institutional rank: “power comes 
from below; that is, there is no binary and all-encompassing opposition between rulers 
and ruled” (Foucault 1990[1978]:94).  
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By examining Foucault’s work in its breadth, the construction of subjects within the 
frameworks of power relations is acknowledged, but also the possibility of such subjects 
to level their own limited, and often momentary, “critique” while enmeshed in these 
very power networks (Allen 2008:21).  As Allen, who also brings a feminist perspective 
to the conversation, explains “power works at the intrasubjective level to shape and 
constitute our very subjectivity, and an account of autonomy that captures the 
constituted subject’s capacity for critical reflection and self-transformation, its capacity 
to be self-constituting”  (2008:2-3).  Importantly, women’s narratives provide the 
intersubjective space where subject formation and realizations/actualizations of the self 
intersect.  It is precisely in this intersubjective space that health negotiation and decision 
making occur. In the intersubjective space, women work towards becoming ethical 
beings (Foucault 1997). This process involves continually engaging in acts of self-
reflexivity or “practices of the self” to achieve one’s goals of the good or moral (Butler 
2008:27-28). When referring to being ethical, Foucault is foundationally speaking of 
engaging in a relationship with oneself in which we create our own telos, which is our 
own code or sets of codes for daily life (Foucault 1997).  Scripting one’s telos “is 
nevertheless not something the individual invents by himself. They are patterns that he 
finds in his culture and which are proposed, suggested and by his culture, his society 
and his social group” (Foucault 1987:11)23.  As a result, in the era of new public health 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
23 Foucault’s use of the male gender only is problematic in this quote and his work 
overall. Theory has also been drawn from Allen (2008), Butler (2008), Douglas (1992, 
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creating one’s own telos can function as forms of “self-surveillance” whereby 
individuals are constantly and actively enacting health measures to keep themselves 
well and away from anticipated risk (Nettleton 1996:43).  Moore also notes that, “the 
new paradigm of health is a deeply gendered project, and without such an 
acknowledgment we forgo an understanding of health promotion as an ‘operation of 
power’ that is rooted in gender norms” (2010:103).  Therefore, in scripting one’s own 
telos, one is engaging in “ethical agency” (Butler 2008:28) or what Allen called one’s 
ability to be “self-constituting” (2008:2). These actions are, nevertheless, predicated 
upon normative understandings of gender, even if these understandings can be 
temporarily destabilized or re-ordered.  
 
Beck and Giddens also address the self in their work.  However, they posit that 
individuals posses an autonomous and rational ego which integrates knowledge to 
administer their lives on a quotidian basis within the risk society environment.  For 
Giddens, this knowledge is based upon the process of “self-therapy” through which one 
constantly self-evaluates and self-administers solutions in the quest for a more fulfilling 
life (1991:70-108).  For Beck, self-orientated action is encapsulated in his concept of 
“disembedded individualization” (2004:63).  This involves being in charge of your own 
personal narrative as prescribed roles along the lines of class, ethnicity or race, which 
are synonymous with the period of first modernity, are no longer tenable.  Beck 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2002[1966]), Lupton (1997a, 1997b), Moore (2010) and Nettleton (1996, 1997) in order 
to incorporate a feminist lens into the analysis. 
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suggests that “under these conditions, individual agency now assumes a central place” 
(2004:65).  
 
Giddens and Beck base their conceptualizations of the self on a person “actively 
engaged in shaping his or her own biography and making decisions according to 
calculations of risk and opportunity” (Petersen 1997:192).  This treatment of the self is a 
classic modernist tale, one which is subtly focused on “a meta-narrative of progress and 
evolving self-consciousness” (Petersen 1997:191).   This rendering of the self runs in 
opposition to views of the self in governmentality approaches to risk and Foucault’s 
later work.24  Neither Foucault, nor those who have updated Foucault’s theories like 
Castel (1991), Giroux (2010), Gordon (1991), Lupton and Petersen (1996), Nettleton 
(1997), Petersen (1997), Rose (2007), Rothstein 2006 and Turner (1997), claim that one 
has control over one’s sense of self.  Instead, individuals are always operating within 
the structures and parameters of power, as detailed by Butler (2008).  Thus, to answer 
research questions two and three – in short, to understand how the intersubjective 
“space” functions – I set out to map women’s lived experiences of negotiating gender 
and risk in relation to the HPV vaccine by drawing theoretical inspiration from 
Foucault’s late writings (1987, 1990[1978], 1997), Allen (2008), Butler (2008), 
Nettleton (1997) and Lupton (1997b).  The spirit of Zaloom’s (2004) work has also 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
24 While Beck’s and Giddens’s risk society theories do not provide an appropriate 
theoretical template to answer questions two and three, the themes of trust and fatalism 
have been lifted from their work to assist in illuminating vaccine decision making by 
students and patients.  The themes of trust and fatalism are not central epistemological 
tenets of Beck’s and Giddens’s writings.  
	   61	  
been threaded throughout data analysis to answer questions two and three.  Zaloom 
posits that risk can, indeed, be a productive force vis-à-vis one’s sense of self in one’s 
daily experiences. Risk is “practiced” (Zaloom 2004:368), a concept akin to Butler’s 
treatment of gender. 
 
Before recounting methodological strategies it is imperative, however, to define what is 
meant by experiences. As Scott states, “what counts as experience is neither self-evident 
or straightforward; it is always contested, always therefore political” (1992:37).25  By 
experiences, I am referring to delving into and magnifying subjectivities as they are 
continually developing. It is important to note that the concept of subjectivities is used 
in its plural form, denoting multiple incarnations. The research project does not seek to 
make women visible in the sense that the missing female voice must be added to the 
archive (Foucault 1999) or the “anti-archive” (Hughes 2003:28), even though such an 
approach would be popular amongst feminist health activists who overlook difference in 
order to “provide the basis for a collective feminist subject” (Sawicki 1991:8-17).  My 
politics lie elsewhere for I concur with Scott, who states that “the project of making 
experience visible precludes analysis of this system and its historicity; instead it 
reproduces its terms” (1992:25).  I do not want to fall into the very trap that Douglas 
(1992) describes – reinforcing the current social “order”.26   In carrying out this 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
25 The approach taken throughout my fieldwork was also political, underscored by the 
theoretical underpinnings of the research project. 
26 As an example of such an approach and results, Scott discusses E.P. Thompson’s 
work.  In looking to contest the closed nature of the category of “class,” Thompson 
positioned experience as a state of “social being – the lived realities of social life” 
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research, there is the danger of re-producing essentialized notions of gender and risk; 
researching women only while critiquing GBA as it is deployed in pharmaceutical and 
governmental discourses which place a primacy on women as a homogenous, static and 
universalized at-risk group could be a recipe for certain critical failure.  I explicitly 
avoid unintentionally re-producing the products of power techniques.  Through the 
archival research, I trace the social, political, cultural and economic locations of HPV 
vaccine-related gendered-risk making in pharmaceutical and governmental discourses.  
This allows me to situate this specific subject formation at a particular point in time.  
This “historicizing” (Scott 1992:26) is crucial in establishing the constructedness of 
gendered risk as a conceptual category.  I also seek to unearth how these concepts of 
gender and risk travel in the social realm between, across and within different groups of 
women.  If experience is “a subject’s history” (Scott 1992:34), it is important to provide 
a critical account of these histories. In doing so, however, it is paramount not to, “mask . 
. . the necessarily discursive character of these experiences” (Scott 1992:31). Women 
hold multiple positionalities through which they develop and re-work their sense of self 
and identity.   Race, class, age, sexual orientation, occupation, medical status and 
religion are all intersectional positions on the identity continuum (Inhorn 2006).  
However, at the same time, “it would be wrong to assume in advance that there is a 
category of ‘women’ that simply needs to be filled in with various components of race, 
class, age, ethnicity, and sexuality in order to become complete” (Butler 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(quoted in Scott 1992:29). While this take on experience does allow for agentive aspects 
of experience to emerge, Thompson’s analysis rests firmly upon the affects/effects of the 
“relations of production”, thereby re-affirming class as a “unifying phenomenon, 
overriding other kinds of diversity” (Scott 1992:29).   
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2007[1990]:20).  This is a tricky line to navigate and efforts to be mindful of these 
issues guided the fieldwork process. As such, a fluid approach to fieldwork and 
ethnography was imperative.   
 
As it turns out, immersing myself in the field (Kendall 1999; Kent 1992; Pratt 1986), in 
combination with being in the right place at the right time, provided the insight and 
contacts to productively widen the scope of the research project. As a result, I was able 
to track women who were at different stages in the lifecycle with diverse HPV vaccine-
related experiences and stories.  Perhaps being in the right place at the right time is 
more than just presenting oneself in a particular milieu. Being flexible also means being 
attuned to moments of change and ambiguity throughout the research process; being 
cognizant of moving currents on-the-ground allows you to place yourself within 
“implosions” (Martin 1994:11).  As Martin states, while drawing on Baudrillard, 
fieldwork has the potential to “fetch . . . [you] up in what has been called implosions, 
places where different elements of the system come into energetic contact and collapse 
in on themselves”  (1994:11).  This only happens if one is present while in the field and 
paying attention. 
 
B] Shifting Research Parameters 
 
In carrying out a flexible approach to the research project, I took a cue from Martin’s 
ethnographic approach in Flexible Bodies: Tracking Immunity in American Culture 
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From the Days of Polio to the Days of AIDS (1994).  In her book, Martin tracks the 
metaphor of the human body, health and the immune system in the 20th century through 
the popular press, on the street and in science laboratories. Following the concepts of 
gender and risk as they are deployed in GBA policy requires an equally creative 
approach: I interviewed university women, mothers and patients at a hospital clinic. Not 
surprisingly, each cohort is associated with an institution that has historically regulated 
women: schools, homes and hospitals.  A fluid approach to ethnography also requires a 
“reconceptualization of ‘the field’; not as a discrete local community or bounded 
geographical area, but as a social and political space articulated through relations of 
power and systems of governance” (Shore and Wright 1997:14).  Wedel et al. (2005) 
similarly describe the field as “often consist[ing] of loosely connected actors with 
varying degrees of institutional leverage located in multiple ‘sites’ that are not always 
even geographically fixed” (39). Thus, for the purposes of this research project, the 
concept of the field is widely framed and steers clear of anchoring premises, including 
cohesively bounded social groupings (Metcalf 2001). The women interviewed lived 
throughout the Greater Toronto Area in many domestic arrangements and the students 
were dispersed across the province in large and small universities and pursued a 
plethora of educational avenues.  Although all patients attended the same hospital clinic, 
it is hard to characterize patients as members of a particular community. Plant posits 
that community is often used as a measure to judge “what society ought to be like” 
(1974:14) and along with this assumption comes the premise that all members share 
cohesive needs, thus requiring the same types of health services (Jewkes and Murcott 
	   65	  
1996).  As research at the clinic revealed, it did not appear as though patients knew one 
another outside the clinic for they rarely ever spoke to one another while presenting for 
their shots and certainly did not sit together in the waiting room. This broadened 
approach to the field is becoming more common in anthropology today.  As Marcus 
states, “fieldwork projects in anthropology are not what they used to be” (2009:1).27   
The research project also did not entail the traditional going away to a field – I forwent 
an anthropological rite of passage by doing research where I live, at home.  I did not 
find this to be problematic as a feminist researcher because “conquering the field far 
away” (Sparke 1996) has unnecessarily sexist undertones, which is a methodological 
approach I wished to avoid. 
 
My initial intention was not to interview mothers, students and patients. To answer my 
research questions, I originally planned to interview women who were being targeted by 
HPV-related government policy and Merck Frosst’s marketing campaigns. I assumed 
that this approach would lead me to two obvious groups of women – mothers of grade 
eight-aged girls and university students.  In beginning the interview process, in fact, I 
only set out to interview the first group, as they were the targets of the only HPV 
vaccine policy in the province. I was familiar with the grade eight vaccination program 
because such a program is held yearly at my children’s school and mothers in the 
various communities I claim membership in are abuzz with it. It made sense to 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
27 However, the anthropological discipline as a whole is reluctant to talk about the 
myriad of ways in which fieldwork is actually carried out for fear of disturbing the 
discipline’s brand; what does not “resemble the classic mise-en-scène of fieldwork” à la 
Malinowsky is often brushed under the carpet (Marcus 2009:4).   
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interview mothers who were being targeted so specifically and clearly to get their 
daughters vaccinated.   Once I passed my proposal defense and received ethics 
clearance from York University (see letter in Appendix B), I did just that.   
 
I was also made aware of the Merck Frosst campaign targeting university-aged women 
by the large advertisements hanging in the student centre at York University and the 
many smaller Gardasil® advertisements that were posted outside the campus health 
clinic and pharmacy, and also in the student centre.  It did not occur to me to interview 
women students until students of my own, like Sylvana, asked to be interviewed. While 
talking to my students before, during and after class, I discovered that campus health 
clinic physicians were actively promoting the vaccine to women students when they 
visited clinics, no matter the reason for the visit. Students would often mention that they 
went into the clinic because of a cold or the flu and would come out with a prescription 
for the vaccine. Thus, it became clear that students were the targets of a clinical HPV 
vaccine policy. While not specifically governmental (although clearly a spillover from 
official provincial policy), similar policies, as research with university students would 
reveal, were being implemented across the province. I had to, therefore, re-assess how I 
conceptualized the term “policy.”  As such, for the purposes of this research project 
“policy” is defined as not only “a piece of government legislation . . . [but] a general 
program or desired state of affairs or, alternatively, as a label to describe outcomes or 
what governments generally achieve” (Wedel et al. 2005:35).  
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Unearthing the student cohort was another pivotal point in the fieldwork process for 
students brought into relief how prevalent HPV infection actually is.  As unexpected as 
the presentation of this cohort was, it was a prescient primer for patient interviews 
which followed, as students’ HPV stories would foreshadow patient HPV diagnoses and 
treatment stories, which outline how patients work to contain, rather than prevent 
protracted HPV infections. 
 
C] Doors Closed, Doors Opened 
 
While I was undertaking the archival research to answer the first research question, I 
began looking for a clinic where I could engage in the more traditional practice of 
participant observation.  The first place I turned to was a school-based vaccine clinic.  
These clinics were mobile and set up in school gyms and lunchrooms across the 
province.  Unfortunately the local health authority refused my request to observe its 
vaccination program in action.  The authority pointed out that participant observation 
would present an ethical quagmire for them as everyone present would have to consent, 
including nurses, teachers, students, parents and this would be too cumbersome a 
process to carry out. I could understand their concern regarding participant observation 
as the school-based clinics were busy and there was no control as to who walked in and 
out. I had read about the difficulty medical anthropologists have in securing participant 
observation rights in clinical settings because of the increasingly tightening patient 
privacy laws (see Martin 2009), so I was not surprised with their decision to decline my 
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request. I had also been worried that in order to observe the mobile clinics I would have 
to get ethics clearance from the school board, in addition to the public health authority.   
 
My second attempt to find a clinical site went much more smoothly.  After having 
found information on the Internet about a hospital-based HPV vaccine clinic at 
Sunnybrook Hospital in Toronto, I decided to find out more about their program.  I was 
not sure if my request would be granted, but figured there was nothing to lose by 
placing a call.  To my pleasant surprise the nurse practitioner who ran the clinic phoned 
back in a timely manner.  Not only was she encouraging about the research project, she 
took the time to explain that many of their patients were not under 26 as I had 
understood from initial research.28 The nurse practitioner explained that there was a 
clause in the 2007 NACI statement which allowed the vaccine to be administered to 
older women at their physician’s discretion. As a result, women older than 26 who 
attended the hospital’s colposcopy clinic were also getting the vaccine when 
recommended by the attending gynecologist.  I had unearthed a second clinical HPV 
vaccine policy.  Hospital gynecologists were recommending the vaccine to patients with 
protracted HPV infections resulting in cervical dysplasia to protect them from future 
infection of HPV strains they had not yet been exposed to.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
28 I had thought the women attending the clinic would be under 26 because at this point 
in time Gardasil® was approved for use in women 26 years of age or younger, although 
this was amended to include women up to the age of 45 a few years later, as is outlined in 
the previous chapter.   
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The nurse practitioner gave me the name and contact details of the physician in charge 
of the vaccine clinic and suggested I approach her directly regarding my research 
request.  I then prepared a research project summary, a list of interview questions and an 
updated CV, which I sent to the physician who oversaw the clinic. The physician 
responded the same day saying that she would be happy to sponsor my research in the 
HPV vaccine clinic.  She explained that I needed to submit my research project 
information to Sunnybrook’s Women and Babies Departmental Research Oversight 
Committee for pre-approval before I could submit the research request to the hospital’s 
overarching Ethics Review Board.  The Women and Babies Departmental Research 
Oversight Committee approved the request except for the participant observation 
component.  The rationale for not approving the participant observation again came 
down to patient privacy. As the vaccine clinic was not held in a dedicated space, 
meaning that an entire Gynecology Department functioned out of the same area of the 
hospital, it was impossible to obtain adequate consent. There was not a single dedicated 
room for vaccination; the clinic nurse moved between different types of rooms – exam 
rooms to medical procedure rooms – in order to administer the vaccine.  It could be 
argued that it might have been appropriate to follow the nurse practitioner around as she 
tended to patients, but this was not an option, as it was not approved. All gynecology 
patients, including new mothers and those being diagnosed with gynecological cancer, 
used the same busy waiting room.  It did not make sense to observe patients in the 
waiting room who were at the hospital for entirely different purposes.  I was, of course, 
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disappointed with the limitations of the approval, but moved forward with the remaining 
components of the project.  
 
All of this being said, I did have plenty of opportunity to observe while I attended the 
hospital clinic as I was posted at the nursing station each week.  Being at the clinic 
provided me with the knowledge of how the clinic functioned, exposing me to the busy 
nature of the gynecology floor, the enormous stress placed on medical professionals, 
nurses and physicians alike, how patients interacted with them, and the families or 
friends patients brought with them as support while signing in and out of the clinic. I 
was also fortunate to watch the clinic in action in two very different hospital 
environments.  When I started my research in June, 2010, the Sunnybrook clinic was 
housed at Women’s College Hospital (WCH). WCH is a much smaller hospital than 
Sunnybrook’s main campus and provided a more intimate clinic setting.  In September, 
2010, when the Sunnybrook main campus renovation was complete, I transferred my 
research to the large, new building when the Women and Babies Department moved.  
As this was an entirely new building, all spaces had up-to-date furniture and equipment 
and the Women and Babies floor was at least four times larger than the clinic had been 
at WCH.  While the clinic at WCH had been busy, the environment at the new 
Sunnybrook building was dizzyingly fast-paced.  The much larger floor meant that a 
multitude of gynecology related departments were functioning out of the same space. 
While I could not write about these observations, as no ethics permission was granted, 
being there augmented my understanding of the HPV vaccination experience within a 
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hospital environment. However, my use of the phrase “being there” is not to be 
construed as “I know because I have been there” which is then translated into “grounds 
for authority” (Moore 1994:2-9).  I posit simply that by being there my interviews were 
richer and my analysis was more nuanced than it would have been if I had not been 
present in the clinic environment. 
 
 The interview component of fieldwork research focused upon gathering narratives, a 
long-standing tradition in medical anthropology (see Kleinman 1988).  Narratives are 
ideal for situating analyses of how women are appropriating, hybridizing or refuting the 
notions of “gender” and “risk” as they are deployed in HPV vaccine related policy – 
whether governmental or clinical – for: 
 
Text, textuality, derived from texto (Latin, to weave), constitutes the locus where 
bodies discursive and material weave fabrics of the self.  The body of each text 
contains two other bodies which shape the text as it shapes them: the physical 
body and the body politic whose materiality the physical body symbolically 
represents. [Smith-Rosenburg 1989:102]   
 
However, as Butler notes, narrative snapshots usually begin in the middle, and accounts 
are “partial, haunted by that for which I can devise no definitive story. I cannot explain 
exactly why I have emerged in this way, and my efforts at narrative reconstruction are 
always undergoing revision. There is that in me and of me for which I can give no 
account” (2008:37).  Biehl et al. (2007) also stress that “subjects are themselves 
unfinished and unfinishable” (15).  As a result there is always a feeling of 
“incompleteness” (Marcus 2009:28) when engaging in narrative research and analysis.  
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Thus, I only claim to capture women while they inhabit the intersubjective space at a 
specific point in time in their lives. Their rationales and recountings are bound to 
change and take different directions at other times. 
 
Once approval from the Women and Babies Department was received to proceed, I 
began filling out the many forms required to make a formal research request to 
Sunnybrook’s Research Ethics Board (see Appendix C).  After completing the forms, I 
brought them to York University’s Faculty of Graduate Studies (FGS) for review and 
signature. After reviewing the application, FGS decided they would only sign them after 
Sunnybrook’s Research Ethics Board approved the project. I then took the forms to 
Sunnybrook and submitted the project for approval. Unfortunately, the approval was 
delayed by the hospital for a few months because the reviewer was out of the country.  
It was finally approved by the hospital on April 23, 2010, after I agreed to make a slight 
adjustment in how data was to be stored (see Appendix D).   
 
In terms of a timeline, I first called the HPV clinic in September 2009 and the project 
was approved seven months later. However, this was not the only delay I encountered. 
Once I received hospital approval, a data transfer agreement (DTA) had to be signed by 
York University and Sunnybrook. York University was concerned about signing the 
DTA on my behalf because of liability issues as I was not an employee of the 
university.  It appeared as though I was the first graduate student who had unilaterally 
negotiated a research arrangement with a hospital. Typically, this is done through a 
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supervisor because graduate student requests to conduct research at hospitals are often 
lab related.  Finally, in June 2010, after my supervisor, as an employee of York 
University, signed the DTA on my behalf, I was able to return the DTA to Sunnybrook 
to be approved. As a result, I started research work at the clinic in June, ten months after 
initial contact with the hospital.  
 
D] Gathering Women’s Narratives 
 
While creating an interview schedule, I was careful to ensure the breadth needed to 
allow the complexity of women’s responses to medicalization to emerge.  Interview 
questions covered such topics as perspectives on cancer causation; cervical cancer 
etiology; experiences with Pap tests, HPV infection and related medical procedures; 
Ontario government policy of inoculating grade eight girls; gendered aspects of the 
vaccine and virus; and how best to implement HPV-related public health initiatives in 
the future.  Interview questions were crafted to unearth how women were processing, 
hybridizing or refuting notions of “gender” and “risk” as they were currently deployed 
in pharmaceutical and governmental discourses in Ontario.  The central objective of the 
interview questions was to understand how health decisions were made in the 
intersubjective space (see Appendix E for the interview schedule).   
 
While drafting the interview schedule, I was aware of how my positionality was 
affecting the questions I asked, how I asked them and to whom I asked them. My 
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positionality influenced the knowledge produced in this research and my experiences 
filtered how I gathered and analyzed other women’s experiences. Throughout my 
fieldwork I had to work to open up the apertures of my lenses – that of a white, married, 
middle-class academic with two children at home.  My experiences, of course, did not 
necessarily reflect those of the women interviewed and their histories did not always 
mirror mine. My narrative and those of the women I interviewed sometimes intertwined 
and, at other junctures, moved in different directions (Keniston 2004:233).  Having 
membership in multiple mother and student communities made me a “connected critic” 
(Bourgeault and MacDonald 2000:153) and as I will discuss towards the end of the 
chapter, also accountable, to a certain extent, for my research findings.  However, 
before I discuss data analysis, I will outline the recruitment strategies I used for each 
cohort and the demographic diversity found within and between each cohort of women 
interviewees (see Appendix F). 
 
1. Mothers 
 
The women interviewed for Chapter Four all had daughters at, near or just past the 
grade eight age and reside in Toronto or its environs.  This was quite a diverse cohort in 
terms of occupation, but not of race or class, as all the women were white and middle 
class.  As a baseline, all the women were middle class homeowners, however a few 
would be considered upper-middle class. All mothers had achieved an undergraduate 
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degree and some held advanced degrees.29  Some mothers worked full-time outside the 
home, some worked full-time in home-based businesses, some part-time outside the 
home and some were raising their children full-time. Mothers were married, divorced or 
never married.  In terms of professions, mothers were engineers, entrepreneurs, 
journalists, professors, business executives and health care professionals.  A few 
mothers had disabilities in the form of mild anxiety disorders. In terms of religious 
affiliation, women ranged from having none to being faithful Christian church 
attendees.30  Most interviews were conducted in person with the mothers around kitchen 
tables, in coffee shops near their homes and at their offices. A few interviews were held 
over the telephone because of the distance between myself and the interviewee or a 
special circumstance (for example, one mother was on bed rest due to pregnancy-related 
complications). 
 
Recruitment was swift and fairly easy as I approached mothers in my own networks 
(see Appendix G for mother and student consent form). Many participants were kind 
enough to suggest friends and relatives, who were, most often, happy to participate.  My 
positionality as a mother of two boys at a school offering the vaccine no doubt 
facilitated recruitment.  Mothers would ask me if I thought they should get their 
children vaccinated at our children’s soccer games or when I volunteered in the school 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
29 This is a high educational attainment rate when compared to Canada overall.  In 2007 
just under 25 percent of Canadians held a university degree (Conference Board of 
Canada, Education Skills – University Completion 2010:2). 
30 I did not, however, have the opportunity to interview lesbian mothers.  I did send out a 
call for interviewees to various organizations where this participation would seem more 
likely, but I received no responses. 
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library for a lunch-time reading program. One mother even invited me out for coffee for 
the sole purpose of soliciting as much information as she could about the vaccine.   
 
2. Students 
 
Students were an unexpected cohort.  Sylvana, introduced in Chapter One, was a 
student of mine who insisted that I interview her because she had to tell me her “HPV 
story.”  Once the term ended and I had finalized and submitted the marks, I applied to 
the York University Ethics Office for an amendment to interview university students. 
This amendment was granted (Appendix H) and I was finally able to interview Sylvana. 
She had followed up her initial request by e-mail after the course finished to offer her 
HPV story again and I was relieved that I could finally accept her request.  I did not, 
however, wish to rely on my own students to fill up this interview cohort. I knew from 
conversations with other students that HPV infection was common in their age group,31 
so I put out a call for interviewees on a few departmental and club listservs at York 
University to widen the recruitment net.  I received a healthy response.  I arranged to 
interview these students on campus.  All students who contacted me for an interview 
kept their appointment.  When I was conducting my interviews with York University 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
31 As an aside, in 2013 as I am writing this, students at another university are still 
approaching me after class to talk about their HPV infection experiences and offering to 
help with my research. When I tell them that my research project is complete, they 
generally look a bit disappointed, but swiftly move to recounting their diagnoses, doctor 
appointments and related procedures.  These conversations still leave me with the 
impression that the “culture of silence” surrounding HPV infection that I write about in 
upcoming chapters persists.    
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students, they would often mention friends and siblings who had similar HPV stories. 
As a result, mid-way through my York University student interviews, I posted a call for 
interviewees on a national, feminist listserv, which is populated by academics, policy-
makers and non-profit managers/executives.  Here again, I received a positive response 
for interviews.  As it turned out, several Canadian women’s studies professors posted 
my call for interviewees on their internal, departmental listservs. This resulted in 
students from across the province contacting me (see the ethics extension letter in 
Appendix I).  I had to make the difficult decision not to accept more interviewees by 
mid-summer 2010 and I capped the number of students I interviewed at 24.   
 
All students interviewed were in the process of earning undergraduate, graduate or 
professional degrees.  Student areas of specialization varied from women’s studies to 
law to kinesiology. I did notice that many students were students in health-related fields, 
particularly nursing. In terms of age, students ranged from the early to late 20s.  Just 
under half of the students were in relationships, engaged or married.  This cohort was 
slightly more ethnically diverse than mothers, with a handful self-describing as being of 
Asian and Afro-Caribbean descent.32   
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  32	  Despite efforts to recruit non-heterosexual students, I was not successful in this regard. 
I did send out a call for participants to an LGBT student group, but despite the 
enthusiasm for my project displayed by the group’s director, I did not receive any 
responses through this recruitment avenue. 
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3. Patients 
 
After receiving approval from Sunnybrook’s Research Ethics Board, I interviewed 20 
women seeking HPV inoculations at Sunnybrook’s HPV vaccine clinic from June 2010 
to December 2010.  Arranging interviews necessitated that I attend Wednesday 
afternoon HPV vaccine clinics in order to firm up telephone interview times or to 
conduct interviews on site. The nurse practitioner in charge of the clinic handled 
recruitment and consent as per hospital research protocol.  Recruitment posters were 
placed in examining rooms at the Women’s College Hospital (WCH) location of the 
Sunnybrook clinic.  (See Appendix J for a copy of the recruitment poster, which was 
approved by Sunnybrook’s communications department.)  Most interviewees explained 
that it was the recruitment chat with the nurse practitioner that piqued their interest in 
participating in the study.  I provided the nurse practitioner with a recruitment letter 
(Appendix K), but it was her passion for women’s health that encouraged patients to 
participate. The nurse practitioner also explained the parameters of informed consent to 
participating patients and oversaw the signing of the form (Appendix L). Patient interest 
in participating in the study was steady, although more patients signed consent forms 
than participated in interviews.  Not all patients who expressed interest in the study 
followed through with their set interviews.   
 
In terms of maintaining confidentiality of interviewees and interview data, Sunnybrook 
confidentiality procedures were followed. A key file, attributing a unique study 
identifier to each participant, was created. This key file resides at Sunnybrook only, on a 
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secure Sunnybrook server.  Research data (including audiotapes and transcriptions of 
the interviews) with unique study numbers and no identifiable information or personal 
health information is kept on an encrypted laptop.33  
 
Regarding participant demographics, just over half of the patients self-described as 
single during interviews, by which they meant they were not in a relationship. Most of 
the remaining patients said they were in long-term, sexually monogamous relationships 
or in casual relationships, which were not sexually exclusive.  One patient was married 
with a child and one divorced without children. Thus, patients at the clinic were, 
primarily, not married or in common law relationships without children.  These 
categories are derived from descriptions provided by interviewees; I did not set the 
parameters within which interviewees described the status of their relationships.  As 
with each other cohort, there was an absence of women who self-identified as lesbian or 
another non-heterosexual orientation in the patient interview group.  Most patients were 
in their late twenties to mid-thirties, with three patients aged 40. That patients were, for 
the most part, over 26 years of age is significant, as popular discourse – particularly in 
the Canadian- and Ontario-based mass media – does not focus on the occurrence of 
HPV infection in this age group.  Nor has much attention been paid to this cohort 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
33 This laptop is encrypted with PGP Whole Disk Encryption, which uses AES 256-bit 
keys algorithm.  Backup copies of the data, in paper form, are kept in a locked filing 
cabinet in my home to allow me to analyze the data.  All data is void of any identifiable 
information or personal health information, as the interview questionnaire did not solicit 
such information.  Electronic and hard copies of interview transcripts were also given to 
the nurse practitioner and reside in a secure location at Sunnybrook, apart from the key 
file.  
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amongst social science academics studying HPV infection and the vaccine, as current 
literature tends to focus mainly upon parental decision-making regarding young girls 
(see Dempsey et al. 2006; Lazcano-Ponze et al. 2001; Ogilvie et al. 2007) and the 
vaccine and minority health (Fernandez et al. 2009; Livingston et al. 2010; Luque et al. 
2011; Luque et al. 2010; Pitts et al. 2009).  
 
In terms of occupational history, patients were employed in solidly middle-class jobs. 
Patients worked as nurses, occupational therapists, dieticians, accountants, account 
executives and journalists.  As these careers require tertiary education, it was not 
surprising that interviewees had attended university or college (and in some cases both) 
and all but one had graduated from a post-secondary institution. Nevertheless, it is 
important to note that identity categories are complex.  Given the high cost of the 
vaccine (it runs at $160 per dose to total $480 for three shots [SHSC 2007]), these 
patient demographics were to be expected, particularly in terms of educational 
attainment and professionally-oriented employment .  However, during interviews it 
became clear that almost half the patients had difficultly putting aside money in their 
budgets for the vaccine; vaccine cost was a concern for them because many did not have 
private health insurance.  About half had saved the money as they felt the vaccine was 
worth a try, even if they had already experienced HPV infection and HPV-related 
interventions to remove abnormal cells. The remaining half of the patients had private 
health insurance, which covered all or a portion of the vaccine costs. Patients were the 
only cohort who addressed the cost of the vaccine. This can be explained by virtue of 
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the fact that mothers were deciding upon a fully paid vaccine and that students, by and 
large, opted not to vaccinate, so cost was not an overriding concern. 
 
I interviewed patients in whichever room was free at the time they agreed to be 
interviewed. This meant that I conducted interviews in a supply room, examination 
rooms and the room where the vaccine was administered which housed the vaccine 
fridge.  Some patients opted to be interviewed over the phone as these patients visited 
the clinic on their lunch hour and needed to get straight back to work after their shot.  
When I spoke to patients over the phone some chose to be interviewed in a quiet space, 
while others spoke to me on their cell phones while going about their daily routines.   
 
E] Participatory Analysis 
 
1. Thematic Mapping 
 
Interview data was reviewed through a “categorical-content” type of narrative analysis 
(Lieblich et al. 1998:13). Lieblich et al. note that categorical-content narrative analysis 
can also be referred to as “content analysis” – a process through which “categories of 
the studied topic are defined, and separate utterances of the text are extracted, classified, 
and gathered into these categories/groups” (1998:13).  I focused more on data in the 
narratives than linguistic structures.  While this analytical approach may sound rigid, 
the methodology takes into account the overarching narrative before identifying 
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common themes and categories, which are formed organically from the narratives, not 
in a pre-determined fashion (Lieblich et al. 1998:112-3).  Categorical-content analysis is 
a technique particularly suited for examining narratives concerning “agency” and “self-
mastery” (Lieblich et al. 1998:17). Transcribing interviews, while a tedious task, forced 
me to immerse myself in the data.  While transcribing I sifted through women’s 
narratives looking for their discussions on the concepts of “gender” and “risk”. Once the 
data was isolated and coded (Shoveller et al. 2010), I looked for the most common 
themes.  These varied by cohort, and sometimes within a cohort.   When coding it is 
important to seek out “recurring, converging and contradictory ideas/codes within the 
interview data” (Shoveller et al. 2010:60).  I then thematically mapped the data within 
and between cohorts.  Diagrams of this conceptual mapping can be found in Chapter 
Seven.  Visualizing how each cohort conceptualized, played with, rejected, processed 
and appropriated the concepts of “gender” and “risk,” along with how they worked 
through secondary themes such as stigma, HPV infection, “containing” HPV, pre-
cancer, etc. not only assisted in organizing each data chapter, it was also helpful in 
pulling all thematic threads together to provide an overarching analysis, which is 
outlined in Chapter Seven. Such analysis is a process and not one that garners quick 
results.  In part, analysis took so long because I had to sift through nearly 70 interviews.  
That in and of itself is an arduous task.  But also because I chose to informally test my 
analysis with participants whenever I could through conference and workshop 
presentations, and because I formally worked with Sunnybrook staff to elicit their 
feedback.  I prepared a separate research report for the nurse practitioner who ran the 
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clinic and the presiding physician. Both reviewed the report and made only a few minor 
recommendations regarding my use of medical terms. They were pleased with my 
analysis and said that the report “really captured” how women experienced HPV 
infection and related medical procedures.  The report was then forwarded to the head of 
nursing at the hospital.   
 
2. When They Hear What You Say 
 
 
“When they hear what you say” is a play on words of the title of the edited volume, 
When They Read What We Write: The Politics of Ethnography (1993). Each chapter in 
this volume outlines experiences of anthropologists who have had their research 
interpreted and received in ways they did not intend or necessarily anticipate. For 
example, in conveying her research among pro-life and pro-choice activists in the 
United States, Ginsberg (1993) recounts how fellow academics interpreted her research 
to mean that she was sympathetic to right wing, right-to-life causes, a viewpoint not 
usually accepted among feminist social scientists.  Her response was to experiment with 
her ethnographic writing by juxtaposing her voice with those interviewed in order to 
differentiate who was saying what.  As Ginsburg states, “I could not let my voice stand 
for my subjects” (1993:174).  This may not seem like an experimental turn now, but at 
the time it was a novel approach to a complex problem.  
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I shared a similar experience to Ginsburg’s on one occasion. While I was working on 
my data analysis, I ventured onto the Canadian social sciences conference circuit for 
two years. While response to my research was routinely positive – my presentations 
generally tended to dominate post-paper question and answer sessions due to the 
topicality of my research – there is one particular incident that stands out. At the end of 
my presentation a prominent Canadian feminist scholar yelled at me.  She screamed that 
I betrayed women by supporting the vaccine. I had, in fact, not supported the vaccine in 
my paper, but presented the varying views women discussed when talking to me about 
the vaccine. It seemed as though my failure to present a unified feminist subject 
(Sawicki 1991) vis-à-vis the vaccine created a problem for her; I did not present data to 
support her feminist activism against the vaccine.  I was frustrated as she had missed 
my argument entirely; I was critiquing the proposition of a homogenous, static and one-
dimensional grouping of women that was propagated through GBA-based marketing 
and policy making.  A graduate student I had interviewed was at the same conference 
presentation. She approached me afterwards and said that I had really captured how she 
felt about the vaccine. She said that I “got it right.”  This buoyed my spirits, but the 
heated exchange was not a pleasant experience.  Nevertheless, being accountable to 
research participants makes one sensitive to how analyses are framed, but also keeps 
one mindful that research really does matter, both inside and outside the academy.  
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Conclusion 
 
My fieldwork experience was protracted, full of ethics approval challenges and there 
was a need to stay attuned to developments on the ground as the HPV vaccine landscape 
in Ontario was continually shifting.   Listening to local-level currents and being flexible 
in my approach allowed me to interview new groups of women that I could not have 
anticipated in my pre-fieldwork research project planning.  This turned out to be a very 
good thing.  Being immersed in multiple communities of women as part of my daily 
living as a mother and a graduate student, along with the research privileges I was 
granted at Sunnybrook Hospital, allowed me to not only delve into how women 
negotiated the concepts of “gender” and “risk” in HPV vaccine decision making, but to 
have the opportunity to listen to their HPV stories as well.  As it turned out, for students 
and patients HPV infection and pre-cancer were a significant part of their HPV vaccine 
negotiation experience.  
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CHAPTER FOUR - “To Vaccinate or Not to Vaccinate?”: 
Mothers Negotiating HPV Vaccination Decision Making for 
Daughters in School-based Immunization Programs    
 
What fabrications they are, mothers. Scarecrows, wax dolls for us to stick pins into, 
crude diagrams. We deny them an existence of their own, we make them up to suit 
ourselves – our own hungers, our own wishes, our own deficiencies. Now that I have 
been one myself, I know. [Atwood 2001:116] 
 
[T]he modern image of a good mother – the full-time, stay-at-home mother, isolated in 
the private sphere and financially dependent on her husband – came as a result of 
industrialization that took work out of the home and repositioned the domestic space, at 
least among the middle class, as an exclusively nonproductive and private realm, 
separate from the public sphere of work. In the Victorian period that followed 
industrialization, the ideology of moral motherhood that saw mothers as naturally pure, 
pious, and chaste emerged as the dominant discourse of motherhood. [O’Reilly 
2004a:5]   
 
Introduction 
 
Having the responsibility of making health decisions for your child – whether a 
daughter or a son – is a heavy proposition.  As a result, mothers I interviewed exhibited 
anxiety, strong emotions (both in terms of enthusiasm and disdain) and uncertainty 
regarding their HPV vaccine decision making.  The stress of HPV vaccine decision 
making was exacerbated by the relatively short period of time they had to make a 
decision. Schools usually gave two to four days to complete and submit vaccine 
permission forms. With such a rushed timeframe, few mothers came out of the 
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experience fully confident in their decision.  There was always an element of “what if?” 
that lingered after the process and hence showed up in the interviews. Mothers who 
opted not to have their daughters vaccinated asked themselves what would happen in 
the long-term. Would their daughters eventually get cervical cancer? Mothers who 
opted to have their daughters vaccinated worried about potential long-term side effects 
of the vaccine. As Carmen, who is prominently featured in this chapter said, “It’s a 
catch -22.”  Mothers could not see a clear-cut, win-win decision.  
 
While decisions varied, mothers took similar paths in the decision-making process. All 
mothers researched the vaccine extensively and talked to other mothers, friends and 
physicians at length about the vaccine.  Some did talk to their daughters about the 
vaccine, but few ventured as far as to frame the discussion in terms of sexual health.  
Instead, they stayed safely within the cocoon of the actual vaccination discussion and, 
mostly, avoided broaching sex and sexual relations altogether.  While mothers consulted 
widely regarding vaccine decision making, their decision making ultimately rested 
within the realm of personal experience – it was not simply a linear, risk/benefit 
equation.  If mothers had experienced HPV themselves, they were more inclined to have 
their daughters vaccinated.  Mothers were also more likely to have their daughters 
vaccinated if they felt comfortable within the medical realm – had had good experiences 
with physicians and exhibited a certain level of trust in the “system.”  In contrast, no 
mother who was suspicious of the medical sphere and business interests, such as “big 
pharma,” allowed her daughter to be vaccinated.  For these mothers, the risks of being 
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vaccinated far outweighed any potentiality of disease. Across the board, though, 
mothers were quite annoyed at the gendering of the vaccine. As many mothers had both 
girls and boys, they wanted to provide what they deemed to be the best health care 
strategies to all of their children. 
 
A] A School-based Vaccination Campaign, HPV Infection Risk Making and 
Mother Making 
 
The first interview with a fellow mother regarding the vaccine took place in September 
2009. This meeting with Carmen, who was 42 years old at the time, is still vivid in my 
memory.  This poised and self-assured community college professor was clearly a bit 
rattled even though she was impeccably dressed in a linen ensemble with a beautiful 
statement necklace made of polished wood cubes; an outfit befitting the warm autumn 
days in southern Ontario.  Carmen’s daughter, Emily, had entered grade eight.  This is a 
transitional time for young adolescents, the last year of middle school before high 
school.  In the large packet of forms to be signed that Emily brought home on the first 
day of school, ranging from pizza ordering to school accident insurance requests, was 
an HPV vaccine consent form.  Carmen brought a copy of the form to the interview.  
The most striking feature of the form was the large letterhead of the regional public 
health authority, highlighting the same logo that could be found on building signs, 
public notices in the newspaper and on posters placed in community spaces. The two-
page form contained a letter to parents, an HPV fact sheet and the boxes to be checked 
for the required dual consent – that of daughter and parent or guardian.   The consent 
	   89	  
form needed to be returned within four days in order for Emily to be eligible for the 
three-phased shot.  As Carmen stated, “We got it on a Tuesday and it had to be in by the 
Friday.” The teachers explained the short turn-around as an administrative matter – time 
was needed to process all the paperwork for the three-part vaccination.  Carmen, 
however, felt the process was rushed; she elaborated:  
 
I spent about three hours on the Wednesday night going back and forth saying 
should we have this done. It’s so new. Looking up the side effects, looking up if 
there were any long-term studies done on it.  It seems pretty safe, but everything 
seems pretty safe when they’re trying to make everybody have it done. 
 
At this point in our interview Carmen paused, and the stress of the decision-making 
process was visible on her face.   This was a look that I would become familiar with 
during my interviews.   
 
Andrea, an energetic entrepreneur whom I interviewed some months later in the winter 
of 2010 in her sun-filled office had a daughter in grade nine when we spoke.  Andrea 
also commented on the narrow window for decision making: 
 
We didn’t have a lot of time, I remember. We had the information and we had to 
make a decision. I think we knew it was coming but the actual information that 
came from public health didn’t give us a huge amount of time.  So I would 
imagine there were people who delayed that decision because they wanted to do 
their own research and they wanted to figure it out.  I know in some cases people 
did go and have the vaccine later on that year and paid for it because they just 
needed more time and they didn’t want to have to do it in that environment [the 
school].  
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After the interview with Carmen, I looked more closely at the public health 
documentation she had brought to the interview.   The letter from the public health 
authority was short, as was the fact sheet.  The half-page letter began by stating that the 
Ontario government was providing the vaccination free of charge.  The official logo of 
the public health authority and the endorsement of the vaccine by the provincial 
government, juxtaposed at the top of the letter, set an authoritative tone for this 
correspondence.  The next paragraph – a mere three and a half lines – provided 
information on HPV. The description stated, “in 2006, there were an estimated 500 
cases of cervical cancer with 10 deaths in Ontario”.34 The paragraph was brought to a 
close by saying that Gardasil®  – the Merck Frosst vaccine purchased by the 
Government in Ontario – “can prevent the HPV infections that cause the majority of 
cervical cancer and genital warts in Canada.” The remaining information in the letter 
focused on logistical aspects of getting the three-dose vaccine and the in-school 
vaccination procedures.  The accompanying fact sheet offered half a dozen pieces of 
information (listed with bullet points) on HPV and the Gardasil® vaccine. The fact 
sheet emphasized that there were on average 400 deaths a year in Canada due to 
cervical cancer.    	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
34 Please note that this document is not cited, as to do so would reveal the residential 
location of many interviewees. 
	   91	  
	  
Figure 4 - Typical Elementary/Middle School Sign in September 
 
Data surrounding HPV and cervical cancer, however, is more complex than was 
presented in this public health literature. One might conclude that the information 
provided by Carmen’s local public health authority was not balanced and wonder what 
purpose the cervical cancer statistics served. 
 
The stress Carmen experienced in making a decision regarding the HPV vaccine for her 
daughter came into relief in the days after she received the HPV vaccination consent 
form.  Answers were not provided for questions such as: Is it safe? Does it really work? 
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And, if so, for how long?  The mothers interviewed attempted to answer their questions 
by engaging in active information gathering concerning the vaccine, or put another way, 
they pieced together public health literacies.35  Carmen discussed how she sought more 
details regarding the vaccine online: 
 
When we got the letter, the first thing that I did was go to the Web site that was 
on the letter, the public health authority web site. It was kind of vague and it was 
sort of “yes” this is great, you should have it done, no problems, blah, blah, blah. 
So I started Googling. That’s a good thing and a bad thing, because of course the 
first thing that pops up on any Google search is Wikipedia, which can be written 
and re-written by whoever wants to add information.  But as I started to go 
through a lot of other web sites, it put my mind at ease a little bit knowing that 
there hasn’t been any long-term effects so far and that there – it was a very, very 
small chance of allergic reactions to it as well. So that was one thing that I was a 
bit concerned about because – she’s – my daughter’s – very healthy. She doesn’t 
even take Tylenol®, so I don’t know how she would react to a lot of 
medications. I think she’s been on penicillin twice in her life and nothing else. 
So I was sort of hesitant about putting drugs in her that can’t leave. 
 
Carmen did not gather information solely through an on-line search, though. Since the 
introduction of the vaccination program in Ontario public schools in 2007, there has 
been a steady stream of newspaper and TV news stories. The vaccine has been covered 
in national and regional dailies such as the Globe and Mail, the Toronto Star and the 
news magazine Maclean’s (Gordon 2009; Gulli et al. 2007; Picard 2007). While it was 
not surprising to see intense news coverage at the onset of the subsidized school-based 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
35 As per Pleasant and Kuruvilla, there are two types of health literacies: clinical and 
public health. In this chapter, public health literacies are meant to signify “the possession 
of knowledge about health . . . . [It] is thus a skill-based process individuals can use to 
identify and transform information into knowledge” (2008:154). 
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program, mass media coverage has been ongoing and particularly noticeable each 
September as the new school year begins.  Carmen elaborated on this: 
 
At first I thought it was just something to scare to people again. When the flu 
shot became really popular everybody was like, “Oh you have to have a flu shot, 
have to have a flu shot.” Everybody was saying you have to have a flu shot. 
Now it’s not really that big a deal anymore. 
 
So I’m finding it’s the same thing with this vaccine or this shot. You get a lot of 
– you have a ton of media coverage about it. They’re playing on some of the 
worst fears that you can get. Either you getting sick and leaving your children or 
your children getting sick, which are your daughters getting sick. 
 
In our discussion, Carmen continued by exploring the different angles mass media 
stories present regarding the vaccine:  
 
When you are reading about it in [an established] newspaper they come at it 
from a very scientific point of view.  They seem to load you up on certain 
statistics but leave out other ones and those other statistics are picked up by 
these more popular media articles and they really play on your emotions. So you 
have the analytical versus the emotional with each of them. 
 
So, they elicit a very different response, When I read a newspaper article about 
it, I say to myself, “well that makes sense, that makes sense.” But, when you see 
a heartbreaking story where a mother is holding on to her daughter and trying to 
protect her, you say to yourself, “Of course, I have to do it.”   
Like the mass media coverage of the vaccine, Merck Frosst’s Gardasil® advertisement 
campaign was ubiquitous.  I encountered Gardasil® advertisements throughout my 
fieldwork on television, in magazines, in pamphlets on the table in my physician’s 
waiting room and even on banners strung up in the student centre at the university.  My 
children even started to point out the advertisements before I spotted them. I was 
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particularly surprised, though, when one Saturday morning my children yelled for me to 
come and see the Gardasil® advertisement that was playing during the commercial 
break of one of their favorite cartoons.  Having had similar experiences, Carmen talked 
at length about the messaging of both the Gardasil® television commercials and print 
advertisements. Carmen recounted what she saw: 
The way they are portraying HPV and cervical cancer, it can happen to you. The 
people they are using in their ads are everyday looking people.  So it sort of hits 
home a little bit. So it makes it all very real. The statistics that they throw up 
about how many women will have – will get HPV. Also, how many adults have 
HPV now and don’t even know it. Do you know what I mean? It’s sort of 
terrifying. Then you think is that me – did they miss something? [when she had 
her last Pap smear.] 
Carmen felt advertisement messaging was “all about protecting your family and 
protecting your daughter and sort of instilling that sort of fear in you that it’s around 
every corner.” Carmen recommended I look at a particular print advertisement that was 
featured in that month’s Chatelaine magazine, a periodical aimed at women that covers 
“family” issues and includes such things as recipes, housekeeping tips, fitness regimes, 
health information and fashion.  Carmen described the advertisement she encountered, 
“Yeah. So it’s in the family section.  It’s a mother and a daughter. The mother’s got her 
arms around her daughter.”  For Carmen the messaging surrounding HPV vaccination 
promotion, whether through public health documentation, mass media articles or the 
Gardasil® campaigns36 was that “good mothers” (O’Reilly 2004a:4, 2010) have their 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
36 The Gardasil® campaign has been a major source of information for mothers across 
the Province of Ontario as governments and public health authorities have not launched a 
public information campaign surrounding the virus and the vaccine.  The lack of a non-
commercialized information campaign is problematic from a public health perspective. 
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daughters vaccinated against HPV; good mothers are responsible for mitigating HPV 
risk for their daughters by getting their daughters inoculated.  
 
Figure 5 – Chatelaine, October 2009 
 
B] On-the-Ground Stress: Negotiating the HPV Vaccine for Daughters 
 
The mothers I interviewed were clearly stressed about the HPV vaccine due to the short 
period of time they had to make a decision.  Additionally, being bombarded with mass 
media messaging that, ultimately, tied their decision to the type of mother they were 
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compounded their stress.  Once this stress had been brought up in our interviews, they 
moved swiftly to their actual HPV vaccine decision-making processes and rationales.  
Pragmatically, HPV vaccine negotiation strategies tended to fall into two groupings: (1) 
mothers who opted to have their daughters vaccinated (12 mothers or 60 percent of 
mothers interviewed); and (2) mothers who did not wish to have their daughters 
vaccinated (six mothers or 30 percent of mothers interviewed). These numbers are 
presented in graph form in Appendix M. The mothers who vaccinated either had their 
daughters inoculated through the school system or by their physician because the 
daughter was older than 13.  When a physician vaccinated a daughter this was done at 
the mother’s expense or paid through an insurance plan. Mothers who did not vaccinate 
chose to opt out of the school-based program because of their concerns regarding “big 
pharma” and the gendering of the vaccine. Two mothers (ten percent of mothers 
interviewed) decided to delay the decision to have their daughter vaccinated. I do not 
focus on these narratives in this chapter because in these two cases, the mothers could 
afford to have their daughters vaccinated at a later date through their private insurance 
plans.  They did not have to rely on state-sponsored vaccination to have their daughters 
vaccinated and this clearly contributed to their decision to wait – they could afford to 
put off a decision until further research on the vaccine would be released. They were in 
the privileged position of being able to delay the vaccination and thus ease their minds 
regarding what was widely perceived as a new vaccine.  However, to place undue 
emphasis on decision-making outcomes would provide a shallow reading of the data. 
	   97	  
Decision making is complex and non-linear.  It reflects not only a mother’s personal 
health-related experiences, but also her mothering strategies.  
 
1. Opting to Vaccinate: Saying “Yes” to Mitigate Cervical Cancer Risk and Sexual 
Health Negotiation Challenges 
 
Andrea recounted a decision-making process that reflects narratives common to the 
mothers interviewed who opted to have their daughters vaccinated.  Andrea worried that 
her daughter, when eventually a mother herself, would not take the precautionary steps 
to ensure that she did not develop cervical cancer.  Andrea explained that mothers often 
“tend to focus on the health of their families, so there may always be a time issue for 
women to be able to go out and get a Pap test. Women probably put it off, focusing on 
their children’s health instead.”  Therefore, as a way to relay the importance of a 
woman’s health, particularly that of a mother, Andrea incorporated her daughter’s 
opinions and views into her decision-making process.  Andrea explained, “She certainly 
had input into the conversation. It wasn’t my decision that said, ‘I’m making this 
[decision] for you.’ We certainly had conversations around what this meant. It was 
something where – and, this is where technology is great – you can go and look at 
information like this on the Internet.”  Besides talking to her daughter, Andrea consulted 
friends, conducted research on the Internet and spoke extensively with her family 
physician.  Andrea detailed this process: 
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I did talk to our paediatrician to get his thoughts. He is a highly experienced 
doctor and he has three daughters as well. He said that if he was in the situation 
where he had to make this decision for them that he would 100 percent go ahead 
and do this. So I think that it was a hard situation to be in as a parent, having to 
make that decision, because it wasn’t my body that I was making the decision 
about, but it was more of a preventative discussion.   
 
I also did talk to other parents, not that I was going to let other people’s opinions 
about what they would do for their child sway what I would do for mine, but 
certainly just to get a range of comments and discussions. 
 
Carmen also incorporated her daughter into the decision-making process:  
 
I wanted her opinion on it too. I didn’t want to say okay, by the way, in three 
days you are going to get stuck with a needle. I didn’t want her to have to be 
surprised by it. So we had a long talk about it. She understands that in the long 
run it could help her. Sure it sucks that you have to get three needles.  
 
Central to Andrea’s decision to have her daughter vaccinated was the mitigating of risk 
for her daughter.  Andrea was acutely concerned about “what will happen in five years 
time? What are the implications of doing something like this?”  Andrea elaborated on 
her assessment of the risk of the HPV vaccine: 
 
It’s very similar to things like meningitis vaccinations or chickenpox 
vaccinations, all of which my children have had because again, I felt 
comfortable looking at the risk around vaccination versus the risk of getting the 
disease or having an illness that could have been prevented or, at least, the 
impact reduced. So, we spent a lot of time talking about this because, it was just 
again – I think that with decisions like that if they affect me only are easier, 
whereas as the parent you take on that responsibility of “what if?” 
 
Carmen also talked about the HPV vaccine’s potential risks; these risks were ever-
present for her: 
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There’s certain risks associated with everything. So, absolutely I’ll be very 
careful watching her [after she gets the HPV vaccine]. After she got her hepatitis 
B shots last year, I spent the next couple of days analyzing. She had a bit of a 
sniffle. She had a bit of a bruise for it, so I was watching to make sure that 
nothing spread. 
 
So, it just puts you on guard. But because it seems so new, I don't know. Even 
the long-term studies I was looking at weren’t very long-term. Do you know 
what I mean? 
 
After talking about potential risks of the HPV vaccine, Carmen zeroed in on her 
rationale for deciding to have her daughter vaccinated:  
 
As a mother the last thing I want to do is have anything bad happen to her. This 
was sort of like a ‘catch-22’ because if I do not let her have it and then if she 
ends up getting cervical cancer I’ll always blame myself because I had that 
chance to get her the shot. So that weighed heavily on my mind. 
 
Heather, a physiotherapist and a mother of four with one daughter in grade eight, also 
clearly expressed the potential risk of vaccines. As we ate lunch on a rainy and dark 
mid-November afternoon in her dining room, Heather explained: 
 
I think there is always risk with a vaccine. I think some people will react badly 
and I think always there is a risk that we are going to find out some day later, 
like with any kind of medication or anything like that, there are some long-term 
effects we didn’t realize. I think that there is always a risk. 
 
For Carmen, Andrea and Heather, the vaccination involved risk, but there was the 
greater risk of not having their daughters vaccinated.  None of the mothers wanted their 
daughter to contract an HPV infection that could eventually lead to cancer, particularly 
if they could have had her vaccinated against it.  However, Heather’s rational for 
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vaccination went beyond a “what if” scenario and was layered with her own health 
history. Heather, who had HPV-related complications in her early 20s also made her 
vaccination decision based on her HPV-related treatment experiences.37  Heather 
detailed contracting an HPV infection, which turned into dysplasia two decades ago: 
 
Actually after university one of my Pap smears came back as irregular and I had 
to go in and have a biopsy done and I was at – how many stages are there in 
cancer? I was at the second, I was not at the final one, but the one before that 
and had to go in and have, I’m kind of embarrassed because I don’t really 
remember a whole lot about it. I had to have a procedure. 
 
So it took a day. You went in in the morning and then I think I went back home 
that night. I had a friend come and stay with me for a few days after that. They 
told me it was HPV. I have met so many people who’ve had it, a friend of mine 
who came to visit from out-of-town recently was going through it at the same 
time and she just started crying one day and I asked, “What’s wrong?” And she 
said just wait a minute and stop [they were driving at the time.] I had exactly the 
same thing.  I said to her, “Remember after university? I had it”. 
 
They [the doctors] told me I had cancer. When they told me, I was on my own. 
I’d split up with my boyfriend, I was living by myself and I was like, “Oh my 
God, I’m going to die.” I remember thinking, “Do I have to tell people?” “What 
do you do about that?” [Meaning did she have to tell past sexual partners.] 
 
I am surprised at how many people you find out about later. Of course, you 
don’t just bring it up [laughs]. It usually comes out if something happens later. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
37 Heather was the only mother who outlined HPV-related treatment experiences when it 
is very likely, given the prevalence of HPV infection, that other mothers had also 
undergone similar procedures. I am not certain why other mothers did not talk about 
contracting HPV infections and can only hypothesize that they were not comfortable 
talking about sexual relations in general, as was evidenced by their unwillingness to talk 
about sex with their daughters.  
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Heather wished to spare her daughter the same experience, particularly the vulnerability 
she felt when diagnosed with an HPV infection. Heather elaborated on challenges 
inherent in sexual health negotiation: 
 
I mean, I don’t ever want her to go through that, and if it's a way to prevent it 
then, you know. And I think if somebody – because you can never trust 100 
percent whoever you are with because they have trusted somebody – you can 
never know 100 percent ever, right. You might even wait until you are married 
and then, lo and behold, they didn’t know and she gets it. She’s going to get the 
shot, everybody should have it.38 
 
Both Andrea and Heather spoke of making a decision on their own.  While they did 
consult peers, physicians and on-line health information and talked to their daughters 
about the impending vaccination, the main responsibility for the vaccination decision 
fell on their shoulders, even though they both had husbands who were active fathers. 
Andrea expanded on how the responsibility for the decision fell to her:  
 
I mean certainly my husband was consulted as well, but I guess that I sort of saw 
it more as a female decision just because I had experienced some of these things 
that no one else in the house had in terms of having had Pap tests and 
understanding some of the preventative things that women do that men don’t 
necessarily have to do. So I think it was primarily me that took the lead on 
looking at the issues and talking to other people. I think mothers tend to do this – 
we are the ones that take on the role of health management in the house. As a 
mother, I was aware that this is another role that you take on making decisions 
for other people. 
 
I think by experiences with my friends is that it was seen as more of a women’s 
issue than one that really involved men [Andrea is referring to her friends’ 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
38 Heather was also the only mother who touched upon vulnerability and sexual health 
negotiation. This theme is explored in more detail in Chapters Five and Six about 
students and patients. 
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decision-making experiences]. So it was not a decision I made in isolation, but it 
was one where certainly I played more of a role than my husband did and my 
daughter also had a decision-making role because it was her body and she was 
the one that was going to experience it. 
 
Heather was even more direct when discussing her role as decision maker in the 
household and her spouse’s role in the process: “If he didn’t agree with it, that would 
just be too bad. I mean he does agree too because he knows everything that has gone on 
[with me] and you know, so he is in agreement, but if he wasn’t in agreement, she 
would be getting it anyway. [She laughs]. I would overrule that.” 
 
Carmen’s husband actively participated in her information search: 
 
At first he said it was up to me. Whatever I decided would be fine. But the more 
he saw that I was stressing about it, the more he stepped up to talk me through it. 
He didn’t make the decision – he didn’t help me make the decision necessarily, 
but he was asking me leading questions. 
 
He was asking me questions that made me go, “Oh, yeah, I didn’t think about 
that or “Oh well that makes sense, so I’ll look at this.” So, it was more helping 
me along rather than saying, “To do it, you have to do it.” 
 
The ultimate decision making did fall to Carmen, but she received spousal support 
throughout the decision-making process, which she felt helped ease some of her stress. 
The support Carmen received from her husband in her research, though, was certainly 
the exception amongst the mothers interviewed. 
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2. Not Vaccinating: Saying “No” to Perceived Health Risks and “Big Pharma” 
 
Colleen, a neighbor with a home-based business and a daughter approaching grade 
eight, emphasized that grade eight girls were being treated like, “a case study. It seems 
like, let’s track these girls and see what happens.” During our interview Colleen spoke 
about how it was her duty to protect her daughter from the dubious interests of “big 
pharma.” Colleen was by far the most animated of the mothers I interviewed.   
 
Colleen was so energized by this topic that when I first arrived at her home and before I 
took off my coat, she began what was to be the first of many lengthy monologues 
concerning the vaccine. Colleen started the interview by explaining: 
  
I looked into it and what, we have three to four hundred deaths a year from 
cervical cancer. We have a death every seven minutes from heart- and stroke-
related disease. And we're spending $300 million and 300 people a year on 
average are dying from cervical cancer. Cervical cancer is quite preventable with 
regular Pap screening. So, what the heck. And this vaccine is only protecting, 
they say, 70 percent of the cases. But there are all these other strains of HPV it’s 
not protecting against.  
 
So why are we spending hundreds of millions of dollars to vaccinate against a 
disease, or at least 70 percent likelihood of getting this, when this is one of the 
few types of cancers that is preventable with screening and they're saying well, 
guess what? You still have to practice safe sex, which people should be 
anyways, and you still have to screen. And there’s no guarantee that you’re still 
not going to get it. 
  
So there’s a huge disconnect. So who wins with the vaccinating? Who’s 
winning? Well, you know who’s winning—the company that’s getting paid 
hundreds of millions of dollars and that’s just from Canada. The same company 
is also manufacturing the vaccine for the States, virtually everyone else. So how 
much money are these guys making? 
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Colleen was referring to Merck Frosst, as the “winner,” and she questioned the 
necessity and effectiveness of the vaccine.  Colleen was not, however, anti-vaccine39 per 
se as she did have her daughter vaccinated with the routine infant schedule.  However, 
Colleen tiered vaccines; she split vaccines into those she deemed mandatory and those 
that were not. Our interview was conducted in the early winter of 2010, just after the 
H1N1 vaccination offering in the fall of 2009, and she was quick to point out that she 
did not immunize herself or family members against H1N1.  Colleen explained:   
 
Here’s the thing with H1N1 – it’s not as necessary. Flu vaccine? It’s the flu. The 
flu mutates constantly. They have no idea what’s coming at us. But they spent 
all this money, they were getting people, they were scaring people into injecting 
themselves and they put adjuvants in the vaccine. And, we don’t even know 
what we are injecting into ourselves half the time. 
 
For Colleen, vaccines that she deemed non-mandatory presented an unnecessary risk to 
one’s health and in the case of the HPV vaccine, this risk would be brought upon her 
daughter.  Colleen’s conceptualization of health risk changed after having a child: 
   
I think that since my daughter has been born, I’ve gotten much more interested, 
I’ve got more invested in my own health. So I’m a little more aware now of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39	  The common perception in popularized and medical discourses of being “pro-vaccine” 
or “anti-vaccine” (Blume 2006; Jacobson et al. 2007; Poland and Jacobson 2001; Poland 
et al. 2009; Streefland et al. 1999) is a simplistic binary that does not represent the 
mothers, students or patients interviewed.   Not one mother mentioned that they decided 
not to have their children vaccinated with the routine measles, mumps and rubella 
(MMR) protocol, which is sometimes linked in popularized discourses to autism 
(McCarthy 2007).  As such, there is a small body of academic literature focusing upon 
parental attitudes towards autism and MMR vaccines (see Petts and Niemeyer 2004; 
Poltorak et al. 2005; Skea et al. 2008). 
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what goes into your body is going to affect how you feel. So I try to eat healthy 
and I try to avoid things that are going to have a negative impact on my health. 
 
But it’s like saying well, if you walk down a dark alley at 2 a.m., you’re going to 
get mugged. Well, no, you’re not necessarily. But if you don’t have to walk 
down that dark alley at 2 a.m. and you can avoid that risk, take another path, you 
know, don’t walk down there. So that’s kind of my attitude towards mitigating 
risk, is that I’m not going to smoke, ‘cause I’m not an idiot. I know that. But I 
did when I was younger. You think when you’re younger that nothing bad can 
ever happen to you, right? You can drive down the road smoking a cigarette and 
eating a Big Mac, going 125 on the highway—not that I ever did that. 	  
You never know what is going to happen to you. And I could get in the car – I’m 
totally jinxing myself – to go to the doctor’s and I might get hit by a truck. I 
don’t mean I’m not going to drive. So, you have to maintain a certain amount of 
– you don’t want to be complacent, but you can only do so much, right? You can 
only do so much.  
 
Colleen’s comments illustrate how she was more vigilant about health risks as she got 
older and became a mother. However, her rendition of risk and public health literacy 
was different than Carmen’s, Andrea’s and Heather’s.  For Colleen, health risk was 
about taking in contaminants, like tobacco, or “unnecessary” vaccines. She also 
believed that as a society we have become more aware of potential risks to the point of 
paralysis. In response to, and in resistance to, living in what she perceived as a “risk 
society” (Beck and Willms 2004), Colleen chose not to over think every potential risk. 
Thus, for Colleen, pharmaceuticals, which are manufactured by for-profit companies, 
bring about greater risk than the HPV virus itself, and she was actively resisting 
Gardasil® advertising that, in her own words, was set to make all mothers “afraid” for 
their daughters.  Therefore, in this line of thinking, Colleen was being a good mother by 
protecting her daughter from the HPV vaccine, both in terms of potential vaccine side 
effects and “doing too much” to avoid perceived and hyped up risk.  Both the vaccine 
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and too much stress were deemed to be “unnatural” and, thus, unhealthy. In keeping 
with wanting to live a “natural” life, Colleen mentioned she only served organic fruits 
and vegetables to her family and abstained from eating goods baked with white flour or 
white pasta or rice.  
 
In terms of vaccine decision making, Colleen, who was married, made all of the health-
related decisions in the family for her daughter: 
 
I make them. I make the decisions, for my daughter and I. For example, the 
H1N1 [vaccine], I didn’t say to my husband, “Do you think we should 
vaccinate?” I said to him, “I’m not being vaccinated, our daughter’s not being 
vaccinated.” And he said, “Well, I probably will.” But he never did. 
 
I mean if it’s a bigger decision, when it involves selling your house and moving 
town, I can’t make those decisions myself. But my husband would not question 
any decision I made about our daughter’s health. Anything to do with this sort of 
thing, to vaccinate or not to vaccinate, it would be solely my decision – the day-
to-day stuff. This to me would not be big picture. I mean, maybe to someone 
else it’s a big-picture decision. To me, like H1N1, there’s no way my daughter is 
being vaccinated. Her whole class could have been dropping like flies; she still 
wasn’t getting that vaccine in her arm. If they would have said she can’t come to 
school without the vaccine, I would have said, “Fine, you know what? Give me 
some homework for her and I’ll keep her home until this whole thing blows 
over.”   
 
The passion Colleen exhibited about this topic was typical of all of the mothers I 
interviewed who decided not to have their daughters vaccinated. Theirs was a passion 
with no room for change and all decisions appeared to be fixed. They were not likely to 
change their minds as their daughters aged, even if they could have afforded to pay for 
their daughters to be vaccinated outside of the subsidized school setting. 
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C] The HPV Vaccine and Adolescent Sexuality 
 
While mothers were happy to talk about the vaccine at length, they were more reserved 
when it came to talking about adolescent sexuality.  Even when a daughter was past the 
grade-eight vaccination age, mothers treated the prospect of sex as a theoretical 
construct, rather than a possibility, if they discussed sexual relations at all.  While 
mothers were reluctant to address teenage sexuality, only one mother, Margot, 
discussed abstinence, although she did not specifically use this term.  The mothers had 
been teenagers in the 1980s and young adults in the early 1990s and therefore were not 
generally of the generation to be actively influenced by abstinence discourse.  While 
abstinence discourses have existed for centuries, the folding of these discourses into 
American public policy was at its height in the early 2000s with President George W. 
Bush’s active promotion of abstinence in American domestic and foreign policy (Gresl-
Favier 2006).   
 
Instead of focusing on sexuality, Colleen talked about how middle school girls 
physically mature at different stages (much faster than her own daughter had), but that 
psychologically they were still “girls” as opposed to young women: 
 
You see that there are kids in their class – these girls that were mature two years 
ago. And the way they were in grade 7 is as mature as they are going to be. You 
know, they have their adult body, they are as tall as they are going to get, they 
are busty, they are fully developed. But they are still little girls in grade 7 and I 
don’t think that has changed a lot. 
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Most mothers still viewed their daughters as “girls” even though they were fast 
approaching, or were even in full-blown puberty.  Carmen, however, was a little more 
practical in this regard and broke the pattern of not wanting to discuss sexual relations 
with a daughter:  
 
I talked to my daughter about it. That was something that was a little bit difficult 
because I knew that I would have to bring up sexuality. We are very open about 
that in that I have talked to her from a very young age about her body, what is 
happening to her body, as she’s getting older. We’ve discussed preliminary 
things about sex and she still thinks it’s gross. So I’m okay with that. 
 
Having to discuss something like this with her, I can see where somebody who 
doesn’t have that sort of the relationship with their child, where they would be – 
where it would be awkward or where it would difficult to do it, because we have 
– I guess because I had her when I was younger and so we’re – I guess we’re 
closer in age than a lot of mother and daughters are.  
 
We have – we still have a little bit of a friendship on top of being parent and 
child. So she was asking some pretty frank questions, like why do only girls 
have to get it. Then someone  – a girl in her class said that only sluts have to get 
it. So I don’t know if that’s coming from her family or if it’s talk that she’s 
hearing. So I had to explain to her that’s absolutely not true. I said – and that’s 
just – so discussing it with her was the one way that she would be okay getting it 
and then that’s when I started to do all of the extra stuff after she went to bed, 
and talked with my husband about it after she went to bed. 
Even though Carmen was more open about talking about sex with her daughter than the 
other mothers, she still had some difficulty having these discussions.  This is interesting 
because the university students who were interviewed (and are featured in the next 
chapter), were quite vocal in wishing that society as a whole and their parents had been 
more open about talking about sex with them.   
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Sexuality and religion did not enter into my interviews with mothers, except for one 
lively interview with a devout, evangelical Christian named Margot. Even observant 
Catholic mothers, such as Carmen, talked about how the Catholic schools they sent their 
daughters to held information sessions for parents that promoted the vaccine.40 The 
school Carmen’s daughter Emily attended holds a meeting for parents every fall geared 
at parents with daughters in grade seven so that they have an entire year to think 
through their vaccination decisions.  An active member of the school’s parent council, 
Carmen explained the reasoning behind the meeting: 
I know there were more strict Catholic parents who were really worried that it 
would have to lead to discussions about sexuality with their daughters at an age 
that, maybe, their daughters weren’t ready for. Or, maybe, the parents weren’t 
ready for. 
 
So, there was talk about how to approach this and how to approach it within the 
community. So our school said the Province is recommending that this be done, 
so we’re going to do it. If there are any hard questions, we’ll answer them within 
a Catholic framework and we’ll go from there. 
The overwhelming majority of mothers I interviewed – 75 percent – were observant in 
their own faith traditions (see Appendix M).   As such, 15 of the 20 mothers described 
themselves as regularly taking part in religious activities.  Of the 15 religiously oriented 
women, ten self-described as Catholic, two as United, two as Anglican and one as a 
born-again Christian.  However, faith did not come to bear upon their decision making, 
save in Margot’s case. Margot, a stay-at-home mother of five, would not vaccinate her 
daughters as she felt vaccination would send the wrong message regarding pre-marital 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
40 As of 2012, of the 29 English-language Catholic school boards in Ontario, only two 
did not permit HPV vaccination in their member schools (Wilson et al. 2012:34-36). 
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sex.  Margot worked hard to shape her household around “Christian values,” as she put 
it.  When talking about STIs, Margot felt strongly that they were linked to promiscuity 
and that there was an appropriate biblical quotation to explain what she meant. Margot 
quoted Galatians 6:8, “The one who sows to please his sinful nature, from that nature 
will reap destruction.” But Margot did not offer the second half of the verse which 
reads: “The one who sows to please the Spirit, from the Spirit will reap eternal life.”  
Margot felt that pre-marital and extra-marital sex would lead to dubious health 
outcomes, including STIs.  At the end of her interview Margot mentioned that she had 
stayed up late the night before in order to gather her thoughts for our chat.  Margot took 
the interview seriously and was anxious about how her born-again Christianity would 
be portrayed in my research.  This brief mention of Margot has been included to note 
that religion only ventured into one mother’s decision-making process. Religious 
objections to the vaccine and related views of sexual morality had been mentioned in 
casual conversations with other academics prior to my fieldwork research, yet in the end 
only one mother raised it as an issue.41  The Christian right in Canada has been largely 
silent regarding the vaccine during its roll out and this is, perhaps, as Epstein and Huff 
suggest, due to the overall de-sexualisation of HPV in the pharmaceutical promotion of 
the vaccine (2010).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
41 This was not surprising as during George W. Bush’s tenure in the United States, 
conservative groups did not tend to object to the vaccine. Only when states advocated for 
mandatory vaccination did conservative groups voice objections to the vaccine. This 
objection was due to the compulsory nature of administering the vaccine and not the 
vaccine itself (Epstein and Huff 2010:221).  
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Conclusion 
 
The mothers who were interviewed for this study were greatly stressed by the decision 
making that they faced surrounding the HPV vaccine. As Carmen stated, “it weighs 
heavily on my mind.”  All mothers, whether or not they decided to vaccinate, were, in 
essence, being good mothers. They researched the vaccine extensively, talked with 
physicians, friends and their daughters in order to come to a decision they felt 
comfortable with.  In the end, decision making rested within the realm of personal 
experience – it was not a linear, risk/benefit equation.  If a mother, like Heather, had 
experienced HPV herself, she was likely to have her daughter vaccinated. If a mother 
was comfortable within the medical realm, she would often view the risks of 
vaccination as she would another shot, such as the chickenpox vaccine or other routine 
childhood scheduled vaccinations. However, this does not mean that mothers who opted 
to have their daughters vaccinated were firm that their decision was without any sort of 
risk.  Their uncertainty was agonizing for them.  For example, Carmen felt she was 
potentially bringing risk to her daughter Emily because there was no body of research 
concerning the long-term risks of the vaccine. However, if she did not get Emily 
vaccinated and she did eventually get cervical cancer, she would never forgive herself.  
Few mothers who decided to vaccinate had the level of certainty that Colleen possessed.  
Mothers like Colleen who distrusted the medical sphere and big business interests, such 
as “big pharma,” were never going to get their daughters vaccinated. For them the risks 
of taking a vaccine far outweighed any potentiality of disease.  Interestingly, Colleen 
called me in the fall of 2012, about two-and-half years after our initial interview. She 
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was livid that her daughter’s high school sent home a letter from the local public health 
authority strongly urging her daughter to be vaccinated as they had declined inoculation 
in grade eight. Colleen felt this was an abuse of authority and would, as she said, “like 
the state to stay out of her mothering decisions.” All of the mothers interviewed also 
wanted the government to stop gendering the vaccine.  Ultimately, mothers enacted 
what they deemed the best health care strategies for their daughters, but the pressure – 
whether it was from pharmaceutical advertisements or public health notices delivered 
via their the local high school – did not sit well with them. 
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CHAPTER FIVE - “Let’s Talk About Sex”: Women 
University Students Share Their HPV and HPV Vaccine 
Stories 
 
"Let’s Talk About Sex" 
 
Punch it, Hurb 
Yo, I don’t think we should talk about this 
Come on, why not? 
People might misunderstand what we’re tryin’ to say, you know? 
No, but that’s a part of life 
 
Come on 
 
[CHORUS] 
 
Let’s talk about sex, baby 
Let’s talk about you and me 
Let’s talk about all the good things 
And the bad things that may be 
Let’s talk about sex 
Let’s talk about sex 
Let’s talk about sex 
Let’s talk about sex 
 
Let’s talk about sex for now to the people at home or in the crowd 
It keeps coming up anyhow 
Don’t decoy, avoid, or make void the topic 
Cuz that ain’t gonna stop it 
Now we talk about sex on the radio and video shows 
Many will know anything goes 
Let’s tell it how it is, and how it could be 
How it was, and of course, how it should be 
Those who think it’s dirty have a choice 
Pick up the needle, press pause, or turn the radio off 
Will that stop us, Pep? I doubt it 
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All right then, come on, Spin 
 
[CHORUS] 
 
Salt’N’Pepa, Let’s Talk About Sex © 1991(First Half of Lyrics Only) 
 
 
Introduction 
 
While Salt’n’Pepa’s successful song was released when North America was grappling 
with the spread of HIV/AIDS and when there was a steady stream of media coverage 
(Patton 1990) which inhabited a large chunk of the mediascape (Appadurai 1990), this 
song kept popping into my head while writing this chapter in the summer of 2012.  Of 
course, the students interviewed for this chapter were mere toddlers or quite young 
when this song was released, but they are essentially “singing its refrain.”  Move ahead 
two decades – with a different STI-related illness, this time HPV instead of HIV – and 
the same cultural orthodoxy of avoiding “talking about sex” persists.  
 
As a result, this chapter is about university students’ HPV stories, as Sylvana so 
eloquently put it. It is about their urging for widespread sexual health education 
concerning STIs, and specifically HPV, and their deliberations surrounding the HPV 
vaccine.  Interviews were intense and emotion-filled events in which students off loaded 
their anxieties about having contracted an STI, most generally genital warts, while 
receiving very little social support. Many felt too stigmatized to share their experiences 
with friends, family and peers.  These experiences led students to strongly urge for in-
school and societal sexual health education programming, which could help to de-
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stigmatize STIs and to bring an element of balance into sexual health negotiation.  
Young women are too often tasked with the responsibility for ensuring “safe” sexual 
health negotiation within sexual encounters and bear the brunt of the blame when an 
STI is contracted.  Women are being positioned as bearers of sexual disease (as is 
demonstrated and reinforced in HPV vaccine advertising and the girls-only school 
vaccination program) and they feel vulnerable within this realm of negotiation on an 
individual level.  The gendering of HPV and the HPV vaccine, both through Merck 
Frosst marketing and within the governmental realm of school-based vaccination 
programming in Ontario, was off-putting to students.  This concern regarding gendering 
and uncertainty vis-à-vis potential long-term side effects meant that the majority of 
students interviewed decided not to get vaccinated or to delay vaccination. Their saying 
“no” to the vaccine was their way of saying “no” to HPV gendering and potential 
vaccine risks.   
 
However, before delving into the stories of university students, it is important to briefly 
describe how this extra cohort became a part of the research project.  Sometimes being 
“in the right place at the right time,” as they say, can result in the field coming to you.  
Throughout much of my graduate education I worked as a teaching assistant and did so 
throughout fieldwork as well.  During my first tutorial in September 2009, students 
began the session in their usual manner – tired and not quite into back-to-school mode.  
However, when I mentioned my research they perked up.  All of a sudden lively 
discussion ensued. The students talked about everything from their sex lives to having 
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had HPV infections to how sexually transmitted infections are socially experienced 
differently for young men and women. They even openly debated whether or not to get 
the vaccine. I was the only one in the room who was shocked about how open the 
students were.  At the close of this first class, Sylvana approached me as students were 
leaving. She wanted to talk to me about her HPV experiences. She was not the only 
female student who spoke with me after class to ask to be interviewed, to seek my 
advice on whether or not to get the vaccine or to share her experience of having 
contracted an HPV infection, but she was the most determined.  
 
 
Figure 6 – Two HPV ads (Gardasil® on the left and Cervarix® on the right) 
in window outside pharmacy beside campus health clinic, 2010 
 
As the course progressed, I began to realize that something was going on with the 
young women in my class. They really wanted and, more importantly, needed to talk 
about their experiences surrounding HPV infection and the HPV vaccine.  The research 
project, with its focus on the HPV vaccine, provided an avenue through which young 
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women could articulate their personal experiences with HPV infection and their 
concerns about whether or not to get the vaccine.  Working while doing fieldwork 
brought unexpected changes to my research; the class I taught was a turning point in the 
research process.  It was during this class that it became apparent how common HPV 
infections were42 and that no one was talking about them publically.  After waiting for 
university ethics approval to interview former students once the course had finished, 
Sylvana was the first student interviewee.  This was in the winter of 2010.  
 
A] HPV Stories: Genital Wart Experiences 
 
 
On that cold afternoon, Sylvana entered my office, took off her large, puffy winter coat 
and sat on the chair set out for her.  She had a large knapsack-cum-suitcase with her and 
she opened it up to reveal several file folders of HPV research and news clippings. 
Evidently, Sylvana had thoroughly prepared for our interview. This was not surprising, 
considering her parents were both physicians, she was a health sciences major and, as 
our interview revealed, she was a frequent medical consumer. After bringing out her 
research from her bag, Sylvana sat down, sighed loudly and asked how I was doing.  
After formal pleasantries were exchanged, Sylvana delved straight into her HPV story. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
42 While HPV infection is common among students, the resulting complications are 
generally not long lasting for young women (which usually manifest in genital warts or 
an abnormal Pap test result). On the other hand, women a few decades older experienced 
multiple abnormal Pap test results over a protracted period of time, which would not 
clear without surgical intervention. These types of HPV infections, the resulting medical 
interventions and HPV vaccine decision making are discussed in the next chapter, which 
focuses on the hospital portion of my fieldwork. 
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Sylvana swiftly recounted her discovery that she was carrying an HPV strain, which 
manifested itself in genital warts:  
 
I was scheduled for a specialist appointment last summer and it was an 
infectious disease appointment and I wanted to go because I have a few enlarged 
lymph nodes and I didn’t know what they are related to. I have had lymph nodes 
enlarged as a teenager and I know that they have gone down to their normal, 
whatever, lymph pathway. They have gone back to a size that you can’t even 
detect them in about two weeks or so. So I know that for my body that wasn’t 
normal and I kept explaining that to my family doctor and she said, “Well there 
is really not much that I can do.” I ended up seeing an infectious disease 
specialist for them. I have the practice of getting all of medical results together 
every time I see a specialist and just presenting them to the specialists just in 
case, you know, they can make sense of something that I can’t tell them.   
 
So it so happens that that day I came from a family doctor with all of my results 
at home and among the results there was this piece of paper that said Condyloma 
Acuminata [genital warts] on it and I was like “Oh, I don’t remember this one.”  
So I read through it and it turns out it was the histopathalogical report from 
when I went to see the dermatologist in the spring for what they call a “skin 
tag.” So both my family doctor and the dermatologist thought that it was just a 
vulvarous skin tag but it turned out it was Condyloma Acuminata, which is 
caused by HPV.  So, I found out my result at home.  I was shocked.  
 
 
Not only was Sylvana startled to find out she had genital warts – without notice from a 
physician or the physician’s office – she was surprised that a lapse in information 
sharing occurred in Canada, as she felt she had received excellent care here, as opposed 
to her experience in her natal country, Slovakia.  Sylvana explained how she reacted to 
the unexpected news and her subsequent course of action: 
 
So then I called the dermatologist’s office and I said, “can I schedule an 
appointment with the doctor?” and then when I saw the doctor I said, “how 
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come nobody called me about this?”  She said, “well I did write down for the 
secretary to call you and nobody called you?”  I said “no.”  So it was just, I 
guess, down to the secretary level that something happened.  Condyloma 
Acuminata is not, it is a big deal but it is not as big of a deal as finding out that 
you have cancer by yourself or something worse.  
 
Sylvana was not alone in her HPV infection story, particularly that of having genital 
warts. Maya, a 27-year-old masters nursing student was researching sexual health 
education as her major research project, and had a similar story.    She described her 
experiences contracting STIs, both herpes and genital warts: 
 
Yeah, I'm so lucky to be in the field that I am and that like, because I have 
definitely felt that isolation before, like I had herpes when I was 19.  I got it 
when I was 19 and I was like, that virus is very complex as well and I think it’s 
so weird because of its very, very serious association between depression and 
herpes.  
 
No one really has ever thought about that, right.  They think, okay, it’s an STI, 
you get it but there’s so much, so many layers of psychosocial stigma attached to 
it.  And it’s very common for people with that.  And I’m sure the same thing can 
be said for HPV.  Personally I think it’s much less severe, like HPV is pretty A-
okay as far as STIs go. 
 
Yeah, in comparison, but there is like, it’s not, we’re not just looking at the 
physical sort of expression of these diseases well, depression is a physical 
ailment as well, but there’s so much emotionally that goes on with women.  And 
that’s not being talked about and it’s not being part of our treatment that we get 
when we have this.  Like you go to a doctor’s office and they like read a result 
and then you have to figure out what you’re going to do with it and then that’s 
really hard when it comes to HPV or when it comes to herpes or any of the STIs.  
We’re not given the support that’s really necessary in order to cope with this. 
 
A culmination of personal experience and academic training led Maya to passionately 
advocate for a social reframing of STIs. Instead of being considered a big or traumatic 
event, she argued that, “people should think of HPV as part of a normal, healthy 
sexuality because it can’t necessarily be prevented, so if you are going to have sex, you 
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are going to end of up getting HPV, probably, at some point. And it will go away on its 
own for the most part. The stigma is so silly because everyone is going to have it at 
some point.” 
 
While Maya was very pragmatic about STIs, Sylvana was not as relaxed and needed 
some time to get over the initial shock of her discovery.43  Additionally, Sylvana was 
worried about the long-term implications of having contracted genital warts.  She talked 
about her fear regarding the impact having an HPV infection today may have on any 
future children she would have: 
 
What really had a tremendous impact at the time was when I found out that I had 
an HPV infection, that had a huge impact and my first thought was: how is that 
going to influence the fact that I want to become a mother one day?  Because it’s 
extremely rare but my understanding is that in some cases children can get 
laryngeal warts while in utero and there are other effects that a woman’s 
infection can have on the child.  So I was really scared that to me that would be 
extremely humiliating to have my, I guess I could call it, irresponsibility of not 
wearing a condom stamped on my child’s body. 
 
Sylvana did not just want to ruminate about the potential future effects of an HPV 
infection, she also needed to share her current experiences: 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
43 It is important to note that while Sylvana was the only student who found out about her 
diagnosis on her own while leafing through her medical records, it was fairly common 
for students with genital warts to be misdiagnosed, sent to the wrong specialist or have to 
visit several physicians before receiving an accurate diagnosis or even a diagnosis at all.  
Students reported that their GPs were stumped when presented with genital warts and a 
referral to a dermatologist was a common route followed when a GP was unsure of what 
to do.  
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I am clear of it now, but my boyfriend is just on his last treatment.  I’ve been 
researching non-stop. I mean, I’ve looked at it. Thank God mine aren't internal . 
. . mine weren’t internal, so they are just on the outside of the surface of the skin 
and that . . . like they said, that’s a low, low type of HPV [low-risk HPV 
strain].44 
 
So they were saying that’s a low-risk type, so I was thanking God for that. I am 
not trying to be explicit, but for my boyfriend, he didn’t have any on the head of 
his penis. I was thankful for that because it would have put me into more 
complications, more problems. I don’t even know what the treatment would 
have been, because that area is so sensitive, like ours internally is so sensitive. It 
was just on the surface of the skin. 
 
Sylvana explained that she and her boyfriend did not even realize they had genital warts 
until her discovery while leafing through her medical records. As we spoke in my office 
on that cold Toronto winter day, I was beginning to understand why Sylvana so urgently 
wanted to talk to me.  She had been holding in a lot regarding her HPV infection. In 
addition to the fear that she was harboring regarding future children and her discomfort 
discussing the details of a genital wart infection and treatment with others, there was 
something else troubling Sylvana regarding her HPV infection: she wanted to know 
how she could protect herself from future HPV infections. 
 
 
B] Talking about Sex: HPV Infection and Sexual Health Negotiation  
 
Sylvana was, understandably, concerned about how she got the genital wart infection.45   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
44 A low-risk HPV strain, as opposed to a high-risk HPV strain, is not oncogenic, 
meaning cancer causing. Strains of HPV which cause genital warts are not thought to 
turn into cancer (Fact Sheet, National Cancer Institute 2012). 
45 While one might assume that Sylvana got the HPV infection from her boyfriend, this 
may not have necessarily been the case.  She may have been the carrier without initial 
symptoms and the one to transfer it to her boyfriend. HPV is a complex virus and 
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Having had only a few sexual partners helped narrow down the source she felt. Sylvana 
explained: 
 
Well, my previous sexual partners were all virgins46 so I knew it was very easy 
for me to bring it down from whom I had it right? So it was clearly from my 
boyfriend and I talked to him about it and I told him clearly that it was from 
him.  That being said, I don’t know if my sexual practices have changed because 
there is not much that you can change in relation to this diagnosis.  
 
When speaking about getting HPV from her boyfriend, Sylvana brought her narrative to 
the issue of relationship fidelity, a concern for many students (and most of the women 
interviewed for this project) because it exposes how vulnerable their sexual health is.  
Students feel susceptible to contracting STIs and do not know how to mitigate this 
feeling.  Sylvana gave her perspective:  
 
Even though – our society is so – we are trying to technologize everything and 
to make everything medicalized and in the end it all boils down to social 
structures and communication.  All sexual transmittable diseases, I think that the 
first step to preventing them is communication between partners and equal 
involvement of both partners in awareness of their risks and just checks ups and 
things like that, like knowing your status related to various diseases and 
knowing your risks and communicating with your partner. So I think that even 
though the medical institutions are trying so hard to detect it and prevent it, 
regardless of how hard they try, if there is no communication at the couple level 
then all of the attempts are just futile. That is what I think.  
 
When there is a breakdown in communication, as Sylvana put it, women are left 
exposed.  At the time of our interview, Sylvana was undecided as to whether or not she 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
infection pathways are not always linear. This often adds to public misunderstandings of 
HPV. 
46 Virginity as defined as having had no vaginal intercourse does not necessarily preclude 
contracting HPV. Any form of genital touching can expose someone to HPV (The Lancet 
2009). 
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would get the HPV vaccine. Her decision hinged upon fidelity  – she felt it prudent to 
get the shot in the future in the event her partner cheated again.  Sylvana explained her 
thought processes regarding the vaccine: 
 
I think it really depends on seeing that it doesn’t boil down to the money or the 
risks, I think it boils down to my relationship with my partner, which is really 
weird because it definitely shouldn’t be like that. I should just really think of just 
getting it. In the end people are just, their natural approach is to just give in to 
trusting the other and hope to just really have a monogamous relationship, at 
least most girls would want that probably – most girls I would say.  Probably in 
the next two years if I find that I can rebuild my confidence in my partner and 
then probably I won’t get it but if not, then I guess I’ll get it. So in the end it just 
depends on my relationship rather than any other factor. 
 
It’s actually really good that you are doing the social anthropology side.  I think 
that in the end this whole HPV thing really, really should come down to, I think 
how much people talk to each other in a couple.  I think that would make such a 
tremendous difference in the spread of the virus. So I think that just worldwide 
people need to communicate more when it comes to sex. 
 
Sylvana’s call for more open communication surrounding sex, whether as a couple, 
among peers or within popular discourse was a common sentiment expressed by 
students.  It is precisely such open communication that was lacking in the Ontario 
government’s school-based HPV vaccination program according to Sylvana.  She 
remarked how an HPV educational campaign was markedly absent from this public 
health initiative.  According to her, a shift in strategy is required: 
  
The Government should really focus on giving people enough education on 
sexual communication within the couple while people are in school and from 
there on when you’re an adult. So it is totally up to everybody whether they 
want to use a condom.  It doesn’t totally protect but I really believe in that. Even 
though they are kind of running away from saying it I really do believe condoms 
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protect against it, at least some of the – and the female condoms even more than 
the male condoms because they cover a larger surface area. I think that once you 
are an adult that’s it.  
 
Maya also advocated for the inclusion of HPV sexual education programs in the school 
curriculum as an integral component, but she felt conversations about sex needed to 
happen on a societal level as well. For Maya, this should be the starting point as many 
North Americans are uncomfortable talking about sex, let alone contemplating a range 
of sexual education programs in schools.  This may, however, be in part because sexual 
education is rarely offered extensively in schools, she thought.  As she discussed the 
circularity of this argument, she was quick to stress that she had not received any sexual 
education while in elementary or secondary school. Maya described her chats with 
fellow sexual health researchers in her graduate nursing program: 
 
Yeah and so, we all talk sort of about our experiences with sexual education 
like, growing up, what practices they used as teenagers versus the practices we 
use and how they kind of evolved to that.  And I had very unsafe sexual 
practices when I was younger, very, very unsafe.  And I guess I didn't really 
have any sexual health education and it wasn't because my parents are right wing 
or anything like that.  It was just kind of not talked about.  Or maybe I didn't 
want to talk about it, I probably didn’t at the time.  I'm sure they tried and I told 
them to screw off or something like that. 
 
But then I had other friends that never had unsafe sex in their whole lives, which 
totally blows my mind.  But then they had very proactive parents that from an 
early age were sort of ingraining this stuff into them, like, this is the science 
behind it.  It’s not scary, it’s not a big deal – this is just what it means. And you 
know I think if I had, maybe, had more of the science, because I have very much 
a science mind, I’ve always studied science, like if I’d had some of that before, I 
think it could have made me make different decisions, possibly.   
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In talking about increasing interpersonal and institutional conversations about sexual 
health education, Maya touched on (as did Sylvana) the vulnerability of women while 
negotiating sexual encounters:  
 
But then there’s also the layer of young girls not being empowered to make 
these decisions as well.  So, that has nothing to do with education.  Like you 
may right know that having unsafe sex, unprotected sex is dangerous but that 
you don’t necessarily have the power to make that choice in the situation. And 
so that adds another dimension to it.  
 
This dimension, as Maya referred to it, was a theme that recurred throughout all of my 
interviews, regardless of whether or not the women were mothers negotiating the 
vaccine for their daughters, university students contemplating being vaccinated or 
gynaecology patients being vaccinated in a hospital setting.  The theme of vulnerability 
or lack of power while negotiating one’s sexual health is explored in more detail in 
Chapter Seven. 
 
C] Gender as it Bears upon HPV Vaccine Decision Making  
 
The lack of sexual education accompanying the current HPV vaccine policy in Ontario 
was not the only aspect of current government programming that upset students; they 
were, overwhelmingly, annoyed by the gendering of the vaccine.  Sylvana, while not 
pleased with the gendering of the vaccine, offered some of the least intense discussion 
in this regard: 
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My thoughts of the HPV vaccine, I don’t – I would have to study a lot more 
about it to just say, “this is what I think about it,” but I think it’s wrong just 
giving it as early as whatever age – 14 is it? Yeah, I think that is the wrong 
approach. I think that what people should be emphasizing their preventative 
measures towards is a lot more screening and especially [for] males. There is a 
huge problem with males because apparently they, like in a lot of sexually 
transmitted diseases, do not show any symptoms whatsoever. It seems like more 
so than women because women have a small chance of not showing any 
symptoms but it seems like in males that they have a better chance of not 
showing any symptoms and having no clue that they have an infection. So it is 
actually incorrect at this point to give vaccines to young children instead of 
funding research to screen people and then funding educational classes in 
schools where you can tell a child, “You have to communicate with your 
partner. You have to get screened if you want to start a long term, stable, 
monogamous relationship and you intend to not use condoms.”  People really, 
really have to be aware that their partners have to be screened before they start 
unprotected sex. Today, this is something that it is pretty much up to the male 
what happens [referring to condom use].  I think that is wrong as right now 
everybody is trying to push towards a more egalitarian approach between the 
two genders.  
 
Sylvana pointed out that in addition to the lack of sexual health education available, 
men, in her experience, were tasked with the decision to use or not use a condom in a 
sexual relationship/encounter.  This was a troubling trend for Sylvana and one that she 
would like to see changed. However, altering such a complex socio-cultural 
phenomenon would be a difficult task, she acknowledged, but one that could be 
addressed in sexual health education. Thus, Sylvana’s thoughts, generally, returned to 
her central tenet that sexual health education is a must. 
 
Maya was also perturbed by the gendering of the vaccine, but was more forceful in her 
discussion than Sylvana.  Maya felt at a loss as to how to manage the complexity of the 
vaccine. For Maya it was difficult to resolve the tension between the vulnerability of 
women negotiating their sexual health and the potential assistance that the vaccine 
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could be in spite of the outright targeting of women – targeting which becomes 
synonymous with blame when women acquire an STI. Maya elaborated on the dilemma 
the vaccine creates as it is described in Gardasil® advertising and provincial in-school 
vaccination programming: 
Well, it’s hard.  Women are meant to feel, made to feel bad about their bodies in 
so many different ways.  And this is another way in which we’re disempowering 
women to make healthy choices and to take their own health into their own hands 
by saying like you need this vaccine because you’re going to have sex, you’re 
going to get dirty, it’s going to make you sick.  And so it’s putting, yeah, it’s so 
tricky.  I think it can be done in a way that it’s empowering and can make women 
healthier but the way it’s being marketed as a gendered vaccine is saying that the 
girls in our society are unhealthy, the girls in our society are intrinsically sexually 
deviant and are going to get STIs and the boys are not and so here’s some way to 
protect them, protect the virginity, protect the innocence of these girls from 
getting sullied with sexually transmitted diseases.  And that just makes me sick 
thinking of it that way. 	  
 
Figure 7 – Gardasil® advertisement targeting young women 
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Maya was not the only one made to feel “sick” about the gendering of HPV. Amber, a 
26-year-old law student was even more outraged than Sylvana and Maya.  She is an 
award-winning student from northern Ontario, and currently enrolled in a university in 
Toronto.  She is the first in her family to attend university and one of the few students I 
interviewed from a working class background (most students were from middle to 
upper-middle class families). Amber is particularly interested in feminist law.  Amber 
was visibly upset when she talked about the gendering of STIs, HPV and the HPV 
vaccine. As our interview progressed, she became more and more agitated – in fact, her 
anger about these issues was clearly palpable by the end of our time together.  Amber 
had a decided opinion in respect to the gendering of STIs: 
 
I think it would be associated with the turn of the 19th century. To my 
knowledge a lot of issues about venereal disease had come up during this period 
and they were very much associated with women.  
 
Even though as we know today, it takes two partners to start transferring things; 
in other words, [it takes] male promiscuous behaviour to often transfer STDs 
and venereal diseases.  And certainly it [STIs] is just still, I guess, associated 
with female, dirty sexual behaviour. STIs are thought to be something that’s 
contracted through “dirty” sexual practices.  
 
Amber elaborated on the gendering of HPV: 
Again I think this has to do with the history of associating certain types of STDs 
and venereal diseases as coming from women.  Even though like as I mentioned 
the contraction and the spread of these diseases has a lot to do with male sexual 
behaviours as well.  One thing when I was doing the research on the vaccine and 
HPV, one thing that they said was the reason why a lot of STDs and venereal 
diseases become associated with women is because oftentimes the symptoms 
appear on women as opposed, and not so much, on men.  And the reason for this 
being that the vagina is really hospitable for the growth of different bacteria and 
viruses.  And so I guess on a man for instance who has HPV but maybe a very, 
maybe not a serious strain or something like that, evidence of HPV won’t come 
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up.  But on a woman who has maybe had it for a very short amount of time like 
she might have signs, visible signs of having contracted the virus. 
 
Even though students exhibited consensus regarding their irritation with the gendering 
of the vaccine, this annoyance did not lead to uniform vaccine uptake decisions.  Some 
students were so turned off by the gendering of the vaccine – both the in-school 
programs and the Gardasil® advertisements – and what they perceived as potential 
vaccine risk because long-term vaccine data does not exist, that they refused to get 
vaccinated. Others were mildly perturbed by the gendering and also worried about 
potential vaccine risks,47 but this resulted in them putting off their decision to a later 
date. Still others grudgingly got vaccinated, but made it clear that this “choice” was by 
no means an endorsement of HPV vaccine gendering.  As Appendix M indicates, 
numerically almost two-thirds of the students interviewed decided not to be vaccinated 
or to delay vaccination decision making (70 percent or 17 out of 24 students). Each of 
the three vaccine decisions is discussed in turn. 
 
1. Saying “No” to Gendering and Vaccine Risk 
 
As concerned with sexual health as Maya was – this was after all the basis of her 
graduate training in nursing – Maya chose not to get vaccinated due to the gendering of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
47 It should be noted that even though students were concerned about potential vaccine 
risk, or long-term side effects, they were not anti-vaccine. Students, as was found with 
mothers, did not suggest that people should not get vaccinated at all. Instead, they felt 
they should be cautious of new vaccines until longer-term research was released. 
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the vaccine and what she perceived as vaccine risk.  Maya explained her position on the 
vaccine and, as a result, her decision-making rationale: 
 
I’m really sceptical about the vaccine, particularly because it’s mass marketed 
towards girls, vaccinating girls and women and absolutely no focus on boys and 
men.  And you know it’s a vaccine for HPV, it’s not a vaccine for cervical 
cancer even though the strains it targets can lead to cervical cancer.  But I just 
feel that if we actually want to reduce cancer we probably should be vaccinating 
everyone. I think it is interesting that they’re targeting only girls and women 
because there hasn’t been any long-term research on the effects of the vaccine so 
we don’t really know what’s going to happen, you know, ten years down the 
line, 25 years down the line with these women who have taken the vaccine when 
they were young girls or teenagers or young women. There’s just not any 
evidence, we don’t know what’s going to happen and I think that’s really 
problematic. 
 
I read recently that at least in the States and some other countries the vaccine has 
now been approved for boys, I guess it hasn’t been in Canada yet.48  But there’s 
no willingness or feeling like there’s a need to promote it for boys and men the 
way that they have for girls and women. There’s no mass campaign to get these 
boys vaccinated even though the vaccine is available which I think is just crazy 
and just really telling. 
 
In addition to being unsettled by the marketing of HPV as a women’s disease in both 
Gardasil® advertisements and the Ontario government’s school-based vaccination 
program, Maya was concerned about long-term vaccine risks. She expanded further as 
to why she decided not to get vaccinated: 
 
It’s just, I mean, not to be like a conspiracy theorist and I wouldn’t say anybody 
is doing this necessarily consciously but what is being said is that it is okay to 
put women and girls at risk of a vaccine that we are not really sure what’s going 
to happen in the long term or how effective it is actually in preventing cancer, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
48 Gardasil® was granted approval for use by boys and men up to the age of 26 by Health 
Canada in February 2010 (CTVNews.ca Feb. 23, 2010). 
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but we’re still going to really promote it for girls, but we’re not going to take 
that risk with boys.  I think that when you look at it with a gendered lens you can 
see that we are really putting girls and women at risk here and we are not doing 
the same with the boys. I think that offering it for free is kind of pushing people 
in the direction of taking it because you know if they don’t get it that year then 
they are going to have to pay hundreds of dollars to get it.  So they may as well 
get it while it’s free. So I think it’s maybe a coerced choice if it’s a choice at all.  
This seems like not the best situation. 
 
I still feel the vaccine hasn’t been properly tested because it hasn’t been around 
for very long, we don’t have the long-term data to see what’s going to happen 
with people who take this vaccine. So I’m wary of anybody taking the vaccine. 
I’m under the impression that the vaccine was really expedited, all the testing 
processes and there’s no long-term data.  There are cases of medical intervention 
for women that have shown detrimental long-term health effects. You know, the 
birth control pill when it was first put out there was no long-term data, then we 
found out that people who take the pill for a long period of time have higher 
chances of stoke. Any sort of health consequences could potentially arise when 
we’re introducing a drug into our bodies. 
 
So I don’t know how anybody can expose themselves to a drug that they don’t 
know how it’s going to affect them in the long term. I think that’s kind of crazy, 
so I wouldn’t advocate for anybody taking the vaccine. 
 
Maya was steadfastly against getting the vaccine for herself due to the gendering of 
HPV and the vaccine in governmental and pharmaceutical discourses.  She was also 
wary of the uncertainty surrounding the long-term effects of the vaccine. Saying “no” to 
the vaccine was Maya’s way of saying “no” to the gendered risk discourses of the 
government and pharmaceutical companies.  However, she was also saying “no” to 
women’s over-medicalization.  Not wanting to take the vaccine was an act taken to 
protect her health by avoiding, what was in her view, unnecessary risk.  Instead, she 
managed the risk of further contracting STIs by using condoms and not engaging in 
unprotected sex unless both she and her partner had had “clean” STI testing, meaning 
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tests were not positive for STIs. Additionally, Maya attempted to stave off cervical 
cancer by getting regular Pap smears, which she arranged every year with her GP.  
 
2. Delaying Decision Making due to Being Put Off by Gendering and Vaccine Risk 
 
While Sylvana was still recovering from the shock of discovering she had genital warts, 
she was contemplating getting the vaccine. She had not come to a final decision and 
was not sure whether she would reach a decision any time soon.  As she frequently 
mentioned during our interview, she had “really mixed thoughts” about the vaccine, and 
she talked about the problems the vaccine presented for her: 
 
It’s definitely an interesting subject. It’s very difficult to navigate this debate as 
a woman who is concerned about these things [her health] personally.  But then 
also, you’re trying to balance all the social factors – the government, 
pharmaceutical, physiological . . . they’re really complicated. I think part of my 
problem [re: decision-making] is that I am so lost in this analysis.  
 
Sylvana balanced worries about her own health and her desire not to acquiesce to 
vaccine marketing and policy that targeted women without considering HPV within the 
context of gender relations.  Thus, for her there was a tug of war between her individual 
concerns and the “bigger picture.” This bigger picture, according to Sylvana, painted 
women in a subordinate, needy, and risky position vis-à-vis HPV and this was reflective 
of her general social location – a position subordinate to men. As Sylvana said, “it’s just 
women who have to make sure that you prevent yourself from getting into trouble or 
you have to make sure you’re taking the pill and that kind of thing to make sure you are 
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not getting pregnant. It’s always the woman who has to do those.”  Sylvana was 
pointing out that women must take social responsibility for their bodies and yet are 
blamed for not protecting themselves against pregnancy. 
 
Sylvana’s delayed decision making primarily because of the gendering of the vaccine, 
which she described as patently unjustified, but her perspective was further complicated 
by her view on pharmaceuticals. Sylvana explained her skepticism of vaccines, nested 
in her distrust of pharmaceutical companies: 
 
I don’t really trust vaccines because of the fact that they’re not really researched 
– they haven’t been on the market for that long. They say they [Gardasil®] have 
been proven to reduce the risks of HPV. But, with HPV there are so many types 
of HPV.   
 
So what is it six, 11, 16 and 18 that it protects? Now, four out of hundred, that’s 
four percent – that’s huge to even just say that it protects you from HPV. Maybe 
those are the more prominent ones – you know what I mean, there’s not too 
much information about that, right? Maybe those are the ones that are easier to 
fight off. Maybe we might get them one day from having sexual intercourse and 
you just fight them off. But, it’s not talked about, right. My boss’s niece got the 
vaccine and she still got warts. That’s why I don’t really trust vaccines. It’s just 
my personal feeling, especially when I hear stories like that. It’s not really 
proven. I don’t know if it’s true what the media, or what was in the news about 
girls getting sick from it [the HPV vaccine]. I don’t know if someone died from 
it or if they made that up, I don’t know. I also think about the example of birth 
control pills in the sixties and they had such a high level of hormones in them 
that they were making women quite ill. They weren’t tested and we weren’t sure 
what was going to happen and some women did end up dying because of it.  It 
just seems to be a repeat of history – all of these things that doctors and 
scientists concoct to help women and to fix women and to save women and, 
ultimately, they don’t know what it’s actually going to do to women. 
 
I don’t like putting stuff in my body that I don’t know exactly what it is and 
what it does. What it essentially is, I get it, a cash grab by a pharma company. 
They’re in the business of selling you stuff that you don’t necessarily need.  
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Not only was Sylvana skeptical of the necessity of the HPV vaccine, she was wary of 
the benefits of the vaccine considering that it covers four out of a 100 HPV strains. For 
Sylvana, claims that the HPV vaccine protects women from cancer were an overblown 
marketing strategy. 
 
It is important to stress that students who delayed making a decision were deeply 
conflicted about the vaccine.  Balancing individual health needs with their distaste for 
the overarching negative messaging concerning women that is attached to the vaccine – 
both in pharmaceutical advertising and Ontario government policy – was a difficult task 
indeed.  They could not reconcile these two aspects of their decision making. As 
Sylvana said, “It’s a hard kind of choice to make. But at the same time, how stupid 
would you feel if you ended up getting cervical cancer and had decided not to get 
vaccinated. I have mixed feelings so it was why I’ve held off on getting the 
vaccination.”   
 
3. Saying “Yes,” but with Strong Reservations due to Gendering  
 
As my interview with Amber was winding down, I was surprised to learn that she did 
indeed get vaccinated against HPV.  Amber’s decision was a bit startling considering 
how passionately she spoke out against the gendering of STIs, HPV and the vaccine, but 
also because she had condemned the vaccine a year earlier in a blog entry (which she 
brought along). The blog post follows: 
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January 10, 2009 
 
Hello Everyone! Happy New Year! 
 
Today’s entry is a rant (and a serious one at that)! To all my women readers out 
there: don’t get the HPV vaccine! Seriously, this is just a grab by big pharma to 
target and stigmatize women for a virus that has little chance of actually turning 
into cancer. That’s right – HPV does not necessarily turn into cancer. Don’t buy 
into the hype. Our bodies don’t need to represent disease. We are not the bearers 
of ill health and “dirty” viruses. Resist this continual characterization of women 
by saying “no.” Say “no” to this egregious portrayal of women and big pharma 
profits. 
 
Please give some thought to HPV vaccination – there is more than there appears 
to this story. There’s no cervical cancer epidemic and no need to inject women’s 
bodies with a drug that has had little testing. Just say “no”! 
 
Yours in earnest, 
 
Amber49 
 
 
Amber’s blog entry and her decision to be vaccinated seem incongruous.  However, the 
inconsistency points to the complexity of vaccine decision making for women. Amber’s 
decision is not necessarily a reversal of her position on the gendering of STIs, HPV and 
the vaccine, but reflects the theme of sexual health vulnerability, discussed by Sylvana 
and Maya as described earlier in this chapter.  Amber outlined what spurred her to 
reconsider getting the vaccine after posting her blog entry: 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  49	  The blog text has been paraphrased as it can be found on the web and may be used to 
identify Amber.	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Okay, so I have a problem, as I mentioned, with the vaccine even though I got it.  
I fundamentally have a problem with it because the way it’s being marketed 
towards girls stigmatizes girls’ and women’s sexualities as being the source of 
the problem – it puts the onus on girls.  Just like when you look at, on having 
responsible protective sex, again a lot of the onus is put on girls to be sort of the 
arbitrators of sexuality so that they have to monitor their partner’s behaviour and 
make sure to take on that responsibility of being responsible for both her and her 
partner without attributing very much responsibility to the man who is involved 
in the sexual relationship. 
 
 
Despite Amber’s strong reservations about the social consequences of vaccine 
marketing and policy, it was personal experience which brought about her change in 
decision making. Learning that a friend had contracted an HPV infection, Amber 
conducted research on HPV: 
 
The only reason why I guess I’ve gained a bit more knowledge about HPV was 
because of my friend.  So before I had the vaccine, I went home [from my 
doctor’s appointment] and I went online and I did some research and it told me 
some more information HPV, which I guess is good to know either way, 
regardless of the issue of the vaccine.  But one thing that I found was it’s very 
difficult to prevent the contraction of HPV when your partner has it.  And they 
were saying that even with the use of condoms, HPV can still be contracted.  
And I guess that’s probably because the virus itself doesn’t exist explicitly on 
the reproductive organs that are, I don’t know, I guess the ones that are used 
orally or penetratively.  I guess, the virus probably exists on other parts of the 
skin that come into contact during sex. So with that knowledge (laughs) and I 
mean another thing that I had read is that throughout a person’s lifetime I think 
there are like 70-some different strains of HPV, is that the number? [I informed 
her that today research indicates there are over a hundred strains50].  
 
Having seen my friend going through having HPV I think it’s a pretty terrible 
thing to go through and it affects I guess who she chooses as a future partner, 
she’s a single woman, right.  So it’s going to affect how her relationships end up 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
50 While different publications list different numbers of HPV strains, generally, HPV is 
reported as having over a hundred different strains (Society of Obstetricians and 
Gynecologists of Canada 2012). 
	   137	  
unravelling and that sort of thing and whom she meets.  I mean a world without 
HPV would be nice.  But I guess my own concern about my sexual health 
outweighed any of the potential problems that might come with it.  And so, 
which is why I decided to get it. 
 
Students like Amber are actively conscious of the societal challenges the current, 
gendered HPV vaccine policy and marketing in Canada bring, but ultimately their own 
sense of sexual health vulnerability takes precedence over these misgivings.   
Witnessing the conflict the decision to get vaccinated brought Amber, the complexity of 
vaccine decision making was made abundantly clear to me. The influence of adverse 
HPV experiences relayed by friends, family and colleagues served as a strong motivator 
for women to get the vaccination. 
 
Conclusion 
 
Interviews with students were emotional and intense exchanges. The pain, shame and 
anxiety attached to having an STI and the few appropriate social channels through 
which to express these feelings and experiences had clearly taken a toll on the young 
women interviewed.  Students wanted to reframe how STIs were viewed in society. 
Instead of being considered a traumatic event, students wished that HPV infection could 
be positioned as part and parcel of a regular sexually active life. As HPV infection 
cannot be prevented, most sexually active individuals will contract a strain of the virus 
during their lifetime. Thus, they argued it is unnecessary to level stigma.  However, at 
the same time, students such as Sylvana, felt they were vulnerable to catching STIs 
from unfaithful partners.  Sylvana delayed decision making to determine if her 
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boyfriend would be faithful to her in the future, after she discovered he had cheated on 
her.  As such, students were concerned about not being able to successfully negotiate 
their own sexual health in their heterosexual relationships.  
 
Overall, students called for more open communication surrounding sexual activity, 
whether it was as a couple, between peers or within popular discourses. Many students 
remarked how an HPV educational campaign was absent from current in-school 
vaccination programming for grade eight girls. Maya advocated that sexual education 
be an integral component of school curriculum, particularly when the HPV vaccine is 
offered in a school.  Students wanted to increase interpersonal and institutional 
conversations about sex.   
 
Additionally, students were generally outraged at the gendering of the vaccine and this 
directly influenced their vaccine decision making.  However, vaccine decision making 
is complex and this was not the only factor influencing negative vaccine uptake as the 
majority of students chose not to be vaccinated or delayed making their decision.  Those 
who chose not to be vaccinated were angry with the gendering of the vaccine, but were 
also concerned about potential long-term vaccine side effects.  As the vaccine was 
relatively new, no long-term studies regarding the vaccine were available and the 
potentiality of the vaccine itself to bring forth risk was too big a chance to take.  Those 
who chose to be vaccinated did so because they knew someone who had contracted 
cervical dysplasia, which required medical intervention.  These inoculated students 
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wanted to avoid undergoing the same stressful and devastating experiences that friends 
and relatives had undergone.  However, the decision to be vaccinated did not mean that 
students like Amber were not concerned about the social impact of the gendering of the 
vaccine.  Amber was acutely aware of increased stigma being leveled against women 
who were infected with HPV without the same critique being directed at men, but she 
deemed that mitigating her sexual health vulnerability through vaccination was a higher 
priority.  
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CHAPTER SIX - Pre-Cancer Experiences: Containing HPV 
Through Negotiating Cervical Dysplasia Treatment and 
Opting to Vaccinate 
 
Risk – n. 1. a chance or possibility of danger, loss, injury, or other adverse 
consequences. 2. a person or thing causing a risk or regarded in relation to risk. [COED 
1999:1244] 
 
The dangers are only too horribly real . . . this argument is not about the reality of the 
dangers, but about how they are politicized. . . . Starvation, blight and famine are 
perennial threats. It is a bad joke to take this analysis as hinting that dangers are 
imaginary. [Douglas 1992:29] 
 
Introduction 
 
For the mothers interviewed, HPV infection was an emerging concern – a potentiality 
for their daughters. For the students interviewed, while frequently having been infected 
with HPV in the form of genital warts, it was temporary; HPV infection was an 
unpleasant experience but their HPV infections did not persist in the long term.  
However, the patients51 at the HPV vaccine clinic often had recurring HPV infections, 
which manifested in the form of cervical dysplasia, and the subsequent need for 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
51 “Patient” is a highly contentious label for this group of interviewees, and the use of the 
term is not meant to invoke the notion of an individual who is a passive recipient of 
health care.  Rather “patient” is used in the sense of an active and heterogeneous category 
of individual who helps shape their experience(s) in the clinic. See the editorial of Social 
Science & Medicine 62 (2006) for a further discussion of ways in which “patient” can be 
framed and interrogated. 
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colposcopies, biopsies and LEEPs.  Their sense of cancer risk had a different frame of 
reference than other interviewees – they had been engaged with cancer risk in the past, 
were in contact with cancer risk in the present and were waiting to see if cancer risk 
would reappear in the future.  Patients with frequent cervical dysplasia presentations are 
in a liminal, pre-cancerous state. They are not deemed healthy, but nor have they been 
diagnosed with cancer.  They are at-risk for cancer, but this risk may never materialize, 
particularly if they undergo interventions to remove the pre-cancerous cells.   
 
This chapter focuses on how patients’ conceptualizations of cancer causation shift with 
the development of a virally induced cancer, their experiences with cervical dysplasia 
diagnosis and treatment, and HPV vaccine decision making.  Patients talked about the 
difficulty of preventing HPV infection and instead looked to contain HPV. HPV vaccine 
decision making among patients was shaped by their experiences with cervical 
dysplasia. This being said, patients had a tempered view of the vaccine and its 
effectiveness, especially given their medical histories.  
 
A] Shifting Perspectives on Cancer and Cervical Cancer 
 
Rebecca was the first patient interviewed at the clinic. Although Rebecca did not blurt 
out her HPV-related anxiety like many of the students, her experience with cervical 
dysplasia was emotion filled.  This became evident as the interview progressed and 
Rebecca recounted her ten-year journey with cervical dysplasia.  We began our 
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conversation with the first interview question (see Appendix E for the interview 
schedule) by talking about what causes cancer in a general sense. Rebecca explained her 
perspective: 
 
What I find with diseases in general, it’s a bunch of factors that come together 
that cause the disease or what have you.  I just want to say with cancers, 
sometimes I think it is related to stress levels and sometimes more stressed 
people are more likely to get it and other times it is related to plastics, because I 
know heating plastics can be bad for your health.  
 
Everything seems to cause cancer, doesn’t it? It seems to be overexposure to 
certain toxins or radiation or genetic factors.  And, sometimes it is just bad luck. 
 
Jennifer, an outgoing 40-year-old senior human resources manager who made a point of 
amiably chatting with both clinic staff and nurses on her visits, came to the vaccine 
clinic on a rainy summer day.  Jennifer referred to cancer as an omnipresent “living 
organism” that is part and parcel of daily living.  For Jennifer, like Rebecca, cancer 
derives from a multitude of risks: 
 
Just something that our body produces naturally and is part of the society that 
we live in.  I think we fight cancer daily and that our immune system is affected 
by sleep, nutrition, any number of factors and that can influence whether or not 
we are able to fight it. Also, obviously, there’s genetics and there’s 
predispositions, but that’s my view. 	  
Jennifer’s statement reflects a sense that risk is ever present.52  These factors that 
increase risk – not enough sleep, food that is not healthy and our own family history of  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
52 This risk society type of thinking is precisely what Colleen, a mother, was critiquing in 
her interview. This points to the vastly different perspectives on risk that manifested 
between interview cohorts. 
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disease – present as stressors that must be continually negotiated in our “battle” (Sontag 
1999) against cancer. The theme of multi-causality (Sontag 1999) is also present in 
Kathryn’s narrative.  Kathryn, a 32-year-old urban planner who works for a municipal 
government located in a suburb of Toronto, explained: 
 
To be honest with you, it’s just the world we live in. Sometimes I think it’s very 
genetic. It’s just something I think that you can’t prevent necessarily. They are 
cells that have gone bad in your system, pretty much. You can’t always prevent 
it. You can prevent some, but not others. This is one, obviously, good example – 
getting the HPV vaccination helps reduce the risk of cervical cancer. There are a 
lot of things you can do, like smoking doesn’t help, the two of them go hand in 
hand. Nasal rim cancer is also an example of smoking and cancer – it is pretty 
common, smoking makes it more likely, so there’s a link there. 
 
Zoe, a 30-year-old high school teacher and the only Franco-Ontarian interviewed at the 
clinic, also talked about how the multiple causes of cancer are simultaneously within 
and outside of one’s control: 
 
I guess my first impression would be that there are cells already in their body 
that would be affected by a certain virus or condition in their life, but my 
understanding is that everyone has cancer cells in their body and it just takes 
certain things to make it come forward. My other understanding for cancer is 
that there are so many different types of cancer, you can’t really know why you 
get it or how you get it, but it’s just … your immune system breaking down, it 
could be the part of the world you live in or it could be what you eat and this 
virus kind of attacking those conditions.   
 
I am thinking stress, maybe smoking might be something, maybe bad diet, if you 
live in a part of the world where there isn’t access to health care, your family 
might have a history of a certain type of cancer that might trigger it as well. So, 
why people get cancer, I have always attributed it to a bunch of varietals, a 
bunch of different elements and then also how their body is behaving. 
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Rebecca, Jennifer, Kathryn and Zoe juxtaposed seemingly incompatible concepts in 
their narratives: the first being that preventing cancer is within your control, that the risk 
of getting cancer can be reined in by lifestyle choices;53 and the second, that cancer risk 
as a polyvalent “thing” cannot be avoided, being brought on by, for example,   
hereditary and environmental factors.  For patients, cancer was an  “invasion” from the 
“outside” (Lupton 1994:58), but could also stem from within – you could bring it on 
yourself.  This double discourse echoes findings by Sontag (1999) and Lupton (1994) 
and other social scientists (see Balshem 1991; Hallowell 2006; Lochlain Jain 2007; 
Matthews 2000; Potts et al. 2007; Potts 2006; Sered and Tabory 1999).  Patients’ cancer 
causation narratives reflect themes already found in existing literature; however when 
they talked about cervical cancer specifically, a shift in their thinking about cancer 
causation and risk occurred.   
 
Rebecca explained that cervical cancer stems from a single factor: “Well it’s caused 
from a virus that is sexually transmitted and for whatever reason, I don’t know why, but 
it attacks the cervix. The root cause is HPV.”  For Jennifer cervical cancer develops 
“because we have cervixes. For cervical cancer, specifically, I believe it is HPV, which 
is transferred through unprotected sex. I believe that’s the main reason, but it does seem 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
53 Attributing cancer to lifestyle choices reflects neo-liberal notions of health whereby 
individuals are tasked with maintaining their health, absolving the state of responsibility in 
providing such services as pollution-free water, adequate housing and accessible health 
care to the underserviced (Lupton and Petersen 1996).  
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to come later on in life.”54 Jennifer was not being glib in her response, but wished to 
point out that being a woman puts one at risk for certain gender-specific diseases and in 
this case HPV targets the cervix.  Kathryn talked about how her cervical dysplasia 
experiences informed her understanding of what causes cervical cancer: 
 
Well, what I would have said a year ago is that you just develop it. Some people 
have a chance of developing it because maybe their grandmother had it or it just 
happens to be in their genes. I have since learned, in the past year, that you 
increase your chance of getting it because of HPV infection and I learnt about 
that, the majority, through television to be honest through the TV ads. The 
Gardasil® ads and from there I had an abnormal Pap test and from there, I 
started to realize that it may or may not be because I have had an HPV infection. 
I have had a couple of abnormal Pap tests. So, I put my abnormal Pap tests 
together with the messaging I had been getting from the TV about Gardasil® 
and started to think, “okay, there is a connection here.” 
 
It is troubling that Kathryn learned more about HPV and cervical cancer from television 
than her GP, from whom she received the results of her abnormal Pap test. 
Unfortunately, as Kathryn’s example illustrates, patients (and the students interviewed) 
did not always receive adequate HPV-related information from their GPs when such 
information would have been helpful in making sense of an abnormal Pap test result.  
Zoe also received differing HPV-related information from various medical 
professionals: 
 
Well, I have to say I have been wondering if we are getting it more now than we 
used to or is it because now we have the technology to find out about it before it 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
54 HPV is not necessarily transmitted through unprotected sex. Condoms do not stem the 
spread of HPV because it is contracted through skin-to-skin contact and not fluid 
exchange.  
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turns into cancer? So, I am not sure if people are getting cervical cancer more 
than they used to or if it’s that we have come to the realization that it is more 
common or not. I have to say what I was warned about when it comes to cervical 
cancer are factors than can really contribute – they are stress, smoking, low 
immune system, and I think these are three main factors I was told about. 
Different nurses and a few doctors agreed on these factors, I have to say, though, 
that it varies a lot the different information I have been getting from different 
hospitals and nurses, doctors. But, that seems to be what they all agree on: 
stress, smoking and immunity. 
 
It is interesting to note that in Zoe’s narrative, nurses and physicians attached 
generalized notions of cancer causation (as stemming from multiple sources) onto 
cervical cancer, while patients linked cervical cancer with one cause, HPV.  Because 
patients equated cervical cancer directly with HPV – a singular, outside agent – it would 
make sense for them to link cervical cancer prevention with avoiding HPV infection.  
This line of thinking was, however, more of a theoretical prospect than a practical 
reality.  Patients did not generally think HPV infection could be avoided unless one 
abstained from all forms of sexual relations.  Kathryn explained, “Basically, even if you 
use a condom, you can still get the virus. So, I mean from that standpoint, I guess to try 
and avoid your risk altogether you would have to be – you would have to not have sex. 
But, I don’t see that as a feasible option for most people.”  Zoe noted that HPV could be 
contracted through oral sex and touching so, “anyone can get it and anyone can have it, 
but it doesn’t always present with symptoms.”  Rebecca looked for other ways to 
manage cervical dysplasia, as forgoing sex was not an option for her:  
 
From what we know so far, it’s sexually transmitted, so abstinence would help 
you not get it. Other than that, I don’t think there is a way to prevent it. So many 
people are carrying it right now, there is a high risk. So, you’ll end up getting the 
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virus and some people will get cancer and some don’t. I, myself, I already have 
HPV, so what I am trying to do is keep my immune system up, so I don’t run 
into anything big. 
 
Rebecca’s approach was not about HPV prevention, but “containment” (Douglas 1992).  
For Rebecca, contracting HPV was inevitable, however she hoped to lessen its 
magnitude and severity through eating fresh foods and making sure she got enough 
exercise and sleep.   
 
For patients, experiencing protracted cervical dysplasia brought the possibility of 
developing cervical cancer to the forefront of their minds.  Kathryn mentioned that 
cervical cancer was “definitively a possibility. I am more concerned about it, for sure.”  
And, Jennifer was forthright in stating, “I think it is a possibility and I would be naïve to 
think I would be excluded from that club.”  When asked if she thought she would get 
cervical cancer, Zoe reflected on her sexual health vulnerability: 
 
I probably will get it. I don’t know – it’s always those who are not promiscuous 
that get bitten in the ass. I don’t know how to explain it. It’s just a karma kind of 
thing. I hope not, but I have always been so paranoid about getting pregnant and 
HIV or so forth. You know, my ex-boyfriend was not a decent human being. I 
feel like I am going to pay the price for him in some way, shape or form. 
 
Patients feared that a sexual partner could infect them with HPV, and that it would 
eventually lead to cervical cancer.  Patients felt that prevention efforts could never be 
full proof, as Rebecca stressed, “I think you can reduce the likelihood, but I think 
people can be unlucky and get it.”  Even though patients viewed cancer and cervical 
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cancer causation differently, they expressed an overall sense of  “fatalism” (Drew and 
Schoenberg 2011) about cancer and cervical cancer. But this fatalism did not prevent 
patients from regularly engaging in Pap testing and receiving the HPV vaccine.  These 
forms of self-care (Foucault 1988) provided a measure of control for patients in a 
situation in which overall avoidance of cervical cancer was thought to be impossible. 
Self-care made them feel a little bit better when, in their view, nothing could be done to 
avoid HPV infection.  Patient self-care merely provided psychological relief – these 
strategies were attempts to control what they could because they could not mitigate 
HPV infection risk.  This approach to risk management differs from Lupton’s (1999b) 
conclusion about pregnant women who control pregnancy risks by engaging in pre-natal 
care and testing.   
 
B] Cervical Dysplasia Diagnoses and Treatment Experiences   
 
Conversations with patients tacked between the topics of cancer, cervical cancer 
causation and risk, and their actual cervical dysplasia experiences.  While patients 
exhibited the same anxiety students demonstrated due to their HPV diagnoses, the 
emotional undertone of patient interviews was different. Patients were weary and tired 
as the constant schedule of Pap re-testing, colposcopies, biopsies and LEEPs had begun 
to wear them down.  Prolonged cervical dysplasia had put patients on a treadmill and 
they were never sure if or when they would be able to step off of it.  Interviews 
provided a rare moment of pause for patients.  Not only were patients able to speak in 
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quiet rooms away from the hustle and bustle of the hospital, they were able to take a 
break from appointments and procedures in order to talk about their experiences. 
 
Rebecca spoke about her first experience with abnormal Pap test results and being 
assigned a cervical dysplasia grade: 
 
I had an abnormal Pap smear – that’s how I found out about all this. The 
abnormal Pap tests started almost ten years ago.  It just started slightly abnormal 
and I didn’t know what that meant. And, then it went a little more abnormal. 
There is a scale of being abnormal, so I have been treated along the way, so it 
doesn’t turn into anything cancerous. So far, there has been a lot of monitoring it 
and a biopsy to see if there were any kind of cancer cells. And, there weren’t, so 
that was good. Recently, I just had a series of LEEP treatments.  It’s a pain in 
the butt. You now, it’s constant, on-going. You wonder if you are going to get 
the phone call that it’s really abnormal this time and what that runs into.  
 
Jennifer, as did Rebecca, required further intervention beyond Pap re-testing.  Jennifer 
stated of her diagnosis: “It’s obviously never pleasant to hear news like that – that it is 
abnormal and could lead to worse stuff”55.  While often considered unpleasant, Pap 
testing was not thought of as an ordeal.  The same, however, cannot be said for 
procedures such as colposcopies and the LEEP.  Jennifer talked about her abnormal Pap 
results, the stigmatizing treatment she experienced from her GP upon diagnosis56 and 
her colposcopy: 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
55 Throughout interviews patients used the word “abnormal” to describe their Pap test 
results, which mirrored medical terminology.  As such, abnormal appeared to be the new 
normal for patients. 
56 Jennifer did not receive her initial abnormal Pap smear diagnosis at the hospital where 
fieldwork was conducted.  Not one patient reported experiencing disparaging remarks 
from hospital staff.  
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It was disappointing. I mean it was really upsetting. I felt unclean, I felt targeted. 
In fact, when I first had the procedure, when I first had a Pap and I started to 
encounter abnormal cells, you know my boyfriend at the time was with me. We 
had just started seeing each other seriously and I said what can we do to prevent 
him from getting it or something and the doctor said something like, “Well, you 
can always get another girlfriend.” I am deadly serious that she said that and I 
will remember that forever. I felt pretty bad, actually. 
 
Colposcopies are not fun. Fear. Pain. He had to take a biopsy and I didn’t have 
any Advil® or anything and, of course, they always show it on the monitor, on 
the screen.  So, I actually got to see my cervix being cut open – without any 
anaesthetic, so that was kind of ugh. Having a piece of your cervix removed 
while watching it was kind of ugh. It was a live camera. 
 
This is why I want to do this study with you because my experience has been 
ugh. I am glad that I am over it now. Thank God I escaped! I felt like there is a 
stigma. Even if they say 80 percent of sexually active people have HPV. When 
you yourself have it and it has been identified, you feel like a pariah and, you 
know, people don’t let you forget it – especially the medical community. 
Obviously, that doctor or nurse, maybe, she was having a bad day – I don’t 
know. 
 
The attending physician used video technology during the colposcopy to project the 
procedure onto a screen, broadcasting the procedure in real time.  This is generally done 
for teaching purposes, but it greatly disturbed Jennifer.  Not only did the biopsy, which 
was performed during the colposcopy, hurt (she had not taken pain medication in 
advance), she also witnessed the cutting and removal of cervical tissue on the screen. 
Jennifer used the term “ugh” multiple times in the interview. Although this term may at 
first seem to have the connotation of  “bland” or “unpleasant,” in the context of her 
narrative “ugh” stood for distress and being upset and emotionally strained.  
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Not only did patients experience pain and anxiety, but an overall feeling of distress 
during their procedures. Kathryn provided similar details regarding her recent 
colposcopy: 
 
I had abnormal cells back in January 2009. I went back six months later, to my 
normal GP to have it done again and the cells were gone. So, I was confused as 
to what happened. Did they just disappear? Then I went back six months later, 
which would have been my yearly Pap test and the cells were back. I was sent to 
have a colposcopy. My doctor very much played it down, saying it’s no big deal. 
The doctor said, “It’s just like a normal Pap, they are just going to snip you a 
little more and it’s fine.” But, having a colposcopy was not fun. It was not what I 
expected. It was a little more difficult to deal with than I had anticipated, than 
my doctor had told me. What I didn’t expect was that I was going to bleed for a 
week afterwards.  I didn’t know. The doctor said you might bleed for the rest of 
the day. Not me – I bled for the rest of the week. I got this overall icky feeling – 
like I needed a shower. I was originally going to go by myself and I am glad that 
I didn’t. I brought my mom with me, so she could drive me home. So, yeah, I 
didn’t feel prepared for what was going to happen. 
 
Kathryn had the urge to “cleanse” herself after a colposcopy which signifies a need to 
purge oneself of an emotional and anxiety-ridden event. It may also indeed be a way to 
rid oneself of the virus and its accompanying abnormal cells.  Additionally, Jennifer 
used the word “unclean” when describing how she felt in response to physician 
judgment.  To choose a word like “unclean” may appear to parrot dominant discourses 
about STIs which focus on “dirty” and “infected” individuals, but Jennifer was 
verbalizing how the physician pointed out that she was different from those who did not 
have an STI-related infection.  Physician choice of words and attitudes towards patients 
leaves them no choice but to try to reassert their morality and self-worth.  
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Zoe’s experiences echo those of other patients; she too had an anxiety-ridden 
colposcopy.  Zoe spoke at length about undergoing a LEEP: 
 
It was a painful and stressful experience. At the beginning, when I first had my 
abnormal results with the Pap test, I was crying because I thought I had cancer. I 
knew nothing about HPV and I didn’t know how many people have it and how 
common it is. At the beginning, I was stressed out about it because I knew 
nothing about it. I went in for a colposcopy and it wasn’t really pleasant, it was 
more unpleasant than painful, I guess. Afterwards, I had a LEEP procedure done 
– about six months later – and that was extremely painful. So I guess, after that 
first week, everything else that is associated with going to the doctor for a Pap 
test, colposcopy or anything to do with HPV has turned out to be a really 
stressful and painful situation, unfortunately. 
 
At the time of their interviews, Kathryn and Zoe were waiting to take part in post-
colposcopy and post-LEEP Pap re-testing in order to find out if they were cervical 
dysplasia free.57   During this period, Kathryn and Zoe were suspended in a liminal, pre-
cancerous state. This is a unique state medically speaking – they are betwixt and 
between being well and sick. They have not been diagnosed with cancer but with pre-
cancerous symptoms that if left untreated could eventually develop into cancer.  As 
Lupton, drawing on Douglas, states (1999b), being in an “in between” state is generally 
“dealt with by societies as impure, contaminated and risky to their integrity” (78). The 
anxiety that women expressed at being in a liminal state was palpable, and waiting for 
Pap re-testing results contributed to their worry.  Moreover, there was a sense of 
isolation if people in one’s social or familial circles were not comfortable talking about 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  57	  Having cervical dysplasia is not a straightforward or constant diagnosis. HPV is most 
certainly an indeterminate and fuzzy virus.  HPV can be transient and differing stains can 
appear at different junctures.  As a result, patients can move in and out of being at risk 
for cervical cancer.	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STIs. As Kathryn mentioned, “I can’t talk about it with anybody.”   Jennifer also stated 
that she did not receive much social support throughout her ordeal, but felt comfortable 
taking part in our interview because her last few Pap tests had been fine: 
 
It is isolating – you don’t want to tell anybody. I can only talk about it because I 
am rid of it. I wouldn’t want to tell anybody if I had it. It’s like you have the 
“couties” or something. It’s like I did it to me, but it didn’t occur out of the 
ether. It got passed along and it’s not because you are a “ho” or something. 
Well, then everybody is a “ho.” It was horrible. 
 
Patient social isolation was augmented by the fact that they were not seen by society at 
large to be susceptible to the virus.  Patients are not the target of HPV vaccine 
marketing; this advertising is aimed at grade eight girls and their mothers, and at 
university-aged women.  Mass media articles are also not written about women in their 
30s and 40s with protracted HPV infections.  Furthermore, patients do not benefit from 
a government-oriented vaccine subsidy.  As a result, patients have been left out of 
popular and policy discourses concerning HPV.58  Patient experiences are not simply a 
topic of public discussion.  Patient bodies are “abject” (Kristeva 1982:1) – bodies at the 
margins of HPV and HPV vaccine-related discourses.  
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
58 Since conducting fieldwork, Health Canada has extended the recommended age of 
vaccination to women up to 45 years of age (Merck Frosst April 26, 2011 press release). 
This change has not been reflected in Ontario-based HPV vaccine policy.  
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C] HPV Vaccine Decision Making   
 
As all patients received the vaccine, it is not surprising they were strong supporters of 
vaccination in general and thought that getting the HPV vaccine was a good idea.  
Jennifer described how it felt to get the “shot,” the term patients and clinic staff used to 
refer to the vaccine: 
 
Well, the actual shot hurts. The first doctor, she warmed up the shot, so that 
when she administered it, it didn’t hurt as much being plunged in, I suppose. 
But, the second nurse, just kind of plunged it in cold. It actually hurt. So what – I 
don’t care. I mean if it prevents cancer, who cares, right? The shot is great – it’s 
just a vaccine. I’m happy there is one. I am really glad there is one. I’m glad we 
have that option. But, I think probably for most folks the price tag would turn 
them off. 
 
When asked if they thought there were any risks associated with the vaccine, both 
Rebecca and Jennifer answered an emphatic “No.”  Rebecca explained her reasoning 
behind getting the vaccine, “For me, it was just to take advantage of what all is 
available today and to be able to reduce the risks for myself.” Jennifer’s decision to get 
the shot was directly related to her cervical dysplasia experiences as she explained, 
“After that LEEP procedure, you know, I really needed to take every step possible to 
never have to deal with any abnormal cells possible.”  However, Jennifer waited a 
period of time before proceeding with the shot due to the cost: 
 
I finally decided to . . . I mean, I asked my health coverage because I noticed it 
wasn’t covered on our plan and I asked to see if it would be covered. It wasn’t 
broadcast and it wasn’t in the literature, we had to specifically ask if this was 
covered and they said it was, but it was not covered electronically. You have to 
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mail it in. It is a bit of a pain to be reimbursed for it. They don’t make it easy.
   
 
Jennifer was fortunate to have private health insurance that covered the vaccine. 
Overall, 45 percent of patients had private health insurance which reimbursed all or 
some of the vaccine cost, 40 percent did not have private health insurance so they had to 
cover the cost out-of-pocket and 15 percent were not sure if they had insurance or if 
their insurance would reimburse them for the vaccine (see Appendix M).  The 
percentage of patients holding some sort of private health insurance is lower than the 
provincial average of 62 percent (Luffman 2005). Patients were more likely to have 
private drug coverage if they were employed in high-wage, unionized, full-time and/or 
permanent jobs.  As my interviews took place in the latter half of 2010, patients were 
still impacted by the 2008-2009 financial recession and many were working in 
temporary contract positions.   
 
Kathryn was also strongly in favour of the vaccine and passionately shared her 
thoughts: 
   
Well, I am pleased I can have it. Not happy to have three doses of it, but if that 
is what you have to do, that’s what you have to do. I wish I had the opportunity 
to have it when I was younger, before I became sexually active.  I think that a lot 
of people aren’t aware of it or they don’t know why people get it or why 13-
year-old girls are supposed to get it. Particularly people my age who don’t have 
children, who are not being told by their school or public health, you know, 
“Your kids need the vaccination.” So I’m 32 and in my group of friends I have, 
between 25 and 35, really don’t know much about it and, subsequently assume 
they don’t need to get it. I think that it should be, knowing what I know now, it 
should be on a list of vaccinations that everyone should get. You know, I have 
	   156	  
my vaccination card from when I was a baby and I hope that one day it will be 
generic enough to be on that list because if it prevents you from developing 
cervical cancer or getting genital warts, why not. 
 
Kathryn’s passion, though, was not without worry regarding the risk attached to the 
vaccine.  Unlike Rebecca and Jennifer, Kathryn ruminated about the vaccine’s possible 
downsides: 
 
I worry that the vaccination hasn’t been around for long enough for me to know 
if it is going to affect me when a couple of years roll around.  That’s why I think 
a lot of my friends aren’t getting it. They assume, “Well, the vaccination hasn’t 
been around very long, so we don’t really know what the effects are going to 
be.” What if it makes you infertile? You know, there are long-term effects we 
don’t know of.  So these things sort of worry me.  It’s not like the vaccination 
has been around for 70 years, but through the research I have done and the 
people who have given me the vaccination and the physician who did my 
colposcopy that those worries – that I don’t have much to worry about. 
 
It was common for patients to recount how their GPs had suggested that they were too 
old to get the shot.  The disappointment and frustration of not being fully informed by 
their GP was a recurring theme among patients. Kathryn spoke about experiencing 
cervical dysplasia at the same time that the Gardasil® advertisements hit the media and 
how she asked her GP about getting the vaccine. Kathryn described a visit with her GP: 
 
Now, I will say I asked my physician once about getting the HPV vaccination 
when it first started coming out on television and I said, “Should I be getting 
this?” and he said, “No, it’s only up to 26”.  So, I said, “okay.”   I wished that 
my doctor was more aware because now it is two years later and I’m now just 
getting the shot, Maybe, in the last two years is when I got HPV. I don’t even 
know how I have it, but maybe I could have prevented it had my doctor been 
informed. Frankly, I’m angry. I am angry he didn’t know that because he does 
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my yearly Paps and it is a common enough issue. He should be more informed 
about it. He wasn’t informed to that level and, in hindsight, I wish he had been. 
 
It was not until many of the patients attended the hospital colposcopy clinic that they 
realized they could, indeed, be vaccinated. Kathryn described the moment she was told 
she was eligible for vaccination: 
 
When I went to have the colposcopy, the physician who did it asked if I had had 
the vaccine. And, I said, “No, I thought you had to be under 26.”  She said, “no, 
that’s not true”. The people they originally studied it on were up to 26, so that’s 
why they can’t communicate about it being over 26 and she wrote me a 
prescription for it. She said, “If you’d like to get it, here you go. You can get it 
and I would encourage you to do it.” At that point, once I realized I was allowed 
to do it, even though I am over 26, I knew I was going to get this because I don’t 
want to have a colposcopy ever again. It’s really not enjoyable at all and really 
the primary reason is I don’t want to have to do a colposcopy or LEEP ever 
again, or whatever the next phase is. That’s the real reason.  
 
I had done a little bit of research about it before and because it was up to 26, I 
had stopped reading.  The moment I was told I was allowed to get it, later that 
night I went home and I did a little bit of research on people getting it over the 
age of 26 and it said you can. So, I picked up the phone and made an 
appointment here. So, it was a quick decision from the moment I was told I was 
allowed to get it. 
 
As Kathryn explained, the primary motivation for patients to get the shot was to avoid 
undergoing further Pap re-testing, colposcopies and LEEPs.  While patients felt 
fortunate to be able to get the vaccine, particularly due to its high cost, they were not 
certain what benefit the HPV vaccine could bring to them as they had already been 
infected with HPV.  As a result, patients exhibited a reserved optimism for the shot – 
their enthusiasm was more conceptual than pragmatic.  Patients were uncertain about 
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the long-term prophylactic benefits of the vaccine, even if it would ward off HPV 
strains they had not been infected with to date.  Zoe expressed this uncertainty: 
 
Well, I’m not quite sure what to think about it. The reason I wasn’t getting it in 
the first few years that I started seeing doctors was that I had abnormal results. I 
didn’t think that it would help as I already have HPV, so why should I get the 
vaccine?  It’s still a little bit uncertain, even yesterday when I went in to do it. 
My boyfriend said: “I don’t know what the point was that we did that or not.”  I 
think that we both felt that it might not hurt, so we might as well get it done, but 
at the same time, we aren’t really sure if it will help the current virus that I have. 
They were saying it might or it might not and will it do anything at all?  So, I am 
not sure. 
 
Zoe explained that it was her gynecologist’s repeated suggestion to get the vaccine that 
convinced her to go through with it.  Zoe talked about reaching her decision: 
 
The past few years that I have been seeing doctors, they have been saying it 
wouldn’t hurt if you get it. They weren’t insisting, but it can’t be that good or 
bad to have it done. Last time I saw my gynaecologist, he recommended I get it. 
So, I thought why not. It’s been a few years that this has been going on and I 
thought it couldn’t hurt or it could do me some good.  
 
Rebecca also expressed similar doubts as to the effectiveness of the vaccine, as she has 
been experiencing HPV-related complications for some time, “Well, I guess that it’s 
fantastic that they have come up with something like this that could save a lot of lives in 
the future if they are targeting the right people. It’s probably too late for me, even 
though I just went through it.”   Patients called into question the effectiveness not the 
efficacy of the vaccine.  Efficacy refers to “how a drug works in an ideal situation 
among highly selected individuals, not about effectiveness, how it works – does it do 
	   159	  
what it is supposed to do – in the ‘real world’ among the general population” (Lippman 
2010:100).   Patients had no doubt the vaccine could potentially work, they just were 
not sure if the vaccine would work for them with their particular medical histories.  
 
Conclusion 
 
Seeking HPV vaccination is a “transformative” (Polzer 2010:71) act for patients. It 
works to give them a small sense of control over the uncertainly brought about by 
cervical dysplasia of many grades and associated Pap test surveillance, colposcopies, 
biopsies and LEEPs.   This sense of control is not the same as the oversimplified 
empowerment message of the Gardasil® advertisements.  These advertisements 
advocate for a certain outcome from vaccination – the avoidance of cervical cancer – 
and sidestep HPV as an STI. Patients are acutely aware of the means through which 
HPV is transmitted and believe that HPV cannot be avoided but only contained.  They 
also do not feel that cervical cancer can be prevented.  As such, their tempered 
enthusiasm for the vaccine was more conceptual than pragmatic. Given their medical 
histories of recurrent cervical dysplasia, patients were not certain if the vaccine would 
help them, but were willing to get vaccinated, particularly when the shot was 
recommended by their gynecologist.  For patients HPV vaccine decision making was 
not a linear cost-benefit analysis focusing on whether benefits outweighed the risks, 
including potential harm and affordability (see Brewer et al. 2007; Chapman, 2010; 
Jacobson et al. 2007; Poland and Jacobson 2001; Poland et al. 2009).  Instead, 
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motivation to get vaccinated stemmed directly from patients’ anxiety-ridden 
experiences with cervical dysplasia.  As such, the high cost of the vaccine did not deter 
patients from getting the shot.  Even though patients questioned whether or not the shot 
would be beneficial to them given their medical histories, they were willing to give the 
shot a try.  
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CHAPTER SEVEN - Women’s Productive Re-Ordering of 
Risk and Gender and Ontological Decision Making 
 
What has emerged from interest in the human body, as it is lived, is a multiplicity of 
bodies, inviting a great many disciplinary points of view and modes of interpretation. If 
bodies and lives are historically contingent, deeply informed by culture, discourse and 
the political, then they cannot be summed up in any one kind of narrative. [Lock and 
Farquhar 2007:2] 
 
Introduction: Situated Risk and Gender 
 
 
Women’s narratives provide the opportunity to examine the plasticity of risk on the 
ground. These accounts are what Boholm (2003) calls the negotiation of “situated risk” 
(158). By examining and analyzing situated risk, anthropologists are able to move 
between three points: grand theory relating to risk; individual accounts of risk 
encounters; and the political, social, historical and economic context in which these 
mediations occur. Situated risk allows anthropologists to “problematize structural 
dimensions” affecting individual risk negotiation and to offer “nuanced ethnographic” 
renderings of these experiences (Boholm 2003:158). This goes beyond existing research 
in other social science fields focusing on risk, which generally zeroes in on either grand 
theory (see Beck and Willms 2004; Castel 1991; Dean 1999; Giddens 1991; Giroux 
2010; Gordon 1991; Ewald 1991; Fox 1997; Petersen 1997; Rothstein 2006) or 
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individual accounts (see Bond et al. 2012; Brown et al. 2013; Crighton et al. 2013; 
Gross and Shuval 2008; Lear 1995; Russell and Kelly 2011; Spencer 2013; Thing and 
Ottesen 2013; Tuinstra et al. 1998; Walls Dr et al. 2010; Zinn 2008), but not both. 
Concentrating solely on grand theory leaves out the important human element of risk, 
and researching only individual experiences, unintentionally reproduces 
sales/governance strategies. Highlighting individual accounts of risk, without adequate 
contextualization, reinforces the new public health’s concept of “the individual-as-
enterprise” (Petersen 1997:198). The individual-as-enterprise tenet promotes one’s self-
regulation through the notion of “healthism,” which emphasizes control over one’s 
health and “posits that the individual has choice in preserving his or her physical 
capacity from the event of disease” (Petersen 1997:198). The emphasis on self-
regulation provides an environment which is ripe for the “privatization of risk” (Lupton 
1999a:5). In the new public health, risk is deployed as a central theme through “an 
emphasis on anticipating and preventing the emergence of undesirable events such as 
illness, abnormality and deviant behaviour” (Petersen 1997:192-3). Castel (1991) posits 
that this is a significant epistemological shift that “has led to the replacement of the 
notion of dangerousness, formerly used to designate the privileged target of 
preventative medical strategies, by the notion of risk” (282). Thus, an individual is now 
signified through a multitude of risk factors. Risk is not conceived of as pertaining to 
actual events, but the immanent possibility of such manifestations. This shift produces a 
far more fertile terrain through which to procure and implement prevention 
programming. In the “individualization of risk” (Dean 1999:133), if a person does not 
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proactively seek out and enact strategies to prevent risk, it is deemed his or her fault for 
not working hard enough to mitigate risk. In the case of the HPV vaccine it is up to 
women to protect themselves and their daughters regardless of the fact that men also 
contract and transmit HPV and acquire HPV-related cancers. Situated risk, due to its 
grounded and contextual approach, avoids these pitfalls. Boholm herself best describes 
it:  
By means of analytical categories and theoretical work, the fluidity and the 
elusiveness of “risk” as it emerges in real life, in contrast to the abstracted 
models of ideal states prominent in much risk research, is provided with form 
and substance, flesh and blood, and human significance. [2003:158] 
 
However, as salient as the situated risk concept is to the research at hand, it does not 
address how gender intersects with risk-related decision making, nor the specific 
governance techniques associated with gendered risk making (as were outlined in 
chapter two). As Lupton observes, “the theorization of risk has tended to neglect the 
insights offered by contemporary feminist theory and the sociology of the body in 
understanding the links between gender, embodiment, subjectivity and risk” (1999a:7-
8). Moore (2010) takes this critique one step further by lamenting that, “among all these 
strands of research – on health inequalities, the medical profession and differences in 
health care provision across female groups – one aspect of ‘classical’ feminist work on 
gender and health was on the wane: the theorization of gender” (99). When risk-
oriented literature does indeed address gender, it examines “women” and treats this 
static category as a pre-given “fact.” This academic treatment “has led to the 
perpetuation of essentialist ideas about sex and gender – the notion that the former 
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directly and naturally entails the latter” (Moore 2010:100). Examples of such literature 
still frequent the academic record today (see Crighton et al. 2013; Gross and Shuval 
2008).  
 
This research project begins to address this theoretical and pragmatic gap. As such, it 
has been an exercise in examining both situated risk and situated gender.59 As is 
discussed in this chapter, the women interviewed actively engaged in the re-ordering of 
risk and gender whilst taking part in HPV vaccine decision making, whether the vaccine 
was for their daughters or themselves. This led women to take part in ontological 
decision making. Vaccine decision making is not the product of individual rational 
choice, but social and cultural processes.  Women’s vaccine decisions were layered into, 
and a result of, their active and situated experiences with gender and risk. Their situated 
experiences of (1) doing mothering, (2) doing gender politics and intermittent risk and 
(3) doing risk outline women’s efforts to be good mothers, strong young women 
merging into adulthood and pre-cancerous patients seeking a “pause” amongst the 
anxiety of their seemingly never ending cycle of medical procedures. All three modes of 
“doing” result in specific vaccine uptake outcomes – the linkages between identity 
making and decision making are layered and non-linear, but strong nonetheless. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
59 Although, Boholm (2003) does not refer to Lock and Kaufert (1998) in her piece, 
situated risk and situated gender are issue specific versions of producing “situated 
accounts” of the “microphysics of power” (Lock and Kaufert 1998:1) as they play out in 
the everyday realm of HPV vaccine negotiation and decision making. 
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A] “Still” Moments and Ethical Agency 
 
During their interviews, the mothers, students and patients who took part in the study 
paused from their daily lives. For the hour or so that an interview took, these women did 
not answer their phones, take care of a child, tend to home work or participate in a 
medical appointment or procedure. Our time together was an opportunity for them to 
exhale and unplug from their daily lives. Interviews can be described as a moment of 
respite, but the pause experienced during interviews is akin to Stewart’s concept of a 
“still life” (2005:328). Not only is a still life a moment of contemplation, it is a 
productive event. Stewart explains, “the word ‘still’ refers both to the state of being at 
rest and to an apparatus used for distilling liquids – a still” (2005:328). Thus, being still 
also holds “a promise that a moment of intensity will emerge” (Stewart 2005:329). This 
intensity surfaced when women reflected on what being a mother, a university-aged 
woman or a patient meant to them and how these gendered identities specifically 
intersected with HPV infection and HPV vaccine risk. Mothers and students ruminated 
on and processed how governmental and pharmaceutical discourses transmitted 
messages about HPV infection and HPV vaccine risk and then hybridized or rejected 
these messages. For patients, it was about how they were “living with risk” (Lupton 
1999b:68), all the while being excluded from the public discourses aimed at mothers 
and students. Patients were not, however, removed from the gendered discourse of 
societal blame when they contracted an STI. Their situation was unique among the 
women interviewed for they had to meditate the murky and uncertain territory of being 
labeled pre-cancerous. All the women, nevertheless, demonstrated that their vaccine 
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decision making was not a linear, cost-benefit analysis focusing on whether benefits 
outweigh risks, including potential harm and affordability. Instead, decision making was 
steeped in their experiences as women, including previous (and current) HPV 
infections, what being a good mother meant to them and how they envisioned gender as 
they mature into womanhood. 
 
Each interview contained much more than just a discussion of the women’s vaccine 
decision making. When taking a pause to be interviewed, each woman created a 
narrative that contributed to her continually developing sense of self. As each narrative 
developed, identity was re-inscribed and re-enforced for it was in the thick of the pause 
that the exterior subject formation of pharmaceutical and governmental discourses and 
the interior realization/actualization of the self intersected. The pause is what Allen calls 
an “intersubjective (rather than a nonsubjective, whatever that might mean) frame for 
feminism” (2008:17).60 Lock and Farquhar utilize the conceptual frame they have 
termed “living” (2007:2). These medical anthropologists state, “to make bodies a topic 
for anthropological, humanistic, sociological, and historical research is to ask how 
human life can be and has been constructed, imagined, subjectively known – in short, 
lived” (2007:2). Whether one places the generative aspects of narratives in a pause, an 
intersubjective frame or within the concept of “living” is secondary – what is important 
to emphasize is what women are doing in these moments. Women are not always 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
60 Biehl et al. (2007:7, 10) also make reference to the term intersubjective. In their 
volume the term denotes experiences across or amongst a grouping of individuals or 
collectivities. 
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portrayed as “doers” or as those who “do,” and in the case of HPV infection and vaccine 
women are positioned as passive recipients and bearers of disease. Being a “doer” is a 
term often reserved for men, as Pandolfi discusses in her research of women and their 
development of self and illness narratives in a southern Italian village (2007:453). As a 
result, it is important to emphasize that the pause of the interview is a space of doing. 
Inspiration for emphasizing what women do also lies with Butler’s (2004) work – her 
well known “doing gender” concept. As per Butler, doing gender is a continual process, 
not a discrete or concrete bodily motion. She elaborates: 
 
Gender is a complexity whose totality is permanently deferred, never fully what 
it is at any given juncture in time. An open coalition, then, will affirm identities 
that are alternately instituted and relinquished according to the purposes at hand; 
it will be an open assemblage that permits multiple convergences and 
divergences without obedience to a normative telos of definitional closure. 
[2007(1990):22] 
 
It is in the space of the pause that women are actively, continually and complexly 
negotiating their sense of self while working to secure their health vis-à-vis HPV 
infection and the HPV vaccine. It involves constantly engaging in acts of self-reflexivity 
or “practices of the self,” including actions, habits, movements and self-framings 
deemed to achieve one’s goals of the “good” or “moral” (Butler 2008:27-28). This is 
what Foucault means when he writes about working towards being an “ethical subject”. 
When referring to being ethical, Foucault is foundationally speaking of “the kind of 
relationship you ought to have with yourself, rapport à soi” (1997:263). When engaging 
in this relationship with oneself, we are creating our own “telos,” or our own set of 
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codes for maneuvering daily life (Foucault 1997:265). Scripting one’s telos is an 
exercise of invoking power, no matter how fleeting or limited it may be. However, 
when writing one’s telos one does indeed draw from the social environs. We do not 
make and re-make our codes in a vacuum, and in the era of the new public health, 
individuals are encouraged to actively develop habits and practices centering on self-
regulation through “healthy lifestyles” (Nettleton 1996:44). This can constitute 
individualized behavior, such as refraining from smoking, moderating drinking, being 
on low-fat diet regimes and limiting the number of sexual partners (Moore 2010:101). 
What happens in one’s surrounding environment matters; even if one is reacting against 
a particular norm, such as what is deemed “healthy” behaviour, this norm is still very 
much present in the revised telos. Butler expands upon the creation and enactment of 
micro scripts within the overarching landscape of macro scripts:  
 
Ethical agency is neither fully determined nor radically free, but is one whose 
struggle or primary dilemma is to be produced by a world even as one must 
produce oneself in some way. This struggle with the unchosen conditions of 
one’s life. A struggle – an agency – is made possible, paradoxically, by the 
persistence of this primary condition of unfreedom. [2008:28]  
 
It is in the negotiation of this unfreedom – immersing oneself in a pause, an 
intersubjective framework or by “living” – that ethical agency becomes possible.  
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B] The Re-Ordering of Risk and Gender  
 
Numerous examples of women taking a pause and crafting their narratives of self and 
identity populate the medical anthropology/sociology record (see Becker 1999; Garro 
2000; Gregg 2003, 2011; Hunt 2000; Kirmayer 2000; Kohler Riessman 2000; Pandolfi 
2007; Rapp 2007; Saukko 2010; Thompson 2005, 2007; Throsby 2010). However, 
something quite specific took place when women spoke of their decisions to have their 
daughters or themselves vaccinated or not vaccinated against HPV. In an overarching 
sense, their ethical agency involved aspects of Thompson’s “ontological choreography” 
(2005). Ontological choreography entails the “dynamic coordination” (Thompson 
2005:8) of various aspects of self and in Thompson’s ethnography it was primarily that 
of trying to become a mother within a fertility treatment-oriented medical encounter. In 
the case of patients, and more fleetingly students, ontological choreography was joined 
by the “biographical disruption” (Bury 1982:167) of being chronically ill. However, 
women’s ethical agency in the pause also pointedly involved the re-ordering of gender 
and risk across all cohorts. For the women interviewed, risk and gender intersected in a 
“productive” (Zaloom 2004:365) manner. In other words, risk and gender were 
practiced when vaccine decision making occurred. HPV vaccine decision making 
provided the key that opened the door to understanding how gender and risk were 
appropriated (to answer research question two) to varying degrees of importance, and 
when health decisions were made (to answer research question three). These decisions 
were linked to the women’s senses of self, and conceptualizations of risk and gender 
differed depending on where a woman was at in her lifecycle journey.  
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The women’s narratives demonstrated that the concepts of risk and gender were 
adjustable ontological modes of doing – risk and gender moved in and out of focus 
depending on the context, but they were always present in some form, no matter how 
faintly. For mothers, risk was a theoretical construct: their daughters were just moving 
into their teenage years and the last thing they wanted to do was explore adolescent 
sexuality with them. HPV risk was a distant proposition. As a result, mothers focused 
much, much more – abundantly more – on gender and doing mothering. For students, 
HPV risk was intermittent because many of them had experienced transient HPV 
infections in the form of genital warts and the beginning of low-grade cervical 
dysplasia. Students were also outraged at the gendering of HPV and the vaccine and 
based their vaccination decisions on the type of gendered being they would like to be – 
one that was not put in a pre-determined, at-risk box. Students also worried about HPV 
vaccine risk as data concerning long-term side effects does not exist. As a result, 
students dealt with both risk and gender as a part of their doing; thus, they were doing 
gender politics and intermittent risk in equal measure. The risk students were doing was 
nothing like the risk patients were living with. Patients felt their risk was so 
encompassing that there was no means to escape it, but only strategies by which it could 
be contained. Because of the intensity of risk for patients, which they recounted in their 
diagnostic and treatment narratives, gender took a backseat. Patients were more focused 
on their HPV infection journey than their gendered senses of self. Narratives across all 
three cohorts indicate that in relation to women’s sense of self, risk and gender are 
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elastic concepts. When risk is distant, a primacy is placed on gender. When risk is 
coming into focus, both gender and risk are ontologically highlighted. And, when risk is 
ever present, risk takes centre stage with gender firmly placed in the shadows. 
 
Figure 8 - Conceptual mapping of the re-ordering of risk and gender 
 
However, before moving onto illuminating how women were entangled in their various 
forms of doing it is important to note that this doing did not reinforce the gendered at-
risk subject formation of pharmaceutical and governmental discourses. Subject 
formations are power strategy configurations which attempt to order individuals or 
groups. These sales/governance strategies are trying to rein in their targets. Order is 
doubly signified here as the word denotes keeping subjects “in order” and prompting 
they follow governance orders. However, instead, this research project traced how 
women re-ordered their lives. As Douglas suggests with the concept of “disorder,” re-
ordering does exhibit “the potential for patterning” (2002[1966]:117). Re-ordering 
presents both a threat to order and the potential to enact power. Thus, while doing 
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women are creatively re-appropriating/rejecting and hybridizing the gendered and risky 
HPV subject formation to productive affect. Butler describes this process of re-ordering: 
 
There is no making of oneself (poiesis) outside of a mode of subjectivation 
(assujettissement) and, hence, no self-making outside of the norms that 
orchestrate the possible forms that a subject may take. The practice of critique 
will thus expose the limits of the historical scheme of things, the epistemological 
and ontological horizon within which subjects come to be at all. To make 
oneself, then, in such a way that one exposes those limits is precisely to engage 
an aesthetics of the self that maintains a critical relation to existing norms. 
[2008:26-27]   
 
Correspondingly, mothers ironically played with the concept of the good mother, 
students rejected mainstream concepts of gender and risk when saying “no” to the 
vaccine, and patients took a step back from the HPV treadmill by being vaccinated and 
setting their own parameters to contain HPV.  Each woman did this on her own terms. 
Risk and gender were folded into the women’s senses of self in myriad ways across, 
between, and within each group of women.61  What governance strategies have tried to 
“fix,” the women interviewed continually unfixed. With this in mind, the details of how 
each cohort was ensconced in its own modes of doing when engaged in HPV vaccine 
decision making is outlined below. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
61 Rapp (1994) also found great variety within and across class groupings when she 
interviewed New York City women regarding amniocentesis. In my study, class is not 
used as a marker because most women interviewed were middle class. 
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C] Doing Mothering 
 
As the narratives in chapter four reveal, mothers were highly invested in issues 
surrounding the HPV vaccine. As Carmen pointed out in our interview, HPV vaccine 
related messaging in pharmaceutical, governmental and mass media discourses 
emphasized that good mothers get their daughters vaccinated. Carmen’s engagement 
reflects the continually negotiated process whereby mothers mediated between 
popularized notions of motherhood and enacted health strategies for their daughters they 
were comfortable with. These health strategies were also mothering strategies. Some 
may argue that the concepts of gender and mothering have been conflated, but doing 
mothering akin to Butler’s performing or doing gender. Gender, says Butler, “is always 
a doing, though not a doing by a subject who might be said to preexist the deed” 
(2007[1990]:34). Doing gender is a continual process, not a discrete or concrete bodily 
motion, as women experienced in doing mothering. Thus, the analysis of HPV vaccine 
decision making among mothers traces the creative energy that “erupts” (Stewart 
2000:245) when motherhood and mothering intersect. 62 Rich explains the 
motherhood/mothering dyad:  
 
I try to distinguish between two meanings of motherhood, one superimposed on 
the other: the potential relationship of any woman to her powers of reproduction 
and to children; and the institution, which aims at ensuring that that potential – 
and all women – shall remain under male control. This institution has been a 
keystone of the most diverse social and political systems. It has withheld over 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
62 This framing is similar to the contact between what Foucault describes as subject 
formation and the development of one’s sense of self or ethics (Allen 2008) as discussed 
earlier in this chapter.  
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one-half the human species from the decisions affecting their lives; it exonerates 
men from fatherhood in any authentic sense; it creates the dangerous schism 
between “private” and “public” life; it calcifies human choices and potentialities. 
. . . [F]or most of what we know as the “mainstream” of recorded history, 
motherhood as institution has ghettoized and degraded female potentialities. 
[1986(1976):13] 
 
However, Rich’s writings on the institutions of motherhood represent one half of her 
theoretical framework, with the other reflecting the everyday act of mothering. On the 
one hand, motherhood comprises the overarching strategies through which women are 
kept under the thumb of the dominant – and, predominantly patriarchal – order. Order is 
a key word here. One measure implemented to keep order was that of the “scientific 
mom” (Thurer 1994:225-6). The scientific mother was created in the first part of the 
20th century when mothers were not considered to be innately qualified to “properly” 
rear their offspring. During this period, the medical establishment dispensed the 
requisite knowledge, procedures and guidelines for raising “healthy” children (Thurer 
1994:225-6). The scientific mom is similar to mothers who are deemed to practice 
“intensive mothering” (Hays 1996:x) today. Resources harnessed in raising children as 
an intensive mother must also be “expert driven” (O’Reilly 2004a:8). On the other hand, 
mothering reflects the on-the-ground workings of being a mother – the re-ordering (and 
sometimes chaotic and dis-ordering) processes as described and defined by women. 
While motherhood is a subjugable form of power and, as Ginn argues, “is a form of 
social control exercised over women as they bear and raise children” (2004:32), 
mothering can function within spheres of agency, what Foucault calls being ethical and 
Butler deems ethical agency. Glenn emphasizes the agentive aspects of mothering: 
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Mothering occurs within specific social contexts that vary in terms of material 
and cultural resources and constraints. How mothering is conceived, organized, 
and carried out is not simply determined by these conditions, however. 
Mothering is constructed through men’s and women’s actions within specific 
historical circumstances. Thus agency is central to an understanding of 
mothering as a social, rather than biological, construct. [1994:3]  
 
When one is able to harness the everyday experiences of mothering on one’s own terms, 
even for a fleeting moment – no matter how covert – the narrative of motherhood can be 
destabilized. This destabilization is evidenced in the narratives of the women 
interviewed, which harnessed the good mother discourse by enacting intensive 
mothering to productive effect. This is not, however, “authentic” mothering (O’Reilly 
2004b:10), for this term inadvertently reifies mothering by bringing forth a singular 
mothering model against which mothers can be judged.  
 
When motherhood and mothering intersected, mothers strategically accommodated, 
rejected and hybridized the institutional directives that were embedded in HPV vaccine 
public health, mass media and pharmaceutical messaging. Each woman drew upon her 
own unique set of experiences in determining the best vaccination measure for her 
daughter. Mothering was enacted through each woman’s re-ordering of dominant HPV 
vaccine related discourses. This re-ordering allowed her to creatively re-formulate her 
identity, self-ascription and sense of self within existing power frameworks. Mothers 
creatively harnessed the good mother discourse and enacted intensive mothering to 
productive effect. Their re-ordering revealed the complicated and often ironic nature of 
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mothering. As such, women initially appeared to echo dominant discourses surrounding 
motherhood, but a closer examination revealed they were re-fashioning the good mother 
precept in novel ways. Engaging in re-ordering while making a vaccine decision for a 
daughter provided the women interviewed with the opportunity to re-produce, re-create 
and re-enforce an aspect63 of their own sense of self – their sense of being a mother. 
 
The active negotiation of being a good mother resulted in vaccine mediation strategies 
that involved opting to get their daughter vaccinated, not vaccinated or delaying the 
decision. But, even within each decision category rationales varied as to why mothering 
strategies were carried out. For example, both Andrea and Heather decided to have their 
daughters vaccinated. Andrea’s mothering strategy was slightly different than Heather’s 
who had HPV-related complications in her early 20s and made her decision based on 
her HPV-related treatment experiences. Andrea provided a salient example of 
formulating health strategies linked to the very conceptualization of mothering, but 
instead of being contradictory, her decision making was steeped in irony.  As Butler 
states, “[the fact] that my agency is riven with paradox does not mean it is impossible. It 
only means that paradox is the condition of its possibility” (2004:3). Andrea sought to 
shield her daughter from the downsides of being an intensive mother some day, all the 
while clearly enacting these canons herself. Andrea’s vaccine decision may have 
mirrored dominant motherhood discourses, but she was, momentarily, attempting to 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
63 Being a mother is but one identity-ascription of the women interviewed. Women also 
identified as professional working individuals, sisters, aunts, partners, daughters and so 
forth, but during interviews their focus was on mothering strategies. 
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disrupt future hegemonic conceptualizations of motherhood so that her daughter would 
not have to do the same when she grew up. Thus, to form her own mothering strategies 
within the context of vaccine decision making and doing mothering was an act of hope. 
She was saying that just because she needed to navigate the maze of motherhood, didn’t 
mean her daughter should have to negotiate these ideological frameworks. While 
Andrea’s creative mothering strategies will not dismantle the overarching structures of 
motherhood, she began to loosen their grip. Her approach was a move to “undo 
restrictively normative conceptions of sexual and gendered life” (Butler 2004:1).  
 
Neither Andrea nor Heather felt that the vaccine posed undue risk to their daughters. 
Andrea believed that the vaccine was similar in terms of risk to other childhood 
vaccines for meningitis or chickenpox. For Andrea, risks associated with contracting 
HPV, meningitis or chickenpox were far greater than any presented by related vaccines. 
While Heather too believed that all vaccines were potentially risky, her experience with 
HPV and related interventions was so strongly etched on her memory that the 
unpleasantness of her HPV experience outweighed any risk related to the HPV vaccine. 
Nor were Andrea or Heather willing to talk to their daughters about potential HPV 
infection risk because they were not comfortable talking to their daughters about 
adolescent sexuality; Carmen was the only mother to undertake this. The concept of risk 
– whether it was the risk of their daughters’ experiencing potential long-term side 
effects associated with the vaccine or the risk of their daughters contracting HPV – was 
kept in the background by mothers like Andrea and Heather.  
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Other mothers interviewed, like Colleen, also invoked the good mother and intensive 
mothering narratives while engaging in vaccine decision making. However, these 
mothers decided against vaccination, and their re-crafting of these discourses took a 
different turn than that exhibited by Andrea and Heather. These mothers re-fashioned 
the popularized conceptualization of the good mother to stand for mothers who did 
extensive research regarding the effects of the HPV vaccine, did not want their 
daughters to be “test” subjects for a vaccine that had not been on the market for very 
long and who cared enough to say “no.” These mothers, Colleen being one such, 
reinforced how pervasive the good mother and intensive mothering discourses are, 
regardless of a vaccination decision. Colleen believed that, as a society, we have 
become hyper aware of potential risks, to the point of paralysis. In response to, and in 
resistance to, living in what she conceived of as a “risk society” (Beck and Willms 
2004), Colleen chose not to over think every potential risk. Thus, for Colleen, 
pharmaceuticals, which are manufactured by for-profit companies, brought about 
greater risk than the HPV virus itself and she actively resisted Gardasil® advertising 
that, in her own words, was set to make all mothers “afraid” for their daughters. Given 
this line of thinking, Colleen was being a good mother by protecting her daughter from 
the HPV vaccine, both in terms of potential vaccine side effects and “doing too much” 
to avoid hyped risk. Both the vaccine and too much stress were deemed to be 
“unnatural” and, thus, unhealthy. Colleen could, however, easily keep this vaccine risk 
at bay – she simply did not have her daughter vaccinated. For Colleen, the concept of 
risk was on her radar, but it was not a primary focus because she felt that she could 
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control the risk through disavowal. For Andrea, Heather and Colleen, HPV infection 
risk was also a far off proposition – their daughters were not yet sexually active (at least 
to their knowledge). For those who opted for vaccination, long-term vaccine side effects 
were years away from materializing, if they developed at all. Thus, for both the mothers 
who had their daughters vaccinated and those who did not, HPV infection and HPV 
vaccine-related risk was considered a far off possibility despite their differing mothering 
strategies. 
 
D] Doing Gender Politics and Intermittent Risk 
 
As is outlined in chapter five, students were unhappy with the gendering of the vaccine 
and STIs, and the potential risk of the HPV vaccine. Student narratives provided a 
window into their uneasiness with how women have historically been are portrayed as 
sexualized beings, and the perceived lack of governmental involvement in setting the 
record straight. In their narratives students strongly critiqued the neoliberal 
individualization of the new public health whereby “social problems become utterly 
privatized and removed from public considerations” (Giroux 2010:4). Students 
discussed this theme by lobbying for de-gendering the vaccine, contesting the stigma 
associated with contracting an STI, and advocating for expanded sexual health 
education in schools and society as a whole, in order to temper the difficulties they had 
encountered in sexual health negotiation. They also expressed general uncertainty and 
mistrust in an age when medical “solutions” are delivered by for-profit entities. This 
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mistrust and uncertainty was explored by student in conversations about living with the 
risk of intermittent HPV infections and their complex attempts to come to a vaccine 
decision they were comfortable with. As student decision making ranged from outright 
refusal to a delay in making a decision to changing one’s mind about getting vaccinated, 
student narratives demonstrated that trust is a nuanced and layered concept when nested 
within situated risk negotiation. 
  
1. De-Gendering and De-Individualization 
 
Students were highly focused on doing gender, but were developing their sense of self 
or ethical identities by doing gender through resistance to being put in a box of the 
“feminine” (Moore 2010:96) by sales/governance strategies. Students were upset and 
angry with the gendering of the vaccine (and, hence, the virus) to the extent that 70 
percent decided not to be vaccinated or delayed their decision.64 The decision to forgo 
vaccination is a form of what Streefland et al. call “non-acceptance” (1999:1709) of the 
vaccination. In non-acceptance, individuals “question the need for vaccination” 
(Steefland et al. 1999:1710). When non-acceptance becomes widespread, collective 
resistance can emerge, but for students decision making occurred on an individual level. 
Historically, there have been many organized movements against vaccination, such as 
the 19th century grassroots campaign against smallpox vaccination in England, and 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
64 Whether or not this form of “negative agency” (Wardlow 2006) puts students at risk 
should be debated, but this is not the focus of the research. Public health policy makers 
and communicators should take note of how gendered framing affects vaccine decision 
making outcomes. 
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current day activism in the Netherlands against rubella and mumps inoculations. For 
students, however, there was “no organization, no active mobilization” (Steefland et al. 
1999:1712).   
 
Interestingly, though, in explaining their reasons for vaccine non-acceptance, students 
moved from the individualized sphere of vaccine decision making to seeking collective 
measures to address vaccine gendering and its social consequences. As Maya stated, the 
gendering of the vaccine and STIs made her feel “sick.” Sylvana described this type of 
gendering as, “the wrong approach.” Amber felt that current day gendering was the 
continuation of negative historical discourses vis-à-vis women that could be traced back 
to the 19th century. Maya’s decision not to get the vaccine and Sylvana’s decision to 
delay were both their way saying “no” to the gendering of the vaccine (and the virus) in 
governmental and pharmaceutical discourses.65 Even Amber, who changed her mind in 
favour of being vaccinated after seeing a friend experience a protracted HPV infection, 
was conscious of the social implications that current, gendered HPV vaccine policy and 
pharmaceutical sales/governance strategies in Canada brought. Amber elaborated, 
“okay, so I have a problem, as I mentioned, with the vaccine even though I got it. I 
fundamentally have a problem with it because the way it’s being marketed towards 
girls, stigmatizes girl’s and women’s sexualities as being a part of the problem.” As 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
65 It is important to note that students did not speak about being targeted because of their 
age. Discourses surrounding youth and risk are rife in public health programming (see 
Brown et al. 2013; Spencer 2013; Thing and Ottesen 2013) and society in general 
(Giroux 2010), but students ranged in age from 20 to 28 and they did not consider 
themselves to be “youth.” 
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Gregg notes, “STDs are . . . particularly stigmatizing for women, for whom cultural 
ideals of premarital virginity, marital monogamy, and respectability clash with the 
reality of sexually transmitted infections” (2011:77).  
 
Sylvana and Maya resisted the subject formation of the risky, HPV-related girl/woman 
by saying “no” to the vaccine, but at the same time they were acutely aware of gender 
imbalances in sexual health negotiation. As such, their vaccine negotiation was rife with 
similar “paradox” (Butler 2004:3) and complexity that mothers experienced. Students 
spoke in great detail about negotiating sexual health as a challenging endeavor (see 
Roche et al. 2005; Richens et al. 2003; Shoveller et al. 2010; Thomas 2005). Sexual 
health gender imbalances brought risk into their daily lives. In practice, as Sylvana 
explained, women experience vulnerability, just as she did when she contracted genital 
warts from her boyfriend when she thought they were in a monogamous sexual 
relationship. Sylvana opined that in an effort to avoid “all sexual transmittable diseases, 
the first step to preventing them is communication between partners and equal 
involvement of both partners in awareness of their risks and just check ups and things 
like that, like knowing your status related to various diseases.” While this would be the 
ideal scenario, Sylvana herself experienced a breakdown in such communication when 
her partner was unfaithful and she was left, as she said, “exposed.”  
 
Maya also spoke about the vulnerability young women experience in sexual encounters. 
She elaborated: 
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But then there’s also the layer of young girls not being empowered to make 
these decisions as well. So, that has nothing to do with education. Like you may 
right know that having unsafe sex, unprotected sex is dangerous but that you 
don’t necessarily have the power to make that choice in the situation. And so 
that adds another dimension to it. 
 
Like Maya, students did not always feel they had the power to press for the use of 
barrier contraceptives while engaging in sexual practices. They might indeed have 
known that not using such measures could lead to STIs, but they did not always feel 
they could advocate for their own health concerns in such situations without alienating a 
male partner. This, coupled with the fact that partners were not always faithful, made 
students feel vulnerable. While Maya’s and Sylvana’s decisions not to be vaccinated 
can be placed within the frame of doing gender through resistance, Amber’s “yes” 
decision can also be viewed as being a form of quiet protest. Amber may not have 
refused vaccination, but she deployed vaccination as a tool to help strengthen her 
position in future sexual health negotiation. Amber revealed, “I guess my own concern 
about my sexual health outweighed any potential problems that might come with it. 
And, so, which is why I decided to get it.” Thus, students demonstrated that resistance 
was as intricate as the paradoxes exhibited by mothers and could not be measured by 
vaccine decision outcomes alone.  
 
Students, overall, urged for a more open climate about sex, sexual relations and STIs. 
They reasoned that if more people talked openly about sex, sexual health negotiation 
would be more balanced; if such a climate existed both men and women would be 
aware of STI risk and take measures to protect themselves. They posited that delivering 
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an STI-related vaccine – the HPV vaccine – in school settings across the province and 
country while not leveraging this program to provide accompanying sexual health 
education was a missed opportunity. Not only did students wish for sexual education 
curriculum to include HPV as a topic, they were convinced that if sexual education was 
covered more frequently and in more depth in both primary and secondary schools,66 
not only would young women be aided in negotiating their sexual health, it would help 
lift the STI-related “stigma” (Goffman 1963). They argued that the more sex, sexual 
relations and STIs were talked about, the more individuals would realize how 
commonplace they were. This would alleviate the compulsion to shroud such 
experiences in silence for fear of being judged. As Maya insisted, instead of being 
considered a big or traumatic event, “people should think of HPV as part of a normal, 
healthy sexuality because it can’t necessarily be prevented, so if you are going to have 
sex, you are going to end up getting HPV, probably, at some point.” Maya did not put 
the onus solely on the educational system, she stressed that society as a whole, must 
also start to “talk about sex.”  
 
By wanting to bring sex and sexual relations into everyday conversation, students were 
not only aiming to ease the stigma – they were trying to resist it. This was an effort in 
re-ordering daily discourse. Through this suggested re-ordering, they resisted the social 
exclusion that resulted from others knowing they had contracted an STI and being 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
66 Lear (1995) also found that young adults reported that the sex education they received 
before university was “woefully inadequate” (1317). 
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depicted as “dirty” or “deviant” women. Although writing about disability, Das 
describes the effects of social exclusion:  
 
The entire discourse of anxiety that surrounds the stigma of deformed bodies 
thus is about reduction of sociality, exclusion from moral community as well as 
subjective feelings of guilt and shame. Being cast out of the social community 
coupled with a diminished sense of worth reduces the capability of the afflicted 
person to seek help even when this is in objective terms, easily available. 
[2001:5]  
 
Student resistance to the gendering of the vaccine and the virus, vulnerability in sexual 
health negotiation, and the stigma associated with STIs were all factors integral to their 
developing sense of self as young women. Their telos involved rejecting being painted 
as “dirty” and “sexualized” women, all the while being acutely concerned about the 
uneven power relations present in sexual health negotiation with male partners. This 
was a complex form of risk negotiation because on the one hand they were out rightly 
refusing to be identified as risky sexual beings, but on the other hand, they were trying 
to find ways to mitigate their risk as sexually active women who had contracted STIs. 
Their prescription for dealing with stigma was increased sexual health education, both 
in schools and in society in general through public health measures. Students attempted 
to adjust the neo-liberal devolution of public health services, which has been rampant 
under the auspices of the new public health paradigm (Lupton and Petersen 1996), by 
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urging for greater sexual health education in schools. As such, students were trying to 
shift the onus for public health education from the individual back onto the state.67  
Thus, their negotiating risk was cast as a re-ordering of existing power structures, but 
not in a way that dissolved the institution currently perpetuating the subject formation of 
the HPV-oriented risky young woman. As for mothers, for students there was “no self-
making outside of the norms that orchestrate the possible forms that a subject may take” 
(Butler 2008:26-27). This speaks to student recognition that risk is a social product – if 
it can be constructed as an individual and gendered problem through sales/governance 
strategies, these premises can also be de-constructed through state provided educational 
programming. 
 
2. Risk, Uncertainty and Trust 
 
Students were also doing a form of risk – they were living with intermittent HPV 
infections. Their risk came and went for several reasons. First, robust immune systems 
(at their relatively young ages) typically clear HPV infections that cause cervical 
dysplasia on their own. Secondly, medical treatments for genital warts ensured that 
these types of infections did not last long and finally, genital warts are the result of low-
risk HPV strains, which do not lead to cancer. As a result, the student’s version of living 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
67 As students wished for the state to re-engage with sexual health education they were 
not engaging in Beck’s notion of subpolitics when opting out of being vaccine 
consumers. As such, students were not taking part in the “re-politicization of areas 
outside the iron cage of bureaucratic politics” (Holzer and Sorensen 2003:80), but were 
seeking to reinsert themselves into governmental apparatuses.   
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with risk focused on the brief HPV infections that they encountered. Students such as 
Sylvana and Maya spoke at length of contracting genital warts, all cases of which 
cleared following medical attention. These cases did not present long-term physical 
effects, save for the emotional toll that contracting an STI brought. However, these 
intermittent experiences caused students to enact their own forms of telos in order to 
mitigate future HPV infection risk. For example, Maya managed her sexual health by 
engaging in sex only with barrier protection unless she and her partner had received 
negative STI tests. She used condoms when necessary and had a Pap test at her yearly 
physical with her GP. These active strategies helped Maya manage sexual health 
negotiation and to keep an eye out for dysplasia. Maya refused the HPV vaccine 
because of its associated gendering, but she was also concerned about potential risks 
because it was a relatively new vaccine without a long-term research profile. Maya 
stated, “so I don’t know how anybody can expose themselves to a drug that they don’t 
know how it’s going to affect them in the long term. I think that’s kind of crazy, so I 
wouldn’t advocate for anybody taking the vaccine.”   
 
Risk was clearly at the forefront of Maya’s mind – not only the risk of contracting an 
STI, but also whether or not there was a risk associated with the vaccine. As Giddens 
notes, the increase of information circulating in what he deems to be the current phase 
of modernity often leads, ironically, to what he calls “non-knowledge” (1991:217). 
Thus, the “question of deciding in a context of uncertainty arises in a radical way” 
(Giddens 1991:217, emphasis in original). Individuals are unable to assess long-term 
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outcomes to such incidents as environmental spills, genetically modified foods and 
emerging medical technologies, like vaccines. This creates a climate of uncertainty in 
which it is difficult to make health-related decisions. When there is uncertainty, 
“[e]verything falls under an imperative of avoidance” for no one wants to be the 
unlucky one who experiences complications, “gets ‘sick’ and many even die as a result” 
(Giddens 1991:217). As an example, Sylvana, who also had experienced genital warts, 
could not bring herself to decide whether or not to be vaccinated. Sylvana, like Maya, 
was concerned about the potential risk of the vaccine. Sylvana did not feel that vaccines 
were generally “well researched” and she was skeptical because the HPV vaccine only 
protects against four strains, when over a hundred strains have been documented.   
Students had little trust in the vaccine. 
 
In a time of uncertainty, trust is a concept that is difficult to navigate. According to 
Giddens: 
 
Trust . . . is basic to a “protective cocoon” which stands guard over the self in its 
dealings with everyday reality. It “brackets out” potential occurrences which, 
were the individual seriously to contemplate them, would produce a paralysis of 
will, or feelings of engulfment. In its more specific guise, trust is a medium of 
interaction with the abstract systems which both empty day-to-day life of its 
traditional content and set up globalizing influences. Trust here generates that 
“leap into faith” which practical engagement demands. [1991:3] 
 
In order to trust in late modernity, Giddens theorizes that an individual must have a 
sense of psychological “security” (1991:18). Continually emerging risks work to 
destabilize a sense of security. The “protective cocoon” that is required in order to go 
	   189	  
out into the world on a daily basis and partake in everyday risk inducing activities, such 
as driving and crossing the street, can be harder and harder to keep on doing in times of 
uncertainty (Giddens 1991:40). The “bracketing-out of possible events or issues which 
could, in certain circumstances, be cause for alarm” is no longer necessarily possible 
(Giddens 1991:127). In short, if an individual’s sense of “basic trust is fragile . . . even 
contemplating a small risk, particularly in relation to a highly cherished aim, may prove 
intolerable” (Giddens 1991:182). 
 
Correspondingly, Sylvana had difficulty trusting pharmaceutical companies. She was 
weary of, as she said, “putting stuff in my body that I don’t know exactly what it is and 
what is does. What it essentially is, I get it, a cash grab by a pharma company.” It is not 
uncommon for individuals to mistrust medical products that have been developed by 
for-profit entities because positive notions of health and health care are more often 
associated with non-profit spheres (Gross and Shuval 2008:553). However, to feel at 
risk after having experienced multiple HPV infections and then having been made to 
feel further at risk by a medical solution, such as the vaccine, left Sylvana at a loss. This 
translated into a delayed decision regarding the vaccine; she put off the decision until 
further longer-term research could be done, at which time she felt she would be able to 
trust the vaccine. Sylvana did not make her decision to delay without reservations, 
though. She stated, “it’s a hard kind of choice to make. But at the same time, how stupid 
would you feel if you ended up getting cervical cancer and had decided not to get 
vaccinated. I have mixed feelings so it was why I’ve held off on getting the 
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vaccination.” The notion of trust did, however, take on various gradations in relation to 
vaccine decision making for students: Maya exhibited patent rejection of the vaccine, 
Sylvana showed uncertainty which resulted in a delay in decision making, and Amber 
demonstrated enough trust to undergo vaccination, even though she did not agree with 
the sales/governance strategies used to promote the vaccine. Student experiences 
demonstrate that trust is a nuanced and layered concept. And, as is exemplified by 
Amber’s change of heart (her initial decision to forgo vaccination was reversed when a 
close friend experienced HPV-related complications), trust can also be dynamic and 
changing.  As Walls Dr. et al. (2010) explain, “critical trust lies on a continuum between 
outright skepticism (rejection) and uncritical emotional acceptance” (147). 
  
Student engagement with situated risk – whether it was the risk of intermittent HPV 
infections or their negotiations of uncertainty and trust vis-à-vis the vaccine –
foreshadowed the intimate interaction patients had with risk. However, patients were 
living with risk associated with pre-cancer diagnoses. This type of situated risk was far 
more intense than the risk experienced by students and provided a milieu whereby the 
vaccine was but one component of their HPV infection experiences. As such, HPV-
related diagnoses and procedures took centre stage.  
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E] Doing Risk   
 
 
What is it like to be between being well and unwell? How did patients at the clinic deal 
with being labeled pre-cancerous? The answer is that they lived with risk on a daily 
basis. Risk operated as the central mechanism through which patients “organize[d] 
the[ir] social world” (Giddens 1991:3). This risk included not only being attributed as 
an at-risk woman by the medical establishment, but actively doing risk. Doing risk 
refers to how the “biographical disruption” (Bury 1982) associated with a chronic 
illness contributed to how women patients developed their sense of self – ultimately, 
their ethical being – at that particular point in time in their lives. As Bury explains 
“Illness, especially chronic illness is precisely that kind of experience where the 
structures of everyday life and the focus of knowledge which underpin it are disrupted. 
Chronic illness involves a recognition of the worlds of pain and suffering, possibly even 
of death, which are normally only seen as distant possibilities or the plight of others” 
(1982:169). 
 
As a result, a person’s sense of identity or self is re-ordered in such a circumstance. And 
in this case patients had to calculate and calibrate how they would respond to their 
shifting environment and how they would engage in “mobili[zing] resources, in facing 
an altered situation” (Bury 1982:169). As per Douglas, “organizing requires classifying, 
and that classification is at the basis of human coordination” (2002[1966]:xvii). Patients 
used the need to re-order their lives in the face of protracted HPV infections and the 
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requisite medical interventions to make sense of what was happening to them. As the 
mothers and students experienced, patient re-ordering took place within existing societal 
frameworks. The making of one’s ethical self always takes place within the confines of 
existing norms. Just as mothers re-appropriated what it meant to be a good mother from 
dominant discourses, patients re-appropriated biomedical definitions of risk by re-
fashioning meanings of risk to reflect their cervical dysplasia experiences. Their lived 
experience with risk was different than how the medical establishment looked at risk. 
Rapp refers to this interchange as the “traffic between biomedical and familial 
understandings” (2000:185). This traffic is essentially the same creative process of self-
making that occurs when motherhood and mothering come together. As with mothers 
and students, patients were also faced with navigating external subject formation, all the 
while developing one’s sense of self or ethics.  
 
Patients exhibited changing conceptualizations of cervical cancer risk that differed from 
their attending general practitioners, who had first diagnosed abnormal cervical cells 
before they were referred to a gynecological specialist. In Zoe’s experience, her GP 
spoke about cervical cancer as stemming from multiple sources (cf. Weiss 1997). While 
patients viewed cancer in general as such, they had differing views of cervical cancer. 
For patients, cervical cancer etiology was not multi-causal, but reflective of a direct line 
of cause and effect: the sexually transmitted HPV virus caused cervical cancer. 
However, even with the direct line that they could draw, patients felt helpless in 
preventing HPV infection. This linear disease pathway was complicated by the 
	   193	  
knowledge there was little one could do to prevent HPV transmission if engaged in 
sexual relations. Using barrier contraceptives was not necessarily going to block HPV 
transfer, as it is based on skin-to-skin contact and not fluid exchange (Braun and Phoun 
2010:50). Therefore, there was no way to protect oneself from HPV unless one 
abstained from all forms of sexual contact. Nor can one be cured of HPV infection for 
the virus can lie dormant for decades. The old rules of health risk management, which 
promote a conception of the self that is motivated to self-regulate – a person who 
actively manages their health through proper diet and exercise and who stays away from 
perceived health risks (Nettleton 1997) –were no longer relevant.    
 
In the case of STIs, the old rules of health management risk would have emphasized 
practicing safe sex – but these rules cannot be applied to HPV. New modes of “self-
care” (Foucault 1988) are required when dealing with HPV, but patients were somewhat 
at a loss as to what they should entail and how they should be carried out. They were at 
a “crossroads” for living with HPV-related risk is “uncharted territory” (Giddens 
1991:142). As Giddens explains, “the individual has to confront novel hazards as a 
necessary part of breaking away from established patterns of behavior – including the 
risk that things could possibly get worse than they were before” (1991:78). As a result, 
patients looked to contain, instead of prevent HPV, which is a distinct, emerging health 
strategy. Jennifer, who had experienced abnormal Pap test results for the last ten years 
and had undergone biopsies, colposcopies and LEEP procedures spoke about bolstering 
her immune system by eating well and exercising in order to not “run into anything 
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big,” meaning having abnormal cells turn into cancer. However, Jennifer was the only 
patient who spoke about doing things on her own through self-regulation to prevent her 
abnormal cells from turning into cancer. The remaining patients, instead, turned to Pap 
tests and other HPV-related procedures, such as colposcopies, to limit the eventual 
development of HPV-related abnormal cells into cervical cancer.  
 
Patient routines of medical appointments and procedures became their form of self-care 
– a new telos to contain HPV-related cervical dysplasia. This telos was devised to deal 
with their protracted living with risk status. As Bury (1982) describes, chronic illness 
involves setting new routines – a “new normal” so to speak. The long term Pap test 
surveillance, which accompanies medical treatment, caused a great deal of anxiety and 
emotional anguish among patients. Experiencing anxiety is a common by-product of 
being classified as “at-risk.” When deemed “at-risk,” it is not possible to maintain the 
“protective cocoon” (Giddens 1991:181) one needs to navigate the risk of day-to-day 
life. As was also seen with students, patients no longer were able to suspend the notion 
of risk after HPV-related diagnoses. Instead, medical encounters became riddled with 
anxiety. Once diagnosed with cervical dysplasia that did not clear on its own, patients 
stepped onto an HPV treadmill and had to stay on it to contain HPV. Rebecca was a 
prime example of this for she had been experiencing abnormal Pap test results, biopsies 
and finally a LEEP for the last ten years. She described her dysplasia as “constantly 
going on” and lived in fear that the next test would be, as she called it, “really abnormal 
this time”. By “really abnormal” she was referring to cancer. Jennifer described her 
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colposcopy experience as involving “fear” and “pain.” Kathryn also had an unpleasant 
colposcopy experience. She spoke about her doctor describing it as a simple procedure 
involving little pain, and comparing it to a Pap test (this happened to several patients 
interviewed). Her experience of a colposcopy, however, could not have been more 
different than that of having a Pap test. Kathryn spoke about bleeding for an entire week 
afterwards and having an overall “icky feeling – like I needed a shower.” Kathryn had 
the urge to “cleanse” herself after a colposcopy. This signifies a need to purge oneself 
of an anxiety-ridden event. Additionally, it may also be a way to rid oneself of the virus 
and its accompanying abnormal cells. Having cervical dysplasia put Kathryn in the 
indeterminate state of pre-cancer – between healthy and unhealthy. The virus and the 
accompanying medical treatment caused “disorder” in Kathryn’s life and “eliminating it 
[was] not a negative movement, but a positive effort to organize the environment” 
(Douglas 2002[1966]:2).  
 
Wanting to re-order their experiences, wanting to alter their pre-cancerous state was, no 
doubt, accelerated by the negative judgment patients received from physicians. Jennifer 
spoke the most passionately in this regard and described how her initial diagnosis of 
dysplasia was “disappointing,” “upsetting” and made her feel “unclean” and like a 
“pariah.” She went as far as to state, “I will remember it forever. I felt pretty bad.” It is 
important to note that Jennifer used the word “unclean” in her response to physician 
judgment. Like Kathryn’s needing a “shower,” she was also, unconsciously, referring to 
the need to purge or clean away – hence, to order or re-order disorder. To choose words 
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like “unclean” may appear to parrot dominant discourses about STIs – which focus on 
“dirty” and “infected” individuals, but Jennifer was actually managing her biographical 
disruption the best way she can.  And, as occurred with the students, having stigma 
leveled against them also affected how patients orchestrated this re-ordering – they were 
reminded by others that they were not the same as they once had been, nor the same as 
those who did not have an STI. In doing so, the medical establishment created and 
reinforced the classification of the “healthy” self versus the “unhealthy other” 
(Crawford 1994). Their choice of words and attitudes towards patients left the patients 
no choice but to reassert their morality and self-worth.68  
 
As a result of not being able to prevent HPV infection, patients expressed a clear sense 
of inevitability about developing cervical cancer. Kathryn and Rebecca felt that there 
was a possibility of developing cervical cancer and Jennifer was more direct in stating 
that she felt it would be “naïve” to think that would not happen. This “fatalism” (Drew 
and Schoenberg 2011) is common among cancer patients and those experiencing 
chronic illness (Bury 1982). This sense of fatalism is also germane to those who feel at 
constant risk. Giddens explains his perspective on risk and fatalism: 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
68 When speaking about my research with a colleague, she described my interviews as a 
Foucaultian confessional.  While the comparison is understandable as patients appeared 
to be undergoing a “therapeutic exercise” (Lupton 2003:31) during interviews, I would 
argue that some may perceive me as having a degree of power as an academic researcher 
working in a hospital setting, but patients appeared to want to talk to me precisely 
because I was not a physician. Perhaps, as well, the fact that they were not required to 
have contact with me beyond the interview, as they were with their physicians, also 
prompted them to be so open. They knew there would be no long term repercussions of 
speaking candidly with me. 
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Fatalism, as I understand it here, differs from stoicism, an attitude of strength in 
the face of life’s trials and tribulations. A fatalistic outlook is one of resigned 
acceptance that events should be allowed to take their course. It is an outlook 
nourished by the main orientations of modernity, although it stands in opposition 
to them. [1991:112] 
 
As Giddens posits, taking on the sense of fatalism seems ironic considering that the 
period of late modernity was supposed to usher in progress and greater control by 
humans over nature. However, instead of feeling any measure of control, patients were 
resigned to “pragmatic acceptance” (Giddens 1991:131) of HPV-related risk as they 
were forced to deal with their pre-cancerous status one day – or procedure – at a time.  
 
Opting for HPV vaccination was another measure of self-care in the telos of containing 
HPV, but it was not deemed to provide any measure of certainty. Jennifer was the most 
optimistic of the patients in terms of the vaccine, but she waited before proceeding due 
to the cost. After some investigation, she confirmed her insurer covered the shot, 
although they did not “make it easy,” as she said, to find this out. Jennifer’s overarching 
motivation to get vaccinated was to avoid more time on the HPV treadmill. Jennifer 
explained she “needed to take every step possible to never have to deal with any 
abnormal cells possible.” Rebecca decided to be vaccinated in order to “take advantage 
of what all is available today,” but did not feel that the vaccine would work for her, 
thinking it was “too late.” Kathryn was happy to find out she was eligible for the 
vaccine when she had been told repeatedly by her GP that she was not. Kathryn was 
worried about possible long-term vaccine effects, but was reassured, through her own 
research and in consultation with her gynecologist, that she would be fine. Kathryn’s 
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decision to be vaccinated was motivated by the fact that she would do anything possible 
to avoid having to undergo another colposcopy, biopsy or LEEP. Her decision was also 
an effort to stave off “the next phase,” meaning cancer. Zoe noted she was not sure if 
the vaccine would help her, but she figured she didn’t have anything to lose by getting 
vaccinated.   
 
During the pause of the interview, Zoe, Jennifer, Kathryn and Rebecca suspended their 
pre-cancerous status – it was as though they temporarily escaped the liminality of pre-
cancer and could put aside the feelings of anxiety associated with being in an 
indeterminate station in life. The women were not passive recipients of medical and 
political technologies when they engaged in HPV vaccination. For patients, vaccination 
was a “transformative” act (Polzer 2010:71) through which they could recharge and 
continue with their self-care before their diagnoses and treatment protocol shifted again 
in response to the mercurial and non-linear qualities of HPV infections. Patients knew 
that the HPV vaccine would not cure them, and were skeptical that it would prevent 
future infection, but they were transformed through vaccination nonetheless. 
 
Before closing this section of this chapter, it is important to reflect upon what patients 
were not saying. What are the “unsaids” (Foucault 1989[1969]:124)? Patients were not 
broaching the subject of gender, their gender, or how gender was projected in HPV-
related pharmaceutical and governmental policy discourses. In the case of patients, risk 
trumped gender. Living with risk while on the HPV-related procedural treadmill was 
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their focus. Gender was not a central component of patients’ senses of self as it was 
with mothers, nor was it a significant factor as demonstrated by students. In essence, 
gender was re-ordered almost right out of the picture. Central to patients’ sense of self 
was how to live with, manage and do pre-cancer risk for protracted periods of time. 
They were more concerned with containing HPV in the hope of staving off cancer than 
anything else. Their own type of ethical agency depended on re-ordering their lives in 
response to biographical disruptions by pulling together their internal resources and 
managing the medical establishment, which often had views of their “risk” that differed 
from they did. Patients had to, ultimately, deal with the anxiety their indeterminate 
health status brought. This was why the pause vaccination brought was such an 
important event through which patients could stop, take a deep breath and prepare to 
move forward, no matter what their on-going diagnoses would be.  
 
Conclusion: Ontological Decision Making 
 
While re-ordering risk and gender, women were making sense of and deriving meaning 
from their everyday lives.  Throughout the processes of re-ordering, women were 
“doing.” Mothers were doing mothering, students were doing gender politics and 
intermittent risk and patients were living with risk. In carrying out each aspect of 
“doing”, women wove nets of experiences, which when assembled helped form their 
ethical being or sense of self. For example, mothers were deeply entrenched in 
performing their versions of being a good mother. This encompassed navigating the 
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opposing spheres of motherhood and mothering and finding a comfortable space for 
themselves somewhere in between these two ideological and pragmatic constructs. This 
navigation was made possible by enacting numerous forms of intensive mothering. In 
intensive mothering, mothers “do” plenty. They researched vaccines, consulted widely 
about their daughters’ health and actively participated in mothering so that their 
daughters would not have to, ironically, be so “hands-on” when they were mothers 
themselves. For the mothers interviewed, mothering was an intrinsic part of their 
situated gender identity as adult women. This sense of identity was so strong that they 
refused to discuss adolescent sexuality as this would mean broaching the issue of their 
daughters growing up, and would mark the beginning of a period in which their 
daughters would shift into womanhood themselves. Intensive mothering cannot be 
practiced with adult children and the women interviewed were not yet ready to 
contemplate a more “hands off” approach to mothering.  
 
Students were also actively fashioning their ethical beings or senses of self when 
navigating HPV vaccine decision making. As women who were emerging into full-
fledged womanhood, students were attempting to mediate gendered stereotypes 
associated with STIs by advocating for the de-gendering of the vaccine. They were also 
strongly critiquing neo-liberal public health measures, which placed the onus for sexual 
health education and negotiation on the individual. Students wished to introduce HPV-
related and STI focused education campaigns into the school system and society as a 
whole. This was in an effort to redistribute the blame associated with contracting an 
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STI. They reasoned if more information circulated regarding HPV, the virus would no 
longer be considered a woman’s issue. These themes were central to how they identified 
as a woman – they wanted to be considered on equal footing with men and declined a 
vaccine, which they associated with gender asymmetry. However, student identity 
making was fraught with tension. While it was clear what type of women they wished to 
be, actually mediating HPV infection risk and the potential risks of the vaccine, proved 
to be rife with uncertainty. Students had begun to experience intermittent HPV 
infections, but felt the vaccine was too “new” to be trusted. Opposition to “big pharma” 
and uncertainty surrounding vaccine side effects caused students anxiety. They felt 
vulnerable to vaccine risks, just as exposed as they felt while negotiating their own 
sexual health. Thus, for students, the concept of situated risk was fraught with continual 
negotiation. Being a strong, certain woman in the face of mistrust and uncertainty was a 
difficult and tenuous ideal to actualize.  
 
While students had opened up the “protective cocoon” Giddens (1991:3) spoke about 
when mediating their mistrust and uncertainty associated with sexual health and vaccine 
negotiation risk, patients had completely emerged from its casing. Patients’ ethical 
agency and sense of self had experienced biographical disruption. Being designated a 
pre-cancerous individual meant their lives had to be completely re-ordered. The old 
health strategies they had followed no longer applied. New strategies to contain, rather 
than prevent HPV had to be assembled. They experienced friction with the medical 
establishment when they were stigmatized by physicians for having contracted STIs and 
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had to continually re-assert themselves as moral individuals in the face of this 
discrimination. They did, nonetheless, reach “pragmatic acceptance” (Giddens 
1991:131) of their status as pre-cancerous. This involved undergoing their medical 
procedures and shifting diagnoses day-by-day, but it also meant that they felt cancer 
was a realistic outcome for them. This fatalism, coupled with the anxiety associated 
from a litany of medical procedures, made patients feel as though they might never get 
off their HPV infection “treadmills.” For patients, situated risk was not a concept, but a 
tangible part of their everyday lives. It required that they shift their approaches to life as 
each diagnosis and treatment came their way. While they recognized that the 
vaccination might not bring a benefit considering their medical histories, they accepted 
the vaccine and the moment of respite it provided.  
 
 
Figure 9 – Conceptual mapping of ontological decision making 
 
As women’s “doing” and identity making was not teleological and rested within a web 
of experiences, so too was their vaccine decision making. The knowledge accumulated 
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through situated risk and gender experiences, or “experience-based knowledge” (Zinn 
2008:443), was then layered to form vaccination decisions. Positing that women took an 
ontological approach to vaccine decision making is a marked departure from existing 
literature surrounding risk decision making. Current risk decision making research 
posits that decision making is the result of linear, cost-benefit analyses (Austin et al. 
2013; Jacobson et al. 2007; Poland et al. 2009; Poland and Jacobson 2001). For 
example, Crighton et al. (2013) argue that such approaches involve “two cognitive 
mediating processes: the threat appraisal process evaluates the potential benefits of 
action as well as the availability of resources (financial or other) to do so” (298). This 
type of linear, cost-benefit analysis also positions decision making as a “rational” and 
individual act. And when individuals do not follow risk prevention directives, they are 
often cast as ill informed or not being able to grasp the complexity of the risk issue at 
hand (Lupton 1999a:2). This approach does not recognize that decision making is “more 
a process than an isolated action” (Hobson-West 2010:280). In short, it misses the 
“situatedness” of risk (and gender for that matter). Ontological decision making is an 
inherently social and cultural process, which is embedded in women’s experiences of 
“mobilizing meanings” (McClure 1991:365) surrounding their efforts to be good 
mothers, strong young women merging into adulthood and pre-cancerous patients 
seeking a “pause” amidst the anxiety of seemingly never-ending cycles of medical 
procedures.  
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CHAPTER EIGHT - Conclusion: Contributions and 
Considerations for Moving Forward 
 
A] Research and Analysis Summary 
 
This research project has been an endeavor in answering three overarching questions: 
(1) How did the HPV vaccine become gendered within the Canadian policy landscape, 
which then lead to gendered public health programming? (2) How do women 
appropriate, hybridize or refute the notions of “gender” and “risk” that are deployed in 
association with the vaccine? (3) How were their experiences with risk and gender 
folded into their vaccine decision making? In an attempt to answer these questions, 
fieldwork took on two phases. In the first phase, the creation and circulation of the 
concepts of “gender” and “risk” that were deployed in pharmaceutical and policy 
discourses vis-à-vis the HPV vaccine were tracked through archival research 
comprising Gardasil® advertising campaigns, popular media accounts, parliamentary 
debates, federal and provincial press releases, accounts of lobbying before the federal 
Finance Committee and federal regulatory decisions regarding the vaccine. As policy 
documents indicate, the federal government developed HPV vaccine policy within a 
GBA frame, which followed the parameters of Merck Frosst’s gender-based marketing. 
Such gender “ideals” rest upon the overarching notion that women are a “feminine” 
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grouping – a homogenous and static “whole” that is inherently at risk for ill health. 
Merck Frosst was the first to deploy these governance techniques as a selling 
mechanism for the vaccine, but if these conceptualizations were not in the ether, they 
would not have been picked up again in policy making.  The policy sphere, as with all 
other facets of daily life, is rife with the circulating, yet static, cultural “ideals” of 
gender and risk. 
 
The archival contextualization provided the requisite background to conduct the second 
phase of research, the tracing of how the concepts of “risk” and “gender” were mediated 
by three different groups of women: mothers negotiating the vaccine for their daughters 
in a school-based immunization program; university students who were targets of HPV 
vaccine promotion in campus health clinics; and patients who simultaneously attended 
hospital-based HPV vaccine and colposcopy clinics.  It was not particularly surprising 
to discover that a multinational pharmaceutical company lead governmental policy 
development, but what was really at the centre of the research was the quest to 
understand how women were negotiating, within everyday contexts, these 
conceptualizations of “gender” and “risk.” How were these concepts folded into their 
vaccine decision making? Perhaps risk was emphasized more than gender, or was it the 
other way around? In answering these questions, the vicissitudes of power were 
examined – how power was deployed and how it was processed.  
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In order to analyze the data gathered, Foucault’s early and late theory (1987, 
1989[1969], 1990[1978], 1991, 1997, 1999) was utilized. Additionally, Douglas’s  
(1992, 2002[1966]) work on risk and the work of those who follow the governmentality 
school of risk (Castel 1991; Gordon 1991; Lupton 1994, 1995, 1999a, 1999b, 2003; 
Lupton and Petersen 1996; Nettleton 1997; Petersen 1997; Rose 2007; Rothstein 2006 
and Turner 1997) were brought into the theoretical fold. Governmentality approaches 
have been critiqued for their predetermined nature (Sawicki 1991:98); however once I 
examined the continuum of this work, tightly woven governance strategies began to 
loosen, and one could even say, began to unravel. By examining Foucault’s work on its 
continuum, I was able to acknowledge the construction of subjects within the 
frameworks of power relations as well as the possibility that such subjects could level 
their own “critique” while enmeshed in power networks (Allen 2008:21). Women’s 
narratives provided an intersubjective space where subject formation and 
realizations/actualizations of the self intersected and it was in this space that health 
negotiation and decision making occurred. In the intersubjective space women worked 
towards becoming “ethical” beings by creating their own “telos” or sets of codes for 
maneuvering daily life (Foucault 1997:265). Scripting one’s telos is a limited act of 
power and this reflects the women’s ability to be “self-constituting” (Allen 2008:2).  
 
The use of early and late Foucault theory, along with writings by Allen (2008), Butler 
(2008), Nettleton (1997), Lupton (1997b) and Zaloom (2004) allowed for the analysis 
of situated risk (Boholm 2003) and gender. This is where this research project makes its 
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greatest contribution to existing social science literature related to risk. Research in 
social science fields focusing on risk, generally zeroes in on either grand theory (see 
Beck 2004; Castel 1991; Dean 1999; Giddens 1991; Gordon 1991; Ewald 1991; Fox 
1997; Petersen 1997; Rothstein 2006) or individual accounts (see Bond et al. 2012; 
Brown et al. 2013; Crighton et al. 2013; Gross and Shuval 2008; Lear 1995; Russell and 
Kelly 2011; Spencer 2013; Thing and Ottesen 2013; Tuinstra et al. 1998; Walls Dr et al. 
2010; Zinn 2008).  Concentrating solely on grand theory leaves out the important 
human element of risk, and exclusively researching individual experiences, 
unintentionally, reproduces sales/governance strategies. However, as important as 
research focusing on situated risk is, it is usually not extended to issues relating to 
gender in a critical fashion (Lupton 1999a). Moore (2010) also notes that if gender is 
addressed in situated risk research, gender is treated with such limited theorization that 
findings usually reinforce gender norms. However, this research project addresses this 
void in the academic record by treating both the concepts of “risk’ and “gender” with 
critical care, all the while producing ethnographic accounts of women’s experiences 
negotiating risk and gender.  
 
As eighteen months of fieldwork delving into situated risk and gender revealed, 
something quite specific occurred when women recounted deciding whether or not to 
have their daughters or themselves vaccinated against HPV. Their ethical agency 
involved aspects of ontological choreography. In the case of patients and more 
fleetingly students, ontological choreography was joined by the biographical disruption 
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of being chronically ill. When ontological choreography and biographical disruption 
intersected, women consciously engaged in re-ordering. Thus, the concepts of risk and 
gender were movable ontological modes – risk and gender shifted in and out of focus 
depending upon the context, but they were always present in some form, no matter how 
faintly. For mothers, risk was a theoretical construct; their daughters were just moving 
into the teenage years and they did not wish to explore adolescent sexuality with them. 
HPV risk was a distant proposition. As a result, mothers focused on gender and doing 
mothering. For students, HPV risk was intermittent for many had experienced transient 
HPV infections in the form of genital warts and the beginning of low-grade cervical 
dysplasia and, moreover, were worried about potential vaccine side effects.   Students 
were also angry with the gendering of HPV and the vaccine and based their vaccination 
decisions on the type of gendered being they would like to be – one that was not put in a 
pre-determined, at-risk box. Students were, therefore, dealing both with risk and gender 
simultaneously. The risk students experienced, however, was nothing like the risk 
patients lived with.  Patients thought their risk was so overwhelming that there was no 
means whereby they could escape it. All they could do was develop health strategies to 
contain it. Due to the intensity of risk for patients, which they recounted in their 
diagnostic and treatment narratives, gender took a backseat.   
 
Narratives across all three cohorts indicate that in relation to women’s senses of self, 
risk and gender were elastic concepts. When risk was distant, a primacy was placed on 
gender. When risk was coming into focus, both gender and risk were ontologically 
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highlighted. And, when risk was ever present, risk took centre stage with gender firmly 
placed in the shadows. In response to the creation and circulation of the gendered and 
risky HPV-related subject formations – which attempt to keep women “in order” and 
prompt them to “follow orders” women re-ordered their lives. Re-ordering, then, 
undermines order and provides the potential to enact power. What sales/governance 
strategies have tried to fix, the women interviewed continually unfixed.  
 
Women’s accounts of situated risk and gender also indicated that women were engaged 
in ontological decision making when deciding whether or not to get vaccinated or to 
have their daughters vaccinated. As women re-ordered, they were also “doing.” Mothers 
were doing mothering, students were doing gender politics and intermittent risk, and 
patients were living with risk. In carrying out each aspect of “doing,” women wove nets 
of experiences, which when assembled helped form their ethical being or sense of self.  
The knowledge accumulated through situated risk and gender experiences was then 
layered to form vaccination decisions. Correspondingly, decision making was not a 
discrete event, but an unfolding process. Ontological decision making was an inherently 
social and cultural process embedded in women’s experiences of finding meaning in 
their efforts to be good mothers, strong young women merging into adulthood who also 
felt vulnerable to sexual health negotiation, and pre-cancerous patients seeking a 
“pause” amid the anxiety of seemingly never ending cycles of medical procedures. 
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B] Theoretical Contributions  
 
 
In terms of theoretical contributions, this research project makes its greatest impact on 
the medical anthropology record in delivering a critical ethnographic account of situated 
risk and gender. However, as a by-product of this focus, four other significant findings 
have come to the fore: 
 
1) Sales/governance strategies – This research project, through the case study of 
the HPV vaccine, highlights how corporations and governments work hand and hand to 
set public health policy in the neoliberal era of the new public health. Merck Frosst and 
the governments of Canada and Ontario deployed vaccine marketing, information and 
public health programming to influence women to be vaccinated through self-
regulation. This individualized approach facilitated the sale of the vaccine and 
reinforced the governance tenets of the new public health, which emphasizes a self-
disciplining approach to regulating “populations.” Both Merck Frosst and the 
governments of Canada and Ontario framed HPV as a “woman’s issue” by cleverly 
harnessing circulating and hegemonic cultural ideals surrounding risk and gender. The 
gendering of HPV aided in creating a “need” for the vaccine and the related in-school 
vaccination programming.  
 
2) Generative pause – In researching situated risk and gender, it became clear that when 
women spoke about their experiences of navigating risk, gender and the vaccine, the 
pause they experienced during interviews was indeed a generative moment. Not only 
	   211	  
were interviews times of contemplation, they were productive events. Mothers and 
students ruminated and processed how HPV infection and HPV vaccine risk was being 
transmitted by governmental and pharmaceutical discourses and how they were 
hybridizing or rejecting these messages. However, women were communicating much 
more than their vaccine decision making process during interviews. When taking a 
pause, each woman created a narrative that contributed to her continually developing 
sense of self. As each narrative developed, identity was re-inscribed and re-enforced, for 
it was in the thick of the pause that the exterior subject formation imposed by 
pharmaceutical and governmental discourses and interior realizations/actualizations of 
the self intersected. Women are not always portrayed as “doers” or those who do and in 
the case of HPV infection and the vaccine women are positioned as passive recipients 
and bearers of disease. It is in the space of the pause that women actively, continually 
and complexly negotiated their sense of self while working to secure their health vis-à-
vis HPV infection and the HPV vaccine.   
 
3) The productive re-ordering of risk and gender – It is important to note that women 
were not reinforcing the gendered at-risk subject formation of pharmaceutical and 
governmental discourses when they were doing mothering, doing gender politics and 
intermittent risk and doing risk. Sales/governance strategies attempt to order individuals 
or groups. In response, women re-ordered their lives. Re-ordering presents both a threat 
to order and the potential to enact power. Thus, while “doing”, women were creatively 
re-appropriating/rejecting and hybridizing the gendered and risky HPV subject 
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formation to productive affect. As a result, the women of each cohort were doing their 
making of self differently depending on their context. Mothers ironically played with 
the concept of the good mother, students rejected mainstream concepts of gender and 
risk when saying “no” to the vaccine, and patients took a step back from the HPV 
treadmill when deciding to be vaccinated and set their own parameters to contain HPV. 
Each woman was doing this in her own way. Women did not exhibit one universal 
formula for interpreting gender and risk that mirrored the flat and totalizing way in 
which gendered risk is constructed and deployed in pharmaceutical and governmental 
policy discourses vis-à-vis the HPV vaccine.   
 
4) Ontological decision making – In demonstrating how women made vaccine decisions 
based on their risk and gender-related negotiation experiences and not on linear-cost 
benefit analysis, this research project departs from existing literature in regard to risk 
related decision making. Current risk decision making research posits that decision 
making is teleological (see Austin et al. 2013; Jacobson et al. 2007; Poland et al. 2009; 
Poland and Jacobson 2001) and a “rational” and individual act. However, this approach 
does not recognize that decision making is an inherently social and cultural process. In 
the case of the women of my study, such a process of decision making was embedded in 
their experiences, whether as mothers trying to be good mothers, strong young women 
merging into adulthood, or pre-cancerous patients seeking a “pause” amid the stress of 
protracted medical procedures.  
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Either combined or used independently, the four concepts of sales/governance 
strategies, the generative pause, the productive re-ordering of risk and gender, and 
ontological decision making provide novel frames through which to engage in and 
analyze situated risk and gender research. 
 
C] Future Pragmatic Research and Policy Considerations 
 
 
From a policy perspective, not much has changed since the Public Health Agency of 
Canada released its report in 2005 entitled Canadian Human Papillomavirus Vaccine 
Priorities Workshop, which called for further Canadian research on HPV and the 
vaccine. While carrying out this research project – from the fieldwork to analysis stages 
– many research voids became glaringly apparent. As such, it is recommend that 
research, leading to renewed policy objectives, be pursued in the following thematic and 
pragmatic areas: 
 
1) Middle school and high school aged boys/young men, girls/young women and 
those across the gender spectrum should take part in research concerning their 
conceptualizations of HPV and the HPV vaccine, not only in terms of sexual health, but 
the gendering of the virus and vaccine. How they process and find meaning within 
publicly circulating HPV and HPV vaccine knowledge is crucial in setting the baseline 
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data required to develop a de-gendered public information campaign regarding HPV 
and the vaccine.  
 
2) Drawing upon the previous research initiative, develop, research and focus-
group test sexual education materials regarding HPV and the vaccine to be included in 
middle school and high school curriculums that de-genders HPV and vaccine health 
communications. 
 
3) Research and focus-group test public education materials regarding HPV and the 
vaccine among individuals across the gender spectrum, to be included in a generalized 
public health education campaign, that decouples gender from HPV. 
 
4) Interview general practitioners regarding their perspectives on HPV and the 
vaccine. This research can be leveraged to develop follow-up information and 
dissemination protocols for patients receiving abnormal Pap test results from general 
practitioners in order to prevent the stigmatizing that women patients and students 
experienced in their medical encounters. 
 
5) Conduct a larger, multi-sited research project across the province, which 
incorporates a greater diversity of women participants in terms of positionality. This 
type of project would analyze the impact of intersectionality (which could range from 
disability status to access to health insurance) on HPV infection experiences, vaccine 
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negotiation and cervical cancer prevention strategies, including Pap tests and post-HPV 
infection diagnosis medical interventions. 
 
When and if these research and policy gaps are addressed, it will be interesting to 
follow changes in HPV vaccine programming in the future in Canada. In 2013 we have 
only reached the beginning of an academic conversation about the HPV vaccine and 
related policy. Policy is very slowly changing on the ground with the province of Prince 
Edward Island agreeing in the first half of 2013 to subsidize boys, along with girls, in 
school-based vaccination programs. Alberta was also in “discussion” during the summer 
of 2013 on this, but to date, an accompanying policy revision has not been made. These 
events may start to change the HPV vaccine conversation among public health policy 
and programming stakeholders across the country.  However, the need to conduct 
research in the area of situated risk and gender will remain. While the specific medium 
through which gendered risk is deployed may change from that of the HPV vaccine to 
another medical “solution” or prevention strategy, the continued presence of 
sales/governance strategies will mean that women will be targets of risk, and have to 
live with risk, for years to come.  
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Appendices 
Appendix A - Glossary 
 
Cervical dysplasia: According to the Canadian Cancer Society’s web site, “dysplasia 
of the cervix means that abnormal changes have taken place in the cells of the cervix. It 
is usually picked up during [a] routine Pap test.” (2011:1). 
 
Cervarix®:  A vaccine produced by GlaxoSmithKline that prevents infection by HPV 
strains 16 and 18, which cause cervical cancer.  The vaccine is administered in three 
doses at zero, one and six month intervals (Product Monograph, GlaxoSmithKline 
2012). 
 
Cervical dysplasia grades: Cervical dysplasia, or cervical intraepithelial neoplasia, is 
classified by grades, which run from CIN (grade 1) to CIN 2 (grade 11) to CIN 3 (grade 
111). CIN is considered mild, CIN 2 moderate and CIN 3 severe. CIN 3 can also be 
referred to as carcinoma in situ (Miller 1999). Abnormal Pap smears do not necessarily 
progress from CIN 1 to CIN 3 in a teleological fashion. Sometimes dysplasia clears on 
its own, or comes back at a different grade; various grades can co-exist (Agorastos et al. 
2005). 
 
Colposcopy: An examination of the cervix that is undertaken after an abnormal Pap test 
result. Sometimes the physician will take a small biopsy of cervical tissue during a 
colposcopy to access the severity of cell change (University Health Services, UC, 
Berkeley 2010). 
 
Gardasil®: A vaccine produced by Merck Frosst to prevent infection of HPV strains 6, 
11, 16, 18, which are related to genital warts and cervical cancer. The vaccine is 
administered in three doses over six months (Information about Gardasil®, Merck Frosst 
2013). 
 
GP: General practitioner, a physician who works as a family doctor. 
 
GBA: Gender-based analysis. 
 
Genital warts: Genital warts affiliated with HPV present on the penis, vagina, vulva, 
cervix and occasionally in the throat.  They are spread through skin-to-skin contact and 
can be hard to detect. Various treatments can be implemented, including freezing or 
using acid or podophyllin to remove the warts (Facts about genital warts, Laurier 
University Health Services 2013). 
 
HPV: Human Papillomavirus. 
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LEEP: An acronym for Loop Electrosurgical Excision Procedure, which is a process 
whereby “a circular or other shaped wire electrode [is used to] excise (remove) 
abnormal tissue on the cervix” (University Health Services, UC, Berkeley 2010:2). 
 
NACI: National Advisory Committee on Immunization. 
 
STI: Sexually transmitted infection. 
 
Summary Basis of Decision: The document released by Health Canada when it has 
approved a pharmaceutical product for use in Canada 
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All sections of this application MUST be completed before it will be considered for 
REB review. A complete application must be submitted to each site where this 
research will take place. A separate detailed protocol must be included with each 
application. See TAHSN Guidelines for Research Ethics Review Involving Human 
Subjects. 
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2A. Is this protocol directly related to a previously approved study at this institution (e.g., 
extension, rollover, subsequent to a pilot study)?  Yes  No 
 
If Yes, indicate name of Principal Investigator: n/a and REB file number: n/a 
 
3. SOURCE OF FUNDING 
 
Sponsor Name: n/a 
Granting Agency 
Name: 
n/a 
Internal Funding: n/a 
Other: n/a 
 Funding obtained 
 Funding applied 
for 
Expected date of decision: n/a 
 No funding 
required 
Explain: n/a 
 
4. INVESTIGATORS 4A.	  PRINCIPAL	  INVESTIGATOR	  CONTACT	  INFORMATION	  AND	  SIGNATURE	  
PRINCIPAL INVESTIGATOR AGREEMENT – I assume full responsibility for the scientific and 
ethical conduct of the study as described in this application and submitted protocol and agree to 
conduct this study in compliance with the Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Human Subjects and any other relevant regulations or guidelines. I certify 
REB ID NUMBER:                                                       (office use only 
) 
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that all researchers and other personnel involved in this project at this institution are appropriately 
qualified or will undergo appropriate training to fulfill their role in this project. 	  
Dept/Div: Obstetrics & 
Gynecology 
Program: Women & 
Babies 
Institution: Sunnybrook & Women's 
College  Health Sciences Centre    Room 
Number:  
Telephone: 416-
 
Pager: 
 
 Fax: 416-  
Street Address: 76 Grenville Street 
City: Toronto Province: Ontario Email:  
 
 
Signature of Principal Investigator 
 
 
Date 
4B. CO-INVESTGATOR(S) CONTACT INFORMATION AND SIGNATURE 
 
CO- INVESTIGATOR AGREEMENT – I agree to participate in this study as described in this 
application and submitted protocol and agree to conduct this study in compliance with the Tri-
Council Policy Statement: Ethical Conduct for Research Involving Human Subjects and any other 
relevant regulations or guidelines. 
 
1 Title: Ms. 	   Last Name: Wyndham-West First Name: Michelle Institution: York University 
Dept/Div: Anthropology Program: PhD  
 
Signature 
2 Title:  Last Name:  First Name:  Institution:  
Dept/Div:  Program:   
 
Signature 
3 Title:  Last Name:  First Name:  Institution:  
 
Dept/Div:  Program:   
 
Signature 
4 Title:  Last Name:  First Name:  Institution:  
Dept/Div:  Program:   
 
Signature 
5 Title:  Last Name:  
 
First Name:  
 
Institution:  
Dept/Div:  Program:   
 
 
Signature 
 
4C. CONTACT PERSON FOR THIS APPLICATION IF NOT THE PRINCIPAL INVESTIGATOR 
(e.g. study coordinator, research administrative contact, research student, institutional 
liaison).  
Not Applicable  
 
Contact’s Role in Study: Co-­‐Investigator 
	   247	  
 
Indicate to whom correspondence should be mailed:  PI  Other  
 
Title: Ms. Last Name: Wyndham-West First Name: Michelle 
Dept/Div: Anthropology Program: PhD Institution: York University 
Telephone: 905-841-
7691 
Pager: n/a Fax: n/a 
Street Address: 2054 Vari Hall, 4700 Keele Street 
City: Toronto Province: Ontario 
 
Email: mwywest@yorku.ca 
 
5. DEPARTMENT/DIVISION/PROGRAM APPROVAL*  
* For institutions that require the PI to be a staff member, approval must come from the 
Department / Division / Program Head of the same institution as the PI.  
 
 
DEPARTMENT/DIVISION/PROGRAM HEAD APPROVAL – I am aware of this proposal and 
support its submission for ethics review. I consider it to be feasible and appropriate. I attest that 
the Principal Investigator responsible for the conduct of this study is qualified by education, 
training, and experience to perform his/her role in this study.  
 
Title: 
 
 Last Name:  First Name:  
 
 
Signature of Dept/Div/Program Head 
 
 
Date 
 
6. STUDY PERIOD 
 
Expected start date: March	  01/2010 Total study duration: 4	  to	  5	  months 
 
7. OTHER ETHICS/SCIENTIFIC/SCHOLARLY REVIEW 
 
 
 
In order to facilitate the REB review 
process through harmonization and 
coordination of REB activity, identify if 
any of the REBs below have reviewed 
and/or approved the study outlined in this 
application (check all that apply): 
*Ethics Review and Approval Status 
(check all that apply and indicate date where 
applicable): 
Application 
To Be 
Submitted 
Applied, 
Review 
Pending 
Reviewed Approv
ed 
 
Baycrest	   	  
   
	  
    
 
 Bloorview Kids Rehab       
 
 Centre for Addiction and Mental Health        
 
 Hospital for Sick Children        
 
 Mount Sinai Hospital        
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 St. Michael’s Hospital    
	  
    
 
 
 
Sunnybrook Health Sciences Centre        
 
 Toronto Rehabilitation Institute        
 
 University Health Network        
 
 University of Toronto       
 
 
 
Women’s College Hospital                     
 
 Other (e.g. Hamilton Health Sciences 
REB, University of Western Ontario 
Health Sciences REB, other GTA 
hospitals): 
York University 
       Aug.	  13/09 
 
Include all relevant correspondence related to ethics and scientific review (e.g. REB 
review letter, replies, approval letter). 
 
8. CLINICAL TRIAL APPLICATION  
This section must be completed for clinical trials only. See TAHSN guidelines for Health 
Canada’s definition of a clinical trial.  
Not applicable  If not applicable proceed to Question 10. 
 
8A. If this study involves any of the following, check all that apply: 
 
 Investigational drug(s) - drug name(s):  
 Approved drug for new indication, dosage, or formulation (e.g. new patient population) - drug 
name(s):  
 Investigational biologics – name(s) of biologics:  
 Investigational natural health products (NHP) – NHP name(s):  
 Investigational medical devices – device name(s):  
 
8B. If this study involves submission to Health Canada under the Food and Drug Act: 
Is Health Canada “No objection letter” or regulatory authorization attached?   Yes  No 
If No, when is it expected?  
 
8C. Provide the FDA IND number (drug studies) or PMA number (device studies): 
FDA IND #: 
 
  Pending  
PMA  #:   Pending  
Not Applicable  
   
Note: final approval will not be granted until the appropriate regulatory approval has been 
received. 
 
9. CLINICAL TRIAL REGISTRATION 
The International Committee of Medical Journal Editors (ICJME) has indicated that clinical trials 
will not be published without the registration of that trial prior to subject enrolment. A clinical trial 
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is defined by ICJME as, "Any research project that prospectively assigns human subjects to 
intervention and comparison groups to study the cause-and-effect relationship between a 
medical intervention and a health outcome. This definition includes drugs, surgical procedures, 
devices, behavioural treatments, process-of-case changes and the like. A trial must have at least 
one prospectively assigned concurrent control or comparison group in order to trigger the 
requirement for registration." 
 
Given the above definition, indicate whether this trial will be registered (e.g., 
www.clinicaltrials.gov, www.controlled-trials.com/isrctn/).   Yes  No  Not Applicable  
 
If Yes, provide registration site: 
 
 
 
 
 
 
Note: Responses to this section are not a substitute for the full protocol.  
 
10. ABSTRACT 
Must be summary of study suitable for lay audience. 
 
(Max ¼ page) 
I am conducting an ethnographic study of Ontario’s cervical cancer prevention policy, including the 
HPV vaccine, as an example of the networks of public health policy.  Critical to this study is the 
collection and analysis of health policy narratives as they are developed across institutions and received, 
refuted or amalgamated by women in their everyday lives.  In examining these narratives, I am focusing 
on notions of risk vis-à-vis HPV and cervical cancer.  The objective is to gain a greater understanding of 
how Ontario-based women negotiate cervical cancer risk, particularly since the introduction of the HPV 
vaccine.  The research is being conducted over three sites, the third of which pertains to Sunnybrook.  
The sites include: (1) textual/archival analysis of institutional risk narratives; (2) interviews with moms 
negotiating their cervical cancer risk and the HPV vaccine for their daughters; and (3) interviews with 
women attending Sunnybrook's HPV clinic.  
 
 
11. RATIONALE AND HYPOTHESIS/RESEARCH QUESTION 
 
11A. Indicate the rationale for this study. 
(Max ¼ page)( 
  
The objective of the research is to gain a greater understanding of how Ontario women negotiate cervical 
cancer risk, particularly since the introduction of the HPV vaccine. It is important to gauge the effect of 
increasing HPV awareness and the HPV vaccine on day-to-day cervical cancer risk prevention practices.  
Existing literature (Ogilvie, et al, 2007; Dempsey, et al, 2006), does not explore women’s responses to 
HPV and the HPV vaccination in an in-depth manner. Further, the Public Health Agency of Canada 
identified the need to research, from a social science perspective, the  “knowledge, attitudes and beliefs” 
of parents and young women regarding the HPV vaccine (2005:iv).  This qualitative research project 
begins to fill that gap by directly exploring “the complexity of women’s responses…, which may range 
from selective resistance to selective compliance” (Lock & Kaufert, 1998:2).    
 
 
 
11B. Indicate the hypothesis for this study or research question. 
(Max ¼ page) 
Research Question Pertinent to Sunnybrook: Since the concretization in medical science of the linkage 
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between HPV and cervical cancer and the introduction of the HPV vaccine, how are Ontario-based 
women negotiaitng cervical cancer risk in their everyday lives? 
 
 
11C. Indicate the significance of the study (i.e. the overall anticipated public and/or 
scientific benefit). 
(Max ¼ page) 
 In addition to filling a void in the academic literature concerning HPV and cervical cancer risk 
negotiation, this project will have direct relevance to the medical and public health communties. The 
research will provide in-depth data regarding the knowledge, attitudes and beliefs of  Ontario-based 
women regarding HPV, the HPV vaccine and cervical cancer screening practices in general. This data 
can be applied to cervical cancer screening program planning and related public health promotion.  
 
 
12. STUDY DESIGN 
Many of these questions apply to clinical research studies. If any of the items are not applicable 
to your study, indicate N/A. 
 
12A. Describe the design and methodology (e.g. pre/post design, pilot, study visits, 
procedures, study intervention).                  
(Max ½ page) 
I am implementing the research project in three phases as mentioned in section 10. The third phase is 
relevant to Sunnybrook.  In the third phase, I will focus upon women’s narratives as they negotiate the 
province’s cervical cancer prevention policy.   In this phase , interviews will be conducted with a cohort 
of 20-25 young women who are clients of the HPV clinic at Sunnybrook Health Sciences Centre. These 
women are negotiating their own cervical cancer risk, with an emphasis on the HPV vaccine.  This stage 
has been developed in consultation with Dr.  and , RN (EC). Interviews with 
Sunnybrook clients will take place over the telephone or in person on a convenient date after a clinic 
visit.  All interviewees will be over 16 years of age and will provide informed consent. Informed consent 
will be obtained by nursing staff and the interviews conducted by Michelle Wyndham-West, PhD 
Candidate, York University. The qualitative data will be unpacked through a “categorical-content” type 
of narrative analysis (Lieblich, et al, 1998:13).  
 
 
12B. Describe the primary outcome measures/goals of the study. 
(Max ¼ page) 
The goal of the research is to gain a greater understanding of how Ontario-based women negotiate 
cervical cancer risk, particularly since the introduction of the HPV vaccine.  This will be assessed by 
gathering and analyzing qualitative data addressing knowledge, attitudes and beliefs concerning HPV, 
the HPV vaccine and cervical cancer risk prevention practices.  Data gathered will, specifically, provide 
in-depth accounts of : (1) risk perceptions vis-a-vis  cervical cancer; (2) HPV awareness and  HPV-
centered knowledge; (3) detailed infromation regarding cervical cancer screening practices; and (4) 
decision-making surrounding the HPV vaccine. 
 
 
12C. List any criteria for premature withdrawal of a subject from the study for safety 
concerns.  
Not Applicable  
(Max ¼ page) 
N/A 
 
 
12D. Is a placebo used in this study?  Yes  No 
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If Yes, explain how this is this justified (e.g. no alternative standard treatment available). 
Include any provisions in place to reduce risks to subjects assigned to placebo (e.g., 
increased monitoring, rescue medication). 
(Max ¼ page) 
N/A 
 
 
12E. Does this study involve deception or intentional lack of disclosure?  Yes  No 
 
If Yes, justify and indicate how subjects will be debriefed. 
(Max ¼ page) 
N/A 
 
 
12F. Will the subject be withdrawn from or denied usual therapy for any condition in order 
to participate in the study or be subject to other restrictions during the study?   Yes  
No 
(This would include medications that are prohibited or restricted in order to be eligible for the 
study or that may be prohibited or restricted during the course of the study.) 
 
If Yes, explain. 
(Max ¼ page) 
N/A 
 
 
 
13. SUBJECT/CONTROLS 
 
13A. Indicate the main inclusion/exclusion criteria. 
(Max ¼ page) 
All clients 16 years of age or older of the HPV clinic will be eligible to take part in the research project. 
Clients under 16 years of age of the HPV clinic will not be eligible to take part in the research project. 
 
 
i) Indicate the age range of eligible subjects: 16 years of age and older 
 
13B. If applicable, indicate the rationale for control group(s). 
(Max ¼ page) 
N/A 
 
 
13C.  
 
Total study enrollment: 20 to 25 clients of the HPV clinic   
Number of subjects to be enrolled at this 
institution: 20 to 25   
Indicate the time period for 
enrollment: March to July, 2010 
Approximate size of eligible population from institution/practice: Anticipate approximately 
100 clients will attend the clinic during a five month period. 
 
13D. Is sample size justified in the protocol?   Yes  No 
 
If Yes, indicate protocol page: 9 
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If No, provide sample size justification. 
(Max ¼ page) 
N/A 
 
 
14. STUDY INTERVENTIONS OR PROCEDURES 
Not Applicable  (e.g. observational studies). If not applicable, go directly to 15. DATA 
ANALYSIS 
 
14A. Document the usual standard of care at this institution for this population. 
Not Applicable  
(Max ¼ page) 
N/A 
 
 
14B. Indicate what procedures are to be carried out in the study, that are not considered 
part of the diagnostic, therapeutic “routine” or indicate how standard of care is altered. 
Attach a copy of all non-standardized instruments (e.g., questionnaires, rating scales). 
(Max ¼ page) 
N/A 
 
 
14C. Indicate the additional risks associated with the study as compared to usual standard 
of care. Do not refer to other sections of this form. 
(Max ½ page) 
N/A 
 
 
 
14D. Indicate duration of study visits and extra time commitment (length, number, and 
frequency of test sessions) for study participation. 
(Max ¼ page) 
N/A 
 
15. DATA ANALYSIS 
 
Briefly explain what methods will be used to analyze study data. 
References to protocol for this question are acceptable. Indicate applicable page(s) of protocol. 
(Max ¼ page) 
12 
 
 
 
 
 
16. RECRUITMENT AND CONSENT 
Not Applicable  
 
Note: Any document to be viewed by the subject (e.g., recruitment posters/letters, 
consent/assent forms, information sheets) must be included with your submission. 
 
16A. Indicate what tools will be used to identify potential subjects for recruitment into the 
study. 
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 Permanent health record/clinical chart (specify source): HPV nursing staff will identify suitable 
interviewees to Michelle Wyndham-West. Michelle Wyndham-West will not have access to health 
records; this priviledge rests with nursing staff only. 
 Existing database (specify): 
 
 
o Does the Principal Investigator maintain the database?  Yes  No 
o If No, identify the entity that maintains the database:  
Note: The creation and maintenance of a database for research purposes is a research activity 
that may require a separate REB application. Consult your institutional REB. 
 Advertisements, including web based recruitment tools (attach) 
 Other (specify):  
 
16B. Indicate who will identify potential study subjects 
 Investigator/study personnel 
 Other healthcare professional (e.g. non-study personnel) 
 Self-referral (e.g. response to advertisement) 
 
i) Identify all persons who will be reviewing health records/identifying information (for 
recruitment purposes).  
 
1 Title: Primary Health Care 
Nurse Practitioner 
Last Name:  First Name:  
Institution: Sunnybrook Qualifications: Rn (Ec), BScN, 
MSc, PHCNP 
Role in Study: Identify 
potential interviewees and 
complete consent process 
 
2 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
3 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
4 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
5 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
 
 
ii) List the identifying information that will be collected, used, or disclosed from the 
records during the course of the proposed recruitment activities. 
  
 Name  Images (e.g., photographic, x-ray, MRI scans) 
 Address  Social Insurance Number 
 Telephone Numbers  Medical Record Number 
 Email Address  Date of Birth 
 Health Card Number  Health Information: (e.g., relating to inclusion 
/exclusion criteria, medications) 
 Other information (specify):  
 
iii) Describe the security measures that will be taken to protect the confidentiality of this 
information. 
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(Max ¼ page) 
Michelle Wyndham-West has been identified as the designated person to ensure the confidentiality of 
identifying data during the recruitment period. It will be necessary to obtain contact details of recruits 
(i.e. telephone number) in order to arrange interviews.  These will be provided by potental interviewees 
and not Sunnybrook. Sunnybrook will provide names only to Michelle Wyndam-West. All telephone 
numbers gathered during the recruitment will be kept at the HPV clinic, both in paper form in a locked 
cabinet and electronically on a secure server. During the recruitment process a key file will be created, 
which assigns a study number for each participant to serve as a future unique study identifier. The key 
file will be housed at the Sunnybrook HPV clinic, both in  paper form in a locked cabinet and 
electronically on a secure server.  The key file will not leave Sunnybrook. 
 
 
iv) Indicate what will happen to this information at the completion of the recruitment 
process. 
(Max ¼ page) 
At the end of a completed interview (hence, the end of the recruitment process), the recruitment related 
data which can serve as identifying, i.e. telephone number, will be destroyed, both in paper and 
electronic form. Paper-based information will be shredded using Sunnybrook's shredding/disposal 
process and electronic data will be erased via the "Permanent Eraser" for Mac, which uses the Gutmann 
method. 
 
 
16C. Indicate who will make initial contact with potential subjects or authorized third party, 
whether they are already known to the subject or authorized third party, and how contact 
will be made (e.g., in person, phone, letter, e-mail, website). Attach a copy of the script  or 
any written materials if applicable.  
(Max ¼ page) 
Initial approach of patients will be undertaken by , RN (EC). Michelle Wyndham-West 
will follow-up with   potential interviewees at the HPV clinic in person if they have expressed interest to 
.  Michelle Wyndham-West will answer all telephone enquiries from individuals responding 
to study recruitment posters. The study recruitment posters will be affixed in the HPV clinic.  Michelle 
Wyndham-West will not be known to the prospective interviewees.  
 
 
16D. Describe the consent process and who will obtain consent (e.g. will consent be 
written, oral, telephone (include script). If the study population requires special consent 
considerations (e.g., child, incompetent adult, unable to communicate), refer to 16E. 
(Max ¼ page) 
The consent process will be completed by , RN (EC), the staff nurse at the HPV clinic.  
The consent process will be completed during the HPV clinic hours while prospective interviewees are 
attending the HPV clinic. Prospective interviewees who have contacted Michelle Wyndham-West for 
study information by phone will be required to complete the consent process with  during 
clinic hours in person.  The study population does not require special consent consideration as all 
interviewees will be over 16 years of age. 
 
 
  i) Indicate if there is a relationship between the subjects and either of the 
following: 
 Person obtaining consent  Yes  No 
    Investigator  Yes  No 
  
ii) If Yes, explain the nature of the relationship (e.g., physician, employer) and what steps 
will be taken to avoid the perception of undue influence. 
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(Max ¼ page) 
The nurse practitioner running the HPV clinic will be obtaining consent and the principal investigator of 
this research project is a physician at the HPV clinic. Michelle Wyndham-West, a PhD candidate at York 
University, will be conducting interviews. Michelle does not hold a relationship with clients at the HPV 
clinic, nor is she employed at the clinic, and this will lessen the perception of undue influence for 
prospective participants. 
 
 
iii) Indicate how much time will be given to subjects to review the information before being 
asked to give consent.  
(Max ¼ page) 
Consent forms will be completed during an HPV clinic visit.  The clinic operates every Wednesday 
afternoon. Prospective participants can use the duration of their clinic visit to provide consent and can 
also take the study information with them and return another Wednesday afternoon to complete the 
consent process. 
 
 
 
16E. Indicate if the research will involve any of the following: 
 
i) Special Considerations (check all that apply): 
 Women of child bearing potential   Genetic research 
 Pregnant women     Tissue samples 
 Healthy volunteers    Fetal tissue or placenta 
 Students      Prisoners 
 Staff  None of the above 
 
 ii) Capacity/Competency (check all that apply): 
 Children less than 16 years of age 
 Emergency patients 
 Individuals temporarily unable to provide an informed consent 
 Marginally incompetent subjects 
 Incompetent subjects 
  None of the above 
 
 Describe how capacity will be assessed for any individuals in 16Eii. 
(Max ¼ page) 
N/A 
 
 
If subjects are incapable of providing consent, provide information on how substitute 
decision makers will be identified. 
(Max ¼ page) 
N/A 
 
 
When inability to provide an informed consent is expected to be temporary, describe what 
procedures will be used to regularly assess capacity and to obtain consent if the 
individual later becomes capable of providing consent. 
(Max ¼ page) 
N/A 
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 iii) Communication Difficulties (check all that apply): 
 Individuals who may require translation 
 Individuals who are illiterate 
 Subjects unable to communicate 
 None of the above 
 
Provide an explanation of what procedures will be used to address any communication 
difficulties (e.g., the use of translated forms, translator, impartial witness).  
(Max ¼ page) 
N/A 
 
 
16F. If potential subjects might be approached for recruitment in other studies, indicate 
the steps that will be taken to minimize the number of times that this will occur. 
(Max ¼ page) 
N/A 
 
 
17. RISK/BENEFIT ESTIMATES 
 
17A. Potential Benefits to Subjects 
No direct benefits anticipated  
 
List anticipated benefits to the subject, if any. 
(Max ¼ page) 
N/A 
 
 
17B. Potential Harms (injury, discomfort and inconvenience) to subject (including 
psychological factors). 
No known risks  
 
 i) List the known risks of study intervention(s) including approximate rates of 
occurrence, severity and rates of reversibility. 
(Max ¾ page) 
N/A 
 
 
 ii) List the risks of any tests, procedures or other protocol-mandated activities that 
are conducted for research purposes only, including approximate rates of occurrence, 
severity and reversibility.  
(Max ¾ page) 
N/A 
 
 
iii) For studies involving placebo, washout, or withholding treatment, list any risks related 
to absence of treatment. 
 Not Applicable  
(Max ¾ page) 
N/A 
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iv) Include a summary of the data regarding reproductive risks such as teratogenicity or 
embryotoxicity of the study drug, any risk with breastfeeding, or risk to men regarding 
conception. 
Risks unknown  
(Max ¼ page) 
N/A 
 
 
v) Indicate whether participation in this study affects alternatives for future care.                     
 Yes  No 
 
 If Yes, explain. 
(Max ¼ page) 
N/A 
 
 
 
18. PAYMENTS 
Not Applicable  
 
18A. Indicate what payment(s) will be provided to subjects or substitute decision makers, 
if applicable. 
 
 Reimbursement for expenses incurred as a result of research 
Amount: N/A  Specify (e.g., travel, meals): N/A 
 Gifts for participation  
Value: N/A 
 Compensation for time 
Amount: N/A 
Provide justification if compensation for time will be provided. (Max 1/4 page) N/A 
 Other forms of compensation: N/A 
 
19. MONITORING 
 
19A. Indicate if there is a plan for monitoring of the study (e.g. sponsor initiated site visits)  
 Yes  No  Not Applicable  
 
If YES, describe. 
(Max ¼ page) 
N/A 
 
 
19B. Indicate if an interim analysis is planned.  Yes  No  Not Applicable 
 
 If Yes, describe briefly. 
(Max ¼ page) 
N/A 
 
 
19C. Indicate if there is a steering committee.  Yes  No  Not Applicable 
 
 If Yes, provide a copy of the terms of reference (mandate) of the steering 
committee. 
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19D. Indicate if there is a data and safety monitoring board (DSMB).   
 Yes  No  Not Applicable 
 
If Yes, forward a copy of the DSMB charter when available or provide a description of the 
DSMB, including its purpose, membership, relationship to the sponsor, and whether the 
committee will review unblinded study data etc. Refer to the protocol as needed. 
(Max ¼ page) 
N/A 
 
 
If No, justify and explain what alternative arrangements are in place to monitor the safety 
data and how the overall risk/benefit information will be communicated to the REB. 
(Max ¼ page) 
N/A 
 
 
20. POTENTIAL CONFLICTS OF INTEREST 
If any of the conflicts listed below apply to any of the Investigators involved in the 
research study or any member of their immediate family, append a letter to the Chair of 
the REB detailing these activities and how they will be managed. Disclose all contracts 
and any conflicts of interest (actual, apparent, perceived, or potential) relating to this 
project. Conflict of interest may also arise with regard to the disclosure of personal health 
information. 
 
 
 Function as an advisor, employee, officer, director or consultant for the study sponsor 
 Have direct or indirect financial interest in the drug, device or technology employed in this 
research study (including patents or stocks) 
 Receive an honorarium or other personal benefits from the sponsor (apart from fees for 
service) 
 Receive direct or indirect financial benefit from the disclosure of personal health information 
 Other 
 None of the above 
 
21. PUBLICATION/DISSEMINATION OF RESULTS 
Indicate how the results will be communicated to subjects and other stakeholders (e.g., 
advocacy groups, scientific community).  
 
 Individual debriefing at end of test 
session 
 Publication 
 Group debriefing  Other (specify): 
 
 
 Letter of appreciation at end of study  No Plan 
 
If no plan is in place, provide justification.  
Not Applicable  
(Max ¼ page) 
N/A 
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22. COLLECTION USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION 
Investigators should comply with the duties set out for researchers in the Personal Health 
Information Protection ACT (PHIPA – effective in Ontario Nov. 1, 2004) and with the privacy and 
confidentiality and consent guidelines outlined in theTri-Council Policy Statement on Ethical 
Conduct for Research Involving Humans.	  	  
 
22A. List all personal health information and personal identifiers (e.g. name, DOB) 
required to be collected. For all non-clinical trials, attach data collection forms. 
(Max ¼ page) 
Personal identifiers to be collected include: name and phone number.   
 
 
22B. Identify all potential sources of this information. 
(Max ¼ page) 
The names of prospective interviewees will be given to Michelle Wyndham-West, PhD Candidate, York 
University, by , RN (EC). Contact details (i.e. telephone number) of prospective 
interviewees will be given by the prospective interviewees themselves to Michelle Wyndham-West. 
 
 
22C. Indicate how study subjects will be identified on data collection forms (e.g. study 
number, initials). 
(Max ¼ page) 
A key fille will be created, which attributes a unique study number to each participant. This key fille will 
reside at Sunnybrook only, in a locked cabinet for the paper copy and on a secure Sunnybrook server for  
the electronic copy.  All data regarding research particpants will be coded as per their unique study 
identifier and stored in a different location than the key file.  
 
 
22D. Indicate how data will be stored. 
 Computerized files (specify): Server    Desktop  Laptop  
 Audio recordings 
 Hard copy 
 Videotape 
 Other (e.g. PDA): 	  	  	  N/A 
 
i) Describe the safeguards to protect the confidentiality and security of the data, including 
any physical and technical safeguards (e.g. data will be stored in a locked and secure 
area, the data will be stored on a secure server that is password protected) 
(Max ¼ page) 
Research data, with unique study numbers will be kept at Michelle Wyndham-West's residence. This 
will ensure that research data is kept in a different location than the key file. All forms of study data, 
including audiotapes and transcribed versions of the interviews will be kept on an encrypted USB key at 
Michelle Wyndham-West's residence. Back-up copies of the data, which will be in paper form, will be 
kept in a locked filing cabinet in Michelle Wyndham-West's home.  All research data will be desroyed 
after five years as per Sunnybrook's policy. Hard copy data will be shredded and disposed of as per 
Sunnybrook policy and all electronic data will be erased permanently using "Permanent Eraser" for Mac, 
which uses the Gutmann method. 
 
 
ii) Indicate who will have access to these data in the future. 
(Max ¼ page) 
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Research data will be available to Dr.  and , RN (EC). Research data will 
be de-identified and include unique study numbers. 
 
 
22E. Indicate if any information that could potentially identify study subjects will be 
disclosed outside of the institution (e.g., names, initials, DOB, OHIP #). 
 Yes  No 
 
If Yes, justify and describe how this information will be transferred and any security 
measures to be used (e.g., anonymized data, secure network upload or download). 
(Max ¼ page) 
Michelle Wyndham-West will gather names and contact information of prospective interviewees while 
at the HPV clininc. This information will be given to Michelle Wyndham-West from the interviewees 
themselves and after informed consent has been obtained by nursing staff. This information will reside 
on Michelle Wyndham-West's laptop in order to be able to arrange interviews. This data will be 
encrypted on Michelle Wyndham-West's laptop in order to ensure the security of the data.  Once an 
interview has been completed an interviewee's name and contact details will be removed from the said 
laptop using the "Permanent Eraser" for Mac, which uses the Gutmann method.  
 
 
22F. If personal health information is to be linked to other databases (e.g., health 
registries, statistics Canada information) provide the following details: 
Not Applicable  
 
i) Describe the data to which the personal health information will be linked. 
(Max ¼ page) 
N/A 
 
 
ii) Explain how the linkages will be made. 
(Max ¼ page) 
N/A 
 
 
iii) Explain why these linkages are required. 
(Max ¼ page) 
N/A 
 
 
22G. Indicate how long the personal health information will remain identifiable and explain 
why. 
Not Applicable  
(Max ¼ page) 
Personal information, comprising soley of name and telephone number, will only remain identifiable 
during the recruitment of an interviewee. Once the interview is complete, this personal information will 
be removed form Michelle Wyndham-West's encrypted laptop via the "Permanent Eraser" for Mac 
function and remain solely with the key file at Sunnybrook. It is vital to have an interviewees name and 
contact details in order to arrange and complete an interview. Once the interview is complete, there is no 
need for this information to reside outside the key file. 
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22H. Identify all persons (in addition to those listed in Q. 16Bi) that will have access to the 
personal health information, their roles in the study, their reason for access, and related 
qualifications. 
1 Title: N/A Last Name: 
 
 First Name:  
Institution:  Qualifications:  Role in Study:  
 
2 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
3 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
4 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
5 Title:  Last Name:  First Name:  
Institution:  Qualifications:  Role in Study:  
 
  
22I. Explain why the research cannot reasonably be accomplished without using personal 
health information. 
(Max ¼ page) 
The only personal health information to be obtained from prospective interviewees will be their names 
and telephone  numbers for recruitment purposes. Withouth this information, it would be impossible to 
arrange an interview. 
 
 
22J. If personal health information will be collected, used or disclosed without consent 
from the individuals to whom the information relates, explain why obtaining explicit 
consent would be impractical.  
(Max ¼ page) 
Informed consent will be obtained from individuals in order to gather their names and telephone number 
with the aim of arranging an interview. 
 
 
22K. Describe any harms or benefits that could arise if personal health information was 
inappropriately released (e.g., embarrassment, refusal of employment or insurance 
coverage, stigmatization of individuals / groups) and how any consequences would be 
addressed. 
(Max ¼ page) 
Research data will be attributed unique study numbers and reside in encrypted form on Michelle 
Wyndham-West's laptop and on an encrypted USB key in order to mitigate the risks of inappropriately 
released personal health information. Once audio files of interviews have been downloaded to the 
encrypted USB key, the original audio recording, which was recorded on a hand-held recording device, 
will be destroyed by deleting the recording.  The key file will not leave Sunnybrook and will reside on a 
secure server. Interviews do not aim to collect any data that can put a participant at risk of 
embarrassment, refusal of employment or insurance coverage or stigmatization. 
 
 
22L. Describe how and when the personal health information will be disposed of or 
returned to the health information custodian. 
(Max ¼ page) 
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Personal health information, including solely names and telephone numberss, will be destroyed once an 
interview is complete, save for this information in the key file, which will reside at Sunnybrook. The 
personal health information will be removed from Michelle Wyndham-West's encrypted laptop once an 
interview is complete using the "Permanent Eraser" for Mac function. 
23. BUDGET
No budget required
Attach an itemized study budget (applies to all full board and expedited review studies). 
The budget should reflect all costs at this institution. 
Indicate whether the funding is sufficient to cover all study costs.  Yes  No 
f No, explain how the shortfall will be made up.  
(Max ¼ page) 
N/A 
Indicate if any investigator will receive direct personal payments from the budget.   Yes 
 No 
If Yes, describe what these payments are for and the amount. 
(Max ¼ page) 
N/A 
24. AGREEMENTS
24A. Contract/Research Agreement 
Indicate whether there is a contract/research agreement involved  Yes  No 
If Yes, provide name of sponsor/agency: 
Provide name of the contract research organization: 	  Not applicable 
24B. Indicate whether the contract/research agreement has been submitted for review and 
signing.  (See institution specific instruction page)  Yes  No 
24C. Indicate if there is external (non-institutional) liability insurance.  Yes  No 
ii) Indicate who will cover reasonable out-of pocket expenses to ensure that immediate
medical care is provided if a subject suffers an injury as a result of participation in the 
study. 
 Sponsor 
 Institution 
 Other (specify): N/A 
24D. Publication Agreements 
i) Indicate if there is an agreement between the Investigator and the sponsor regarding the
use, publication or disposal of the data.  Yes  No  Pending 
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ii) If Yes, Indicate whether the funding agency or sponsoring company places any
restrictions on publication of findings or reporting interim results.  Yes  No 
Pending 
iii) If Yes, explain any restrictions.
(Max ¼ page) 
N/A 
25. MATERIAL TRANSFER AGREEMENT
Indicate if there is a material transfer agreement (MTA) involving human material for this 
study. This refers to an agreement for transfer of biological materials (e.g. tissues, cell lines) 
from the institution to another institution or entity.  Yes  No 
If Yes, attach a copy of the agreement. 
26. INFORMATION SHARING
Indicate if there is an information sharing agreement.  Yes  No 
If Yes, attach a copy of the agreement.   
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Appendix D – Sunnybrook Approval Letters 
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Appendix E –Interview Schedule 
MICHELLE WYNDHAM-WEST, PHD DISSERTATION RESEARCH - 
DRAFT ONE-ON-ONE INTERVIEW SCHEDULE  
Background: 
Start off asking basic demographic information to open up the conversation (I can also 
explain a bit about my background if this would help in making people at ease, but the 
focus should remain on the interviewees) 
• Are you single or in a long-term relationship? If you have a partner, please
describe his/her background. 
• How old are you?
• What is your occupation? (i.e. Are you a student? What are you studying? Do you
work part-time or full-time? What area do you work in?) 
• Please describe your educational history.
• How would you describe your religious affiliation? This includes not feeling
attached to a particular religion and organized forms of religious practice. 
• How would you describe your ethnic background?
Risk, cervical cancer & HPV: 
• Why do you think people get cancer? Please list some of the reasons/factors that
you think come into play when getting cancer. 
• Where did you learn about these risks? (Family, friends, media, doctor, nurse,
other sources, etc.) 
• Why do you think women get cervical cancer? Please list some of the
reasons/factors that you think come into play when getting cervical cancer. (Possible 
prompts can include genetics, lifestyle, sexual activity, HPV, environmental influences, 
etc.) 
• Where did you learn about cervical cancer risks? (Family, friends, media, doctor,
nurse, other sources, etc.) 
• Do you think cervical cancer can be prevented? If so, how? If not, why not?
• Are there particular activities women can engage in or not engage in to prevent
from getting cervical cancer? Do you take part or not take part in these activities in order 
to prevent cervical cancer? 
• How would you describe HPV? (i.e. How does a person get HPV? What happens
when they get HPV?) 
• How do you think HPV is linked to cervical cancer?
• How has recent attention to the links between HPV and cervical cancer in the media
(mostly in reference to the vaccine) influenced how you think about cervical cancer? 
• Do you think you will get cervical cancer? Please explain why or why not.
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• Have you been identified as being “at-risk” for cervical cancer (i.e. had an “abnormal”
Pap smear)? If the answer is yes, please describe this experience, including how this was 
monitored and/or treated and your recollections/feelings about the experience(s). 
Cervical cancer screening & risk prevention: 
• If you have had a Pap test, please describe your experiences of Pap smears. Can offer a
description of a particular test that stands out in memory or general impressions gathered 
over the years. 
• Why do you think it is important to have Pap smear tests? Please explain why or why
not. 
• Do you feel there are risks associated with having a Pap smear? Please explain.
• Have you been tested for HPV? Do you think women should be tested for HPV? Please
explain why or why not.  Is this preferable over a Pap smear? Please explain further. 
• Has recent media coverage surrounding the links between HPV and cervical cancer
(mostly in reference to the vaccine) influenced your decision to seek or not to seek a Pap 
smear or HPV test? Please explain. 
• What do you think about the HPV vaccine?
• Do you feel there are risks associated with having the HPV vaccine? If yes, please
explain. 
• What do you think about the provincial government recommendation that grade 8 girls
be vaccinated free of charge through the public school system? 
• Do you think the vaccination policy should be opened up to provide vaccinations free of
charge for young women/women in other age groups or boys/young men?  Please explain 
why or why not. 
• How did you reach the decision to have the HPV vaccination? What resources did you
draw upon in making your decision?  
Other areas of interest & bringing interview to a close: 
• Are there other topics you would like to talk about? Are there questions you think
should be included in this interview? 
• If you have any questions, concerns or additional information to add after this
interview, please feel free to contact me by e-mail at mwywest@yorku.ca. 
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Appendix F – Interviewee Profiles 
Patients 
Pseudonyms have been assigned, identifying information has been altered and all 
patients live in the Greater Toronto Area  
1) Monica, 28, nurse, single (but, in on and off-again relationship with male), lives
in large urban centre.
2) Rebecca, 40, manager of a retail store, married with one child, lives in large urban
centre
3) Jennifer, 40, HR senior manager, single, lives in large urban centre
4) Kathryn, 32, urban planner, single, lives in large urban centre
5) Maggie, 26, physiotherapist, single, lives in large urban centre
6) Naomi, 28, MBA student, in a new heterosexual relationship, lives in large urban
centre
7) Zoe, 30, high school teacher, married, lives in large urban centre
8) Jill, 40, sales rep., single, lives in large urban centre
9) Christine, 28, paralegal, single, lives in suburbs
10) Allison, 40, chef, in a relationship, lives in the country
11) Laurie, 35, graphic artist, in a relationship, lives in suburbs
12) Adrianna, 28, nurse, single, lives in a large urban centre
13) Emily, 29, accountant, single, lives in large urban centre
14) Megan, 27, freelance writer and editor, engaged, lives in large urban centre
15) Sylvia, 34, dietician, single, lives in large urban centre
16) Liz, 26, occupational therapist, engaged to be married, lives in the suburbs
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17)  Heather, 26, advertising account executive, in a long-term relationship, lives in a 
large urban centre 
18)  Sara, 24, graduate student, single, lives in large urban centre 
19)  Nicole, 25, journalist, in a casual relationship, lives in large urban centre 
20)  Alicia, 37, social worker, single, lives in large urban centre 
 
Mothers 
Pseudonyms have been assigned and identifying information has been altered. 
 
1) Karen, 44, married with three kids, engineer, lives in a suburb of Toronto 
2) Alexandra, 38, married with two kids, entrepreneur, lives in the countryside 
outside of Toronto 
3) Margot, 38, stay-at-home mother, married, five kids, lives in Toronto 
4) Serena, 45, journalist, married with three kids, lives in Toronto 
5) Gabrielle, 39, academic, married with three children, lives in Toronto 
6) Carole, 41, stay-at-home mother, married with two children, lives in suburb 
outside Toronto 
7) Giuliana, 36, stay-at-home mother with part-time business from home, married 
with three children, lives in Toronto 
8) Carmen, 39, college professor, single, one daughter, lives in Toronto 
9) Andrea, 43, entrepreneur, married, mother of three, lives in suburbs of Toronto 
10)  Mary, 36, public relations executive, married, mother of two, lives in Toronto 
11)  Heather, 40, physiotherapist, married, mother of four, lives in Toronto 
12)  Colleen, 36, runs home-based business, married, mother of one, lives in Toronto 
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13)  Kathy, 48, lawyer, married, mother of three daughters and a son, lives in Toronto 
14)  Rachel, 39, librarian, single, mother of 1, lives in Toronto 
15)  Tracey, 41, high-school teacher, mother of one, lives in Toronto 
16)  Bronwyn, 40, freelance journalist and editor, married, mother to three children, 
lives in Toronto 
17)  Annabelle, 46, nurse, married, mom of two, lives in suburbs of Toronto 
18)  Joanne, 38, journalist, married, mom of three, lives in Toronto 
19)  Camille, 38, stay-at-home mother, married, four children, lives in suburbs of 
Toronto 
20)  Fiona, 40, policy analyst with provincial government, single, mom of two, lives 
in Toronto 
Students 
Pseudonyms have been assigned and identifying information has been altered. 
 
1) Ellen, 26, nursing student, single, from Kingston but lives in Ottawa during the 
academic year 
2) Sonia, 24, nursing student, single, lives in Toronto 
3) Marie-Josee, 28, graduate student in the life sciences, single, lives in Ottawa 
4) Kim, 26, master’s student in history, married, lives in Kingston 
5) Sam, 22, kinesiology undergraduate student, in a relationship, lives in Toronto 
6) Brittany, 22, physiotherapy student, in a relationship, lives in London, Ontario 
7) Sydney, 22, nursing student, engaged, lives in Peterborough 
8) Jamie, 28, medical student, in a long-term relationship, lives in Ottawa 
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9) Madeleine, 23, anthropology undergraduate student, lives with partner in Ottawa 
10)  Stacie, 20, women’s studies undergraduate major, single, lives in a suburb 
outside of Toronto 
11)  Morgan, 22, French literature undergraduate major, single, lives in Toronto 
12)  Amber, 26, first year law student, single, from North Bay, but lives in Toronto 
during academic year 
13)  Emily, 22, master’s student in environmental studies, in a relationship, from 
Sarnia, but lives in Toronto during academic year 
14)  Sylvana, 27, master’s student in public health, engaged, from Slovakia, but is 
Canadian permanent resident and lives in Toronto 
15)  Molly, 21, biology major, in a relationship, international student from Barbados, 
lives in Toronto for academic year 
16)  Sadie, 23, mater’s student in public health, single, lives in Toronto 
17)  Tovah, 27, master’s student in nursing, in a relationship, from London, Ontario, 
but lives in Toronto during school year. 
18)  Stephanie, 24, kinesiology undergraduate major, in a relationship, lives in 
Toronto 
19)  Trish, 22, psychology major, in a relationship, lives in Toronto for academic 
year, but is from Arnprior, Ontario 
20)  Katie, 24, Bachelor of Education candidate, singles, lives in Toronto 
21)  Jasmine, 21, sociology undergraduate major, lives in Toronto 
22)  Jacquie, 28, PhD student in women’s studies, married, lives in Toronto 
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23) Lison, 27, master’s of social work student, single, is from France, but has
Canadian permanent residency and lives in Toronto
24) Maya, 27, master’s in nursing student, single, is from Nova Scotia, but lives in
Toronto permanently now
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Appendix G – Mother and Student Consent Form 
Individual Informed Consent Form for In-Depth Interviews - 
CONSENT TO PARTICIPATE 
I agree to participate in a research project called “Risk, biological citizenship & gender: 
an ethnographic exploration of HPV and cervical cancer prevention policy in Ontario”, 
conducted by Michelle Wyndham-West, a doctoral candidate in anthropology at York 
University. The information will be used in the writing of Michelle Wyndham-West’s 
dissertation. I understand that information I provide will be audiotaped and will be kept 
in the strictest of confidence. It is anticipated interviews will take approximately 45 
minutes to an hour to complete. I also understand that I may choose not to respond to 
questions and may withdraw from this interview any time in the process. I understand 
that any information that I give will not be attributed to me by name and that every effort 
will be made to protect the confidentiality of the information I provide. Confidentiality 
will be provided to the fullest extent possible by law. I understand any notes or audio 
taping of my interview will be kept in locked storage and destroyed once the study is 
complete.  This study proposes minimal risk to participants as the study focuses upon the 
collection of individual narratives and will not affect access to medical services regarding 
cervical cancer prevention. Your decision not to volunteer will not influence the nature of 
your relationship with York University either now, or in the future. In the event you 
withdraw from the study all associated data collected will be immediately destroyed 
wherever possible. 
If you have questions about the research in general or about your role in the study, please 
feel free to contact Dr. Naomi Adelson, Department of Social Anthropology, by 
telephone at (416) 736-2100 or by e-mail at nadelson@yorku.ca.  The researcher can also 
be reached by e-mail at mwywest@yorku.ca. Additional information regarding the 
research project can be found at http://www.yorku.ca/gradanth/students.html. This 
research has been reviewed by the Human Participants Review Subcommittee (York 
University’s Ethics Review Board) and conforms to the standards of the Canadian Tri-
Council Research Ethics guidelines.  If you have any questions about this process, or 
about your rights as a participant in the study, please contact the Manager, Research 
Ethics, York University, 309 York Lanes, telephone 416-736-2100 ext. 55914. 
I (fill in your name here), consent to participate in “Risk, biological citizenship & gender: 
an ethnographic exploration of HPV and cervical cancer prevention policy in Ontario” 
conducted by Michelle Wyndham-West.  I have understood the nature of this project and 
wish to participate.  I am not waiving any of my legal rights by signing this form.  My 
signature below indicates my consent. 
___________________    Date_______________________ 
Participant 
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____________________ Date________________________ 
Principal Investigator 
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Appendix H – York University Ethics Amendment Application to Interview 
Students 	  
REQUEST FOR APPROVAL of an AMENDMENT to an 
APPROVED PROTOCOL 
 
 
Who should complete this form:  Researchers requesting approval of a change  
to an approved ethics protocol  
 
Instructions:    Please complete this form and submit it to,  
Alison Collins-Mrakas, Manager,  
Office of Research Ethics, 
Room 309 York Lanes  
Or, electronically to: acollins@yorku.ca  
 
 
Principal Investigator: Michelle Wyndham-West 
 
Project Title: Enacting biological citizenship through risk and gender: an ethnographic 
exploration of HPV and cervical cancer prevention policy in Ontario 
 
Certificate #: STU 2009 - 103 
 
 
Which element(s) of the protocol require(s) amendment (i.e. risks, 
participant pool, recruitment method etc.)? 
Participant pool 
 
 
Please describe the proposed amendment:  
I would like to add a participant pool of 20 York University students (female only and 16 years of 
age or older) to my current research.  If permission is granted, I will recruit said participants by 
affixing recruitment posters around the university and putting ads in the student newspaper. 
 
 
 
Does this represent a substantive change to the approved protocol? Why 
or why not?  
This does not represent a substantive change of the approved protocol.  All parameters of the 
approved protocol will stay the same and the interview schedule provided on pages 68 to 69 
(Appendix B) in the protocol will be used for interviewing York University students.  The student 
interviews will augment the current research that is underway. 
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NOTE: 
(i.) If the changes ARE substantive, please note that a full committee review is required. 
Please re-submit a revised HPRC protocol to the HPRC/Manager Research Ethics at your 
earliest convenience. 
(ii.) If there are changes in your Informed Consent Form, please append the revised copy.  
 
 
 
 
_____M. Wyndham-West___________    ___Dec. 1/09__________________  
              P.I. Signature                            Date 
 
 
 
COMMITTEE REVIEW (To be completed by Manager, Research Ethics and/or 
HPRC member(s) only) 
 
 
 
Comments: 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________  
 
 
 
Recommendation:________________________________________________ 
 
 
 
 
 
Reviewed by:   __________________________  ______________________ 
               Title                     Signature 
 
 
    __________________________ 
               Date 
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Appendix I – York University Ethics Extension 	  
 
 
 
 
Memo 
 
To:      Michelle Wyndham-West, Department of Social   
Anthropology 
 mwywest@yorku.ca 
 
From: Alison M. Collins-Mrakas, Sr. Manager and Policy Advisor, 
Research Ethics 
(on behalf of Daphne Winland, Chair, Human Participants Review 
Committee) 
 
Date:    Monday July 19th, 2010 
 Re:	   	  Ethics	  Approval	  
 
Enacting Biological Citizenship through Risk and Gender: An Ethnographic 
Exploration of HPV and Cervical Cancer Prevention Policy in Ontario 
 
I am writing to inform you that, with respect to the above-noted project, the 
committee notes that, as there are no substantive changes to either the 
methodology employed or the risks to participants in and/or any other aspect of 
the research project, a renewal of approval re the above project is granted. 
  
Should you have any questions, please feel free to contact me at:  416-736-5914 
or via email at:  acollins@yorku.ca. 
 
Yours sincerely, 
   Alison M. Collins-Mrakas M.Sc., LLM 
   Sr. Manager & Policy Advisor, Research Ethics 
Office	  of	  research	  ethics	  (ore)	  Fifth	  Floor,	  YRT	  	  
4700 Keele St. 
Toronto ON 
Canada  M3J 1P3 
Tel  416  736 5914  
Fax 416 736 5837 
www.research.yorku.ca 
Certificate #:   STU 2009 
- 103 
 
Renewal Approved:  07/19/10 
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Appendix J – Sunnybrook Recruitment Poster 
	  
	  
	   	  
 
Principal Investigator: Dr.   
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Appendix K – Sunnybrook Recruitment Letter 
Recruitment Letter for Clients of Sunnybrook’s HPV Vaccine Clinic  – 
Dear Sunnybrook Clinic Attendee: 
Michelle Wyndham-West is a PhD student at York University and she is currently 
researching Ontario’s cervical cancer prevention policy, including the HPV vaccine.  
She is investigating how women negotiate cervical cancer risk for themselves and, 
particularly, in respect to the HPV vaccine. This project is being carried out in 
conjunction with Sunnybrook Health Sciences Centre and Dr.  is serving 
as the Principal investigator of the research project. 
If you are interested in participating in the research project, please find attached a 
consent form to be signed.  If you have questions about the research, please feel free to 
contact Michelle Wyndham-West by e-mail at mwywest@yorku.ca. Additional 
information regarding the research project can be found at http://www.yorku.ca/
gradanth/students.html.   This research has been reviewed by the Human Participants 
Review Subcommittee (York University’s Ethics Review Board) and conforms to the 
standards of the Canadian Tri-Council Research Ethics guidelines. 
Thanks so much for your time and consideration. 
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Appendix L - Sunnybrook Consent Form 
 
 
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
	  
 
Full Study Title: An ethnographic exploration of HPV and Cervical Cancer Prevention 
Policy in Ontario.  
 
Principal Investigator: Dr.  Women and Babies, Sunnybrook Health 
Sciences Centre. Telephone number: 416- . 
 
Sponsor: This study is not being funded. Michelle Wyndham-West, a PhD student 
at York University, who is working with Dr. , is receiving a 
scholarship from the Canadian Institutes of Health Research. 
 
______________________________________________________________________ 
 
INFORMED CONSENT 
 
You are being asked to consider participating in a research study.  A research 
study is a way of gathering information on a treatment, procedure or medical 
device or to answer a question about something that is not well understood.  This 
form explains the purpose of this research study, provides information about the 
study procedures, possible risks and benefits, and the rights of participants.  
 
Please read this form carefully and ask any questions you may have. You may 
take as much time as you wish to decide whether or not to participate.  Please 
ask the nurse at the HPV clinic to clarify anything you do not understand or 
would like to know more about. Make sure all your questions are answered to 
your satisfaction before deciding whether to participate in this research study. 
 
INTRODUCTION 
 
You are being asked to consider participating in this study because you have or 
are attending Sunnybrook’s HPV vaccine clinic. 
 
The objective of the research is to gain a greater sense of how Ontario women 
think about cervical cancer risk, particularly since the introduction of the HPV 
vaccine.  We are trying to understand how increasing HPV awareness and the 
HPV vaccine is influencing cervical cancer risk prevention, such as practices like 
Pap tests. Existing research does not explore in detail how women think about 
HPV and the HPV vaccination. This narrative-based research project, meaning 
women will be interviewed one-on-one regarding their thoughts on HPV, the HPV 
vaccine and general cervical cancer prevention, begins to fill that gap.   
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WHY IS THIS STUDY BEING DONE? 
 
The purpose of this study is to record women’s thoughts and experiences in 
regard to cervical cancer risk since the introduction of the HPV vaccine.  This will 
be done by holding one-on-one interviews with women who are attending or who 
have attended Sunnybrook’s HPV clinic.  
 
WHAT WILL HAPPEN DURING THIS STUDY? 
 
If an HPV clinic attendee is interested in taking part in the research study, the 
participant will fill out the informed consent form with the HPV vaccine clinic 
nurse. Once the informed consent form is complete, Michelle Wyndham-West 
will arrange a one-on-one interview at your convenience. The interview will be 
held either over the telephone or in person. Interviews will be about 45 minutes 
in length and will be recorded via audiotape. Interviews will cover participant’s 
views and experiences regarding: (1) risk and cervical cancer; (2) HPV 
awareness; (3) cervical cancer screening, such as Pap tests; and (4) how you 
came to the decision to have the HPV vaccine. 
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
 
About 20 to 25 people will participate in one-on-one interviews.  The study is 
expected to take five months to finish and the results should be known in the fall 
of 2011.   
 
WHAT ARE THE RESPONSIBILITIES OF STUDY PARTICIPANTS? 
 
If you decide to participate in this study you will be asked to do the following: 
 
Participants will be asked to take part in one interview, which is expected to take 
approximately 45 minutes.  Interviews can be conducted over the telephone or 
in-person at the Sunnybrook HPV vaccine clinic outside regular clinic hours. 
Interviews will be scheduled at a time and date,which is convenient for you. 
Participants may choose not to answer a question or a series of questions during 
the interview. Participants may end the interview at any point throughout the 
interview.   
 WHAT	  ARE	  THE	  RISKS	  OR	  HARMS	  OF	  PARTICIPATING	  IN	  THIS	  STUDY?	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There are no medical risks to you from participating in this research study, but 
taking part in this study may make you feel uncomfortable.  You may refuse to 
answer questions or stop the interview at any time if you are uncomfortable.  
 WHAT	  ARE	  THE	  BENEFITS	  OF	  PARTICIPATING	  IN	  THIS	  STUDY?	  
 There	  are	  no	  medical	  benefits	  to	  you	  from	  taking	  part	  in	  this	  research	  study.	  	  	  
CAN PARTICIPATION IN THIS STUDY END EARLY? 
 
The investigator may decide to remove you from this study without your consent 
for not keeping a pre-arranged interview appointment. You can also choose to 
end your participation at any time.  
 	  
WHAT ARE THE COSTS OF PARTICIPATING IN THIS STUDY? 
 
Participation in this study will not involve any additional costs to you. 
 
ARE STUDY PARTICIPANTS PAID TO PARTICIPATE IN THIS STUDY?  
 
You	  will	  not	  be	  paid	  to	  participate	  in	  this	  study.	  	  	  
 
DOES THE INVESTIGATOR HAVE ANY CONFLICTS OF INTEREST?  
 
There are no conflicts of interest to declare related to this study.  
 
 
WHAT ARE THE RIGHTS OF PARTICIPANTS IN A RESEARCH STUDY? 
 
All participants in a research study have the following rights: 
 
1. You have the right to have this form and all information concerning this 
study explained to you and if you wish translated into your preferred language.  
 
2. Participating in this study is your choice (voluntary). You have the right to 
choose not to participate, or to stop participating in this study at any time 
without having to provide a reason.  If you choose to withdraw, your choice will 
not have any effect on your relationship with Sunnybrook Health Sciences 
Centre or its HPV clinic. 
 
3. You have the right to receive all significant information that could help you 
make a decision about participating in this study. You also have the right to 
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ask questions about this study and your rights as a research participant, and to 
have them answered to your satisfaction, before you make any decision. You 
also have the right to ask questions and to receive answers throughout this 
study. If you have any questions about this study you may contact the person 
in charge of this study: Dr. , tel.: (416) . If you have 
questions about your rights as a research participant or any ethical issues 
related to this study that you wish to discuss with someone not directly 
involved with the study, you may call Dr. Philip C. Hébert, Chair of the Sunnybrook 
Research Ethics Board at (416) 480-4276.   
 
4. You have the right to have any information about you that is collected, 
used or disclosed for this research study to be handled in a confidential 
manner. 
 
If you decide to participate in this study, the investigator(s) and study staff will 
look at your personal health information and collect only the information they 
need for this study. “Personal health information” is health information about 
you that could identify you because it includes information such as your; 
• name,  
• address,  
• telephone number,  
• date of birth,  
• new and existing medical records, or  
• the types, dates and results of various tests and procedures. 
 
The following people may come to the hospital to look at your personal health 
information to check that the information collected for the study is correct and 
to make sure the study followed the required laws and guidelines:  
 
• Representatives of the Sunnybrook Research Ethics Board, a group 
of people who oversee the ethical conduct of research studies at 
Sunnybrook. 
 
Access to your personal health information will take place under the 
supervision of the Principal Investigator. 
 
In addition, any study data about you that is sent outside of the hospital will 
have a code and will not contain your name or address, or any information 
that directly identifies you.  “Study data" is information about you that is 
collected for the research study, but that does not directly identify you.   
 
Study data that is sent outside of the hospital will be used for the research 
purposes explained in this consent form.  
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The investigator, study staff and the other people listed above will keep the 
information they see or receive about you confidential, to the extent permitted 
by applicable laws. Even though the risk of identifying you from the study data 
is very small, it can never be completely eliminated.  
 
When the results of this study are published, your identity will not be 
disclosed.   
 
The Principal Investigator will keep any personal information about you in a 
secure and confidential location for five years and then destroyed as required 
by Sunnybrook policy.  
 
5. By signing this consent form, you do not give up any of your legal rights.  
 
6. You have the right to receive a copy of this signed and dated informed 
consent form before participating in this study.  
 
7.  You have the right to be told about any new information that might 
reasonably affect your willingness to continue to participate in this study as 
soon as the information becomes available to the study staff.   
 
8. You have the right to access, review and request changes to your 
personal health information. 
 
9.  You have the right to be informed of the results of this study once the 
entire study is complete. If you would like to be informed of the results of this 
study, please provide your name, address and telephone number to Michelle 
Wyndham-West, PhD Student, York University, tel.: . 
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DOCUMENTATION OF INFORMED CONSENT 
Full Study Title: An ethnographic exploration of HPV and Cervical Cancer 
Prevention Policy in Ontario.  
Name of Participant:  ________________________________________ 
Participant/Substitute decision-maker 
By signing this form, I confirm that: 
• This research study has been fully explained to me and all of my
questions answered to my satisfaction 
• I understand the requirements of participating in this research study
• I have been informed of the risks and benefits, if any, of participating in
this research study 
• I have been informed of any alternatives to participating in this research
study 
• I have been informed of the rights of research participants
• I have read each page of this form
• I authorize access to my personal health information and research study
data as explained in this form 
• I have agreed to participate in this study or agree to allow the person I am
responsible for to participate in this study ____________________________	  	  	  	  	  	  	  	  ____________________________	  	  	  	  	  	  	  	  _____________________ 
Name of participant/Substitute       Signature            Date 
decision-maker (print)	  	  	  	  	  	  	    
Person obtaining consent 
By signing this form, I confirm that: 
• This study and its purpose has been explained to the participant named
above 
• All questions asked by the participant have been answered
• I will give a copy of this signed and dated document to the participant____________________________	  	  	  	  	  	  	  	  ____________________________	  	  	  	  	  	  	  	  _____________________	  
Name of Person obtaining             Signature      Date 
consent (print) 
Statement of Investigator 
I acknowledge my responsibility for the care and well being of the above 
participant, to respect the rights and wishes of the participant as described in this 
informed consent document, and to conduct this study according to all applicable 
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laws, regulations and guidelines relating to the ethical and legal conduct of 
research.	  ____________________________	  	  	  	  	  	  	  	  ____________________________	  	  	  	  	  	  	  	  _____________________	  
Name of Investigator (print)                    Signature    Date 
ASSISTANCE DECLARATION □ (check here if not applicable) 
 The participant/substitute decision-maker was assisted during the consent 
process as follows: 
q The consent form was read to the participant/substitute decision-maker, 
and the person signing below attests that the study was accurately 
explained to, and apparently understood by, the participant/substitute 
decision-maker.  
q The person signing below acted as a translator for the 
participant/substitute decision-maker during the consent process.  He/she 
attests that they have accurately translated the information for the 
participant/substitute decision-maker, and believe that that 
participant/substitute decision-maker has understood the information 
translated. 
____________________________	  	  	  	  	  	  	  	  ____________________________	  	  	  	  	  	  	  	  _____________________	  
Name of Person Assisting (Print)           Signature    Date
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Appendix M – Interview Data 
Graph 1 - Vaccine Decisions 
Graph 2 - Mothers and Religion 
Graph 3 - Patient Health Insurance 
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